
<html lang="en"     class="pb-page"  data-request-id="033f169e-91c1-4b60-b676-eb1c0416602a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.5b01909;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-7;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance" /></meta><meta name="dc.Creator" content="Kazimierz  Wiśniewski" /></meta><meta name="dc.Creator" content="Javier  Sueiras-Diaz" /></meta><meta name="dc.Creator" content="Guangcheng  Jiang" /></meta><meta name="dc.Creator" content="Robert  Galyean" /></meta><meta name="dc.Creator" content="Mark  Lu" /></meta><meta name="dc.Creator" content="Dorain  Thompson" /></meta><meta name="dc.Creator" content="Yung-Chih  Wang" /></meta><meta name="dc.Creator" content="Glenn  Croston" /></meta><meta name="dc.Creator" content="Alexander  Posch" /></meta><meta name="dc.Creator" content="Diane M.  Hargrove" /></meta><meta name="dc.Creator" content="Halina  Wiśniewska" /></meta><meta name="dc.Creator" content="Régent  Laporte" /></meta><meta name="dc.Creator" content="John J.  Dwyer" /></meta><meta name="dc.Creator" content="Steve  Qi" /></meta><meta name="dc.Creator" content="Karthik  Srinivasan" /></meta><meta name="dc.Creator" content="Jennifer  Hartwig" /></meta><meta name="dc.Creator" content="Nicky  Ferdyan" /></meta><meta name="dc.Creator" content="Monica  Mares" /></meta><meta name="dc.Creator" content="John  Kraus" /></meta><meta name="dc.Creator" content="Sudarkodi  Alagarsamy" /></meta><meta name="dc.Creator" content="Pierre J. M.  Rivière" /></meta><meta name="dc.Creator" content="Claudio D.  Schteingart" /></meta><meta name="dc.Description" content="Glucagon-like peptide-2 receptor agonists have therapeutic potential for the treatment of intestinal diseases. The native hGLP-2, a 33 amino acid gastrointestinal peptide, is not a suitable clinica..." /></meta><meta name="Description" content="Glucagon-like peptide-2 receptor agonists have therapeutic potential for the treatment of intestinal diseases. The native hGLP-2, a 33 amino acid gastrointestinal peptide, is not a suitable clinica..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 25, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01909" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01909" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01909" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01909" /></link>
        
    
    

<title>Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01909" /></meta><meta property="og:title" content="Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0004.jpeg" /></meta><meta property="og:description" content="Glucagon-like peptide-2 receptor agonists have therapeutic potential for the treatment of intestinal diseases. The native hGLP-2, a 33 amino acid gastrointestinal peptide, is not a suitable clinical candidate, due to its very short half-life in humans. In search of GLP-2 receptor agonists with better pharmacokinetic characteristics, a series of GLP-2 analogues containing Gly substitution at position 2, norleucine in position 10, and hydrophobic substitutions in positions 11 and/or 16 was designed and synthesized. In vitro receptor potency at the human GLP-2, selectivity vs the human GLP-1 and GCG receptors, and PK profile in rats were determined for the new analogues. A number of compounds more potent at the hGLP-2R than the native hormone, showing excellent receptor selectivity and very low systemic clearance (CL) were discovered. Analogues 69 ([Gly2,Nle10,d-Thi11,Phe16]hGLP-2-(1−30)-NH2), 72 ([Gly2,Nle10,d-Phe11,Leu16]hGLP-2-(1−33)-OH), 73 ([Gly2,Nle10,d-Phe11,Leu16]hGLP-2-(1−33)-NH2), 81 ([Gly2,Nle10,d-Phe11,Leu16]hGLP-2-(1−33)-NHEt), and 85 ([Gly2,Nle10,d-Phe11,Leu16]hGLP-2-(1−33)-NH-((CH2)2O)4-(CH2)2-CONH2) displayed the desired profiles (EC50 (hGLP-2R) &lt; 100 pM, CL in rat &lt;0.3 mL/min/kg, selective vs hGLP-1R and hGCGR). Compound 73 (FE 203799) was selected as a candidate for clinical development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01909"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01909">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01909&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01909&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01909&amp;href=/doi/10.1021/acs.jmedchem.5b01909" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3129-3139</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01894" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01912" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kazimierz++Wi%C5%9Bniewski">Kazimierz Wiśniewski</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Javier++Sueiras-Diaz">Javier Sueiras-Diaz</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guangcheng++Jiang">Guangcheng Jiang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Galyean">Robert Galyean</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Lu">Mark Lu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dorain++Thompson">Dorain Thompson</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yung-Chih++Wang">Yung-Chih Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Glenn++Croston">Glenn Croston</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Posch">Alexander Posch</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Diane+M.++Hargrove">Diane M. Hargrove</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Halina++Wi%C5%9Bniewska">Halina Wiśniewska</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=R%C3%A9gent++Laporte">Régent Laporte</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+J.++Dwyer">John J. Dwyer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Qi">Steve Qi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karthik++Srinivasan">Karthik Srinivasan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Hartwig">Jennifer Hartwig</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicky++Ferdyan">Nicky Ferdyan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Monica++Mares">Monica Mares</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Kraus">John Kraus</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sudarkodi++Alagarsamy">Sudarkodi Alagarsamy</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pierre+J.+M.++Rivi%C3%A8re">Pierre J. M. Rivière</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Claudio+D.++Schteingart">Claudio D. Schteingart</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Phone 1 (858) 657-1597. E-mail: <a href="/cdn-cgi/l/email-protection#723913081b1f1b1700085c251b011c1b170501191b32141700001b1c155c111d1f"><span class="__cf_email__" data-cfemail="8ec5eff4e7e3e7ebfcf4a0d9e7fde0e7ebf9fde5e7cee8ebfcfce7e0e9a0ede1e3">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01909&amp;href=/doi/10.1021%2Facs.jmedchem.5b01909" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3129–3139</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 17, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 December 2015</li><li><span class="item_label"><b>Published</b> online</span>25 March 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 April 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01909" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01909</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3129%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKazimierz%2BWi%25C5%259Bniewski%252C%2BJavier%2BSueiras-Diaz%252C%2BGuangcheng%2BJiang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D7%26contentID%3Dacs.jmedchem.5b01909%26title%3DSynthesis%2Band%2BPharmacological%2BCharacterization%2Bof%2BNovel%2BGlucagon-like%2BPeptide-2%2B%2528GLP-2%2529%2BAnalogues%2Bwith%2BLow%2BSystemic%2BClearance%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3139%26publicationDate%3DApril%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01909"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1360</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01909" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Kazimierz&quot;,&quot;last_name&quot;:&quot;Wiśniewski&quot;},{&quot;first_name&quot;:&quot;Javier&quot;,&quot;last_name&quot;:&quot;Sueiras-Diaz&quot;},{&quot;first_name&quot;:&quot;Guangcheng&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Galyean&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Dorain&quot;,&quot;last_name&quot;:&quot;Thompson&quot;},{&quot;first_name&quot;:&quot;Yung-Chih&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Glenn&quot;,&quot;last_name&quot;:&quot;Croston&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Posch&quot;},{&quot;first_name&quot;:&quot;Diane&quot;,&quot;last_name&quot;:&quot;M. Hargrove&quot;},{&quot;first_name&quot;:&quot;Halina&quot;,&quot;last_name&quot;:&quot;Wiśniewska&quot;},{&quot;first_name&quot;:&quot;Régent&quot;,&quot;last_name&quot;:&quot;Laporte&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;J. Dwyer&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Karthik&quot;,&quot;last_name&quot;:&quot;Srinivasan&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Hartwig&quot;},{&quot;first_name&quot;:&quot;Nicky&quot;,&quot;last_name&quot;:&quot;Ferdyan&quot;},{&quot;first_name&quot;:&quot;Monica&quot;,&quot;last_name&quot;:&quot;Mares&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Kraus&quot;},{&quot;first_name&quot;:&quot;Sudarkodi&quot;,&quot;last_name&quot;:&quot;Alagarsamy&quot;},{&quot;first_name&quot;:&quot;Pierre&quot;,&quot;last_name&quot;:&quot;J. M. Rivière&quot;},{&quot;first_name&quot;:&quot;Claudio&quot;,&quot;last_name&quot;:&quot;D. Schteingart&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;3129-3139&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01909&quot;},&quot;abstract&quot;:&quot;Glucagon-like peptide-2 receptor agonists have therapeutic potential for the treatment of intestinal diseases. The native hGLP-2, a 33 amino acid gastrointestinal peptide, is not a suitable clinical candidate, due to its very short half-life in humans. In search of GLP-2 receptor agonists with better pharmacokinetic characteristics, a series of GLP-2 analogues containing Gly substitution at position 2, norleucine in position 10, and hydrophobic substitutions in positions 11 and/or 16 was designed and synthesized. In vitro receptor potency at the human GLP-2, selectivity vs the human GLP-1 and GCG receptors, and PK profile in rats were determined for the new analogues. A number of compounds more potent at the hGLP-2R than the native hormone, showing excellent receptor selectivity and very low systemic clearance (CL) were discovered. Analogues 69 ([Gly2,Nle10,d-Thi11,Phe16]hGLP-2-(1−30)-NH2), 72 ([Gly2,Nle10,d-Phe11,Leu16]hGLP-2-(1−33)-OH), 73 ([Gly2,Nle10,d-Phe11,Leu16]hGLP-2-(1−33)-NH2), 81 ([Gly2,Nle10,d-Phe&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01909&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01909" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01909&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01909" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01909&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01909" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01909&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01909&amp;href=/doi/10.1021/acs.jmedchem.5b01909" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01909" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01909" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (727 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01909%26sid%3Dliteratum%253Aachs%26pmid%3D26986178%26genre%3Darticle%26aulast%3DWi%25C5%259Bniewski%26date%3D2016%26atitle%3DSynthesis%2Band%2BPharmacological%2BCharacterization%2Bof%2BNovel%2BGlucagon-like%2BPeptide-2%2B%2528GLP-2%2529%2BAnalogues%2Bwith%2BLow%2BSystemic%2BClearance%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D7%26spage%3D3129%26epage%3D3139%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292161" title="Modification">Modification</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/jmcmar.2016.59.issue-7/20160414-01/jmcmar.2016.59.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/medium/jm-2015-01909v_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01909&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Glucagon-like peptide-2 receptor agonists have therapeutic potential for the treatment of intestinal diseases. The native hGLP-2, a 33 amino acid gastrointestinal peptide, is not a suitable clinical candidate, due to its very short half-life in humans. In search of GLP-2 receptor agonists with better pharmacokinetic characteristics, a series of GLP-2 analogues containing Gly substitution at position 2, norleucine in position 10, and hydrophobic substitutions in positions 11 and/or 16 was designed and synthesized. <i>In vitro</i> receptor potency at the human GLP-2, selectivity vs the human GLP-1 and GCG receptors, and PK profile in rats were determined for the new analogues. A number of compounds more potent at the hGLP-2R than the native hormone, showing excellent receptor selectivity and very low systemic clearance (CL) were discovered. Analogues <b>69</b> ([Gly<sup>2</sup>,Nle<sup>10</sup>,<span class="smallcaps smallerCapital">d</span>-Thi<sup>11</sup>,Phe<sup>16</sup>]hGLP-2-(1−30)-NH<sub>2</sub>), <b>72</b> ([Gly<sup>2</sup>,Nle<sup>10</sup>,<span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>,Leu<sup>16</sup>]hGLP-2-(1−33)-OH), <b>73</b> ([Gly<sup>2</sup>,Nle<sup>10</sup>,<span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>,Leu<sup>16</sup>]hGLP-2-(1−33)-NH<sub>2</sub>), <b>81</b> ([Gly<sup>2</sup>,Nle<sup>10</sup>,<span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>,Leu<sup>16</sup>]hGLP-2-(1−33)-NHEt), and <b>85</b> ([Gly<sup>2</sup>,Nle<sup>10</sup>,<span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>,Leu<sup>16</sup>]hGLP-2-(1−33)-NH-((CH<sub>2</sub>)<sub>2</sub>O)<sub>4</sub>-(CH<sub>2</sub>)<sub>2</sub>-CONH<sub>2</sub>) displayed the desired profiles (EC<sub>50</sub> (hGLP-2R) < 100 pM, CL in rat <0.3 mL/min/kg, selective vs hGLP-1R and hGCGR). Compound <b>73</b> (FE 203799) was selected as a candidate for clinical development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Glucagon-like peptide 2 (GLP-2) is a 33 amino acid gastrointestinal (GI) hormone that is produced by enteroendocrine cells in the small and large intestine and released into circulation following food intake. GLP-2 is synthesized by posttranslational processing of proglucagon by prohormone convertase 1/3.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The sequences of the human (hGLP-2) <b>1</b>,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and the rat (rGLP-2) form of the hormone as well as the sequence of an analogue in the clinical development are shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>.</div><div class="NLM_p">Compound <b>1</b> exerts its numerous biological responses through a specific GLP-2 G-protein coupled receptor that is abundantly expressed in the small intestine, colon, and stomach.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> The biological actions of <b>1</b> have been extensively reviewed in the scientific literature.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9 ref10">(5-10)</a> In mice, exogenous <b>1</b> was shown to stimulate intestinal growth through increased proliferation and decreased apoptosis of mucosal epithelial cells. The trophic effect was specific for the intestinal mucosa, as <b>1</b> had no effect on the growth of other tissues.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Other biological actions of <b>1</b> in the gastrointestinal tract include enhancement of nutrient absorption,<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> stimulation of mesenteric<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and intestinal blood flow,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and modulation of motility.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Compound <b>1</b> exhibits anti-inflammatory activity in the small<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> and large intestine and improves barrier function.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Despite being efficacious in these models, the potential use of <b>1</b> as a therapeutic agent is hampered by its unfavorable pharmacokinetic profile with elimination half-life in humans of about 7 min.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This short circulating half-life stems from the hormone sensitivity to cleavage of its N-terminal dipeptide by the ubiquitous serine protease enzyme dipeptidyl-peptidase IV (DPP IV) and formation of the cleavage product GLP-2 (3−33),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> a weak partial agonist/antagonist at the GLP-2 receptor.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">Although a substantial effort has been undertaken to identify GLP-2 agonists suitable for clinical development, the literature on SAR studies of GLP-2 analogues is sparse and in most cases limited to patents and patent applications.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> A single replacement of the Ala<sup>2</sup> residue with Gly led to the DPP IV resistant analogue <b>2</b> (teduglutide, [Gly<sup>2</sup>]hGLP-2, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), with an improved PK profile and superior intestinotrophic properties as compared to the native hormone in mice.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/medium/jm-2015-01909v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Sequences of human and rat GLP-2 and an analogue in the clinical development. Differences from the hGLP-2 sequence are marked in bold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01909&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>2</b> has been demonstrated to be efficacious in a variety of animal models of disease, including inflammatory bowel disease,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> short bowel syndrome and TPN-induced intestinal atrophy,<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> and chemotherapy<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> and radiation-induced gastrointestinal mucositis.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">The Drucker group conducted a comprehensive Ala-scan of <b>2</b> and an SAR study on position 2 substitutions.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Only conservative replacements (Gly, Ile, Pro, Aib, or <span class="smallcaps smallerCapital">d</span>-Ala) of the Ala<sup>2</sup> residue were well tolerated by the rGLP-2 receptor and resulted in analogues more potent than the native hormone in a functional cAMP-based assay. Receptor binding data for the Ala-scan showed that many residues in <b>2</b> (i.e., 17, 20, 22, 23, 25, 26, and 30) were crucial for rGLP-2R recognition. This was recently confirmed in an NMR and molecular modeling-based study.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Most of the Ala substituted compounds exhibited markedly reduced production of cAMP, with notable exceptions of analogues modified in positions 7, 8, 11, 16, and 24.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p">Analogue <b>2</b> has shown a half-life of 3.0–5.5 h in humans following subcutaneous administration.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In patients with short bowel syndrome, once daily treatment with <b>2</b> significantly reduced the parental nutrition requirements and improved intestinal function.<a onclick="showRef(event, 'ref35 ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37 ref38 ref39">(35-39)</a> In patients with moderate to severe Crohn’s disease, treatment with <b>2</b> resulted in a trend for improvement in the Crohn’s Disease Activity Index score.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Compound <b>2</b> has been recently approved by the US FDA and the EMA for use in patients with short bowel syndrome requiring parenteral support. Other GLP-2 analogues in clinical trials are [Gly<sup>2</sup>,Glu<sup>3</sup>,Ser<sup>8,11</sup>,Leu<sup>10</sup>,Ala<a onclick="showRef(event, 'ref16 ref24 ref28'); return false;" href="javascript:void(0);" class="ref ref16 ref24 ref28">(16, 24, 28)</a>]hGLP-2-(1–33)-Lys<sub>6</sub>-NH<sub>2</sub> (ZP1846)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> for the treatment of chemotherapy-induced diarrhea and [Gly<sup>2</sup>,Glu<sup>3</sup>,Thr<sup>5</sup>,Ser<sup>8</sup>,Leu<sup>10</sup>,Ala<a onclick="showRef(event, 'ref11 ref16 ref24 ref28'); return false;" href="javascript:void(0);" class="ref ref11 ref16 ref24 ref28">(11, 16, 24, 28)</a>]hGLP-2-(1–33)-Lys<sub>6</sub>-NH<sub>2</sub> (ZP1848)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> for the treatment of Crohn’s disease (<a href="http://www.zealandpharma.com" class="extLink">www.zealandpharma.com</a>).</div><div class="NLM_p last">In search of GLP-2R agonists with superior pharmacodynamics (PD) and PK profiles relative to <b>2</b> and the compounds in clinical development, we designed and synthesized a new series of 83 GLP-2 analogues modified in positions 11 and/or 16. To render DPP IV stability, position 2 was fixed with Gly and the Met<sup>10</sup> residue was replaced with the more chemically stable isosteric norleucine. The compounds were screened in <i>in vitro</i> functional assays at the hGLP-1, hGLP-2, and hGCG receptors and their pharmacokinetic properties determined in rats. We describe here the discovery of potent and selective GLP-2 analogues with unprecedented exceptionally low systemic clearance (CL).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45657" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45657" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The native GLP-2 contains five Asp residues including one (Asp<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a>) immediately followed by a Gly residue. This particular sequence is very prone to side-reactions due to the formation of aspartimide and subsequent ring opening. Indeed, our initial efforts to synthesize the analogues by Fmoc strategy in a single run resulted in rather complex mixtures containing multiple byproducts (β-shifted peptides, piperidides and truncated peptides). The presence of desHis<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> peptides indicated that the peptide chain termination via nucleophilic opening of aspartimide by the α-amino group of the Gly<sup>2</sup> residue was forming the corresponding 1,4-piperazine-2,5-diones<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> or 1,4-diazepine-2,5-diones.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Aspartimide formation has been extensively studied in the literature.<a onclick="showRef(event, 'ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46">(44-46)</a> Strategies to suppress this unwanted side reaction include the addition of HOBt to the piperidine solution,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and the use of piperazine instead of piperidine for the Fmoc group removal.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Various aspartic acid side chain protecting groups, more sterically hindered than the commonly used t-butyl group, have been proposed.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49, 50)</a> TFA-labile backbone protecting groups offering total suppression of aspartimide formation such us Hmb,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Dmb<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> or Dcpm,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> have also been introduced. In our laboratory, we have elaborated yet another strategy to avoid the aspartimide formation. Since all analogues would have a fixed N-terminal tetrapeptide ending with the Gly<sup>4</sup> residue, the C-terminal parts of the peptides were assembled up to position 5 and the remaining four amino acids were coupled racemization-free as tetrapeptide Boc-His(Trt)-Gly-Asp(tBu)-Gly-OH, <b>3</b>, prepared separately on 2-chlorotrityl resin.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Because of the bulkiness of the 2-chlorotrityl linker, side reactions such as diketopiperazine and aspartimide formation are greatly suppressed on chlorotrityl resin. Indeed, the crude <b>3</b> could be used in the fragment condensation step without purification as it contained the des-trityl compound as the sole impurity.</div><div class="NLM_p">Our initial SAR effort was focused on reducing the size of the GLP-2 molecule, which could result in analogues with potentially lower cost of manufacturing. Since hGLP-2 (3–33) is an antagonist/weak agonist of the hGLP-2R<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and hGLP-2 (11–33) is a very weak agonist with poor efficacy <i>in vitro</i>,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> C-terminal truncations seemed to be the only viable strategy to generate shortened and still potent GLP-2R agonists. Position 2 in the truncated peptides was fixed with Gly for DPP IV stability.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The truncated analogues were evaluated <i>in vitro</i> at the hGLP-1R, hGLP-2R and hGCGR. The shortest analogue synthesized in this series, [Gly<sup>2</sup>]hGLP-2 (1−25)-NH<sub>2</sub>, <b>10</b>, was found to be inactive as a hGLP-2R agonist <i>in vitro</i>. Somewhat surprisingly, the 30-mer peptide <b>6</b> turned out to be the most potent truncated agonist <i>in vitro</i> with a modest 2.4-fold loss of potency at the hGLP-2R <i>in vitro</i> relative to <b>2</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). It is interesting to note that this corresponds to shortening the peptide chain by one full helical turn, but investigating the structural consequences of this change was beyond the scope of our work. Peptides <b>4</b>−<b>10</b> showed excellent selectivity vs both hGLP-1R (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) and hGCGR (data not shown). Based on the results of this preliminary evaluation, the SAR program was continued with 30-mer peptide amides. Also, based on the SAR exploration of position 2 in rGLP-2 reported by DaCambra et al.,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and the results of an expanded internal exploratory study of position 2 (data not shown) we elected to prepare all further analogues with the Gly<sup>2</sup> modification and with replacement of the oxidation and alkylation-prone Met residue in position 10 by the isosteric Nle (analogues <b>11</b>–<b>86</b>, <a class="ref internalNav" href="#tbl2" aria-label="Tables 2">Tables 2</a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Evaluation of Truncated Analogues of the [Gly<sup>2</sup>]hGLP-2 (1–<i>n</i>)-NH<sub>2</sub> General Structure</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">hGLP-2R</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">hGLP-1R</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">Selectivity<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">n</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Potency ratio<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> vs <b>2</b></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">Efficacy (%)</th><th class="colsep0 rowsep0" align="center">hGLP-1R/hGLP-2R</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">0.07</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">520</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">7400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">0.09</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >11000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">0.29</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >3400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">0.48</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >2000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >4500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">0.63</td><td class="colsep0 rowsep0" align="left">7.0</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >1500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> > 900</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >900</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"> >30</td><td class="colsep0 rowsep0" align="left"> >330</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">N/A</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">EC<sub>50</sub> (hGLP-1R)/EC<sub>50</sub> (hGLP-2R).</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">All compounds are fully efficacious at the hGLP-2R except for inactive compound <b>10</b>.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">EC<sub>50</sub> (analogue)/EC<sub>50</sub> (<b>2</b>).</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Compound <b>1</b> is the native hormone and an Ala<sup>2</sup> peptide (see <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a> for the sequence). Compounds <b>1</b> and <b>2</b> are C-terminal acids.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">No agonism up to the highest concentration tested (1000 nM).</p></div></div></div><div class="NLM_p">To better understand the SAR of the GLP-2 molecule, a <span class="smallcaps smallerCapital">d</span>-scan of the [Gly<sup>2</sup>,Nle<sup>10</sup>]hGLP-2 (1−30)-NH<sub>2</sub> peptide (<b>6</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) was performed. Replacing each residue with its <span class="smallcaps smallerCapital">d</span>-enantiomer could provide valuable information on the structural requirements for the GLP-2 receptor recognition/activation. Moreover, this strategy could render analogues with improved hGLP-2R specificity, potentially more resistant against proteolytic degradation in plasma, and with better PK properties. A <span class="smallcaps smallerCapital">d</span>-scan of the closely related gastrointestinal hormone GLP-1 (GLP-1-(7−36)-NH<sub>2</sub>) identified several positions (8, 17, 18, 30, 34, 36) where the inversion of configuration was well tolerated by the GLP-1R in both binding and functional assays.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Results of a <span class="smallcaps smallerCapital">d</span>-Scan of the [Gly<sup>2</sup>,Nle<sup>10</sup>]hGLP-2 (1−30)-NH<sub>2</sub> (<b>6</b>) Molecule</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">hGLP-2R</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">hGLP-1R</th><th class="rowsep1 colsep0" align="center">Selectivity<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">Position (<span class="smallcaps smallerCapital">d</span>-Aaa)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Potency ratio vs <b>6</b><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">hGLP-1R/hGLP-2R</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b><a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">N/A</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >4500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">4 (<span class="smallcaps smallerCapital">d</span>-Ala)</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">0.91</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >5000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">5 (<span class="smallcaps smallerCapital">d</span>-Ser)</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">7 (<span class="smallcaps smallerCapital">d</span>-Ser)</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">0.86</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >5200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">8 (<span class="smallcaps smallerCapital">d</span>-Asp)</td><td class="colsep0 rowsep0" align="left">16<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">9 (<span class="smallcaps smallerCapital">d</span>-Glu)</td><td class="colsep0 rowsep0" align="left">7.1</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">10 (<span class="smallcaps smallerCapital">d</span>-Nle)</td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >4300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">11 (<span class="smallcaps smallerCapital">d</span>-Asn)</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">0.73</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >6200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">12 (<span class="smallcaps smallerCapital">d</span>-Thr)</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">6.8</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >660</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">13 (<span class="smallcaps smallerCapital">d</span>-Ile)</td><td class="colsep0 rowsep0" align="left">0.35</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >2800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">14 (<span class="smallcaps smallerCapital">d</span>-Leu)</td><td class="colsep0 rowsep0" align="left">8.9</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">16 (<span class="smallcaps smallerCapital">d</span>-Asn)</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">6.8</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >660</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">17 (<span class="smallcaps smallerCapital">d</span>-Leu)</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >380</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">18 (<span class="smallcaps smallerCapital">d</span>-Ala)</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >220</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">19 (<span class="smallcaps smallerCapital">d</span>-Ala)</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">20 (<span class="smallcaps smallerCapital">d</span>-Arg)</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >450</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">21 (<span class="smallcaps smallerCapital">d</span>-Asp)</td><td class="colsep0 rowsep0" align="left">0.47</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >2100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">24 (<span class="smallcaps smallerCapital">d</span>-Asn)</td><td class="colsep0 rowsep0" align="left">0.43</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >2300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">25 (<span class="smallcaps smallerCapital">d</span>-Trp)</td><td class="colsep0 rowsep0" align="left"> > 30</td><td class="colsep0 rowsep0" align="left"> > 130</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">29 (<span class="smallcaps smallerCapital">d</span>-Thr)</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >220</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">30 (<span class="smallcaps smallerCapital">d</span>-Lys)</td><td class="colsep0 rowsep0" align="left">0.38</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> >2600</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">EC<sub>50</sub> (hGLP-1R)/EC<sub>50</sub> (hGLP-2R).</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Compounds are fully efficacious at the hGLP-2R unless indicated otherwise.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">EC<sub>50</sub> (analogue)/EC<sub>50</sub> (<b>6</b>).</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Compound <b>6</b> is a Met<sup>10</sup> analogue.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">No agonism up to the highest concentration tested (1000 nM).</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">Partial agonist at the hGLP-2R.</p></div></div></div><div class="NLM_p">The modifications of compound <b>6</b> with <span class="smallcaps smallerCapital">d</span>-enantiomers of the native amino acids were well tolerated in positions 4, 7, 10, 11, 13, 21, 24, and 30, with the <span class="smallcaps smallerCapital">d</span>-Asn<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> analogue <b>17</b> being slightly more potent <i>in vitro</i> than the parent compound <b>6</b>. In the N-terminal portion of the peptide, loss of potency was observed in positions 5, 8, 9, 12, and 14. In the C-terminal portion, losses by epimerization appeared in positions 17, 18, 19, 20, 25, and 29, all of which were found to be oriented toward a hydrophobic binding cavity in a model of the extracellular domain of the hGLP-2R.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The most severe loss of <i>in vitro</i> potency was observed for the Trp<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> analogue <b>28</b>. These results do not completely mirror the losses of binding potency or cAMP production at the rGLP-2R (at 1 nM peptide concentration) in the DaCambra Ala-scan.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> For example, Ala replacement in positions 4, 10, 13, or 30 of <b>1</b> resulted in significant loss of functional activity at the rGLP-2R while we observed only minimal effect on EC<sub>50</sub> at the hGLP-2R in our <span class="smallcaps smallerCapital">d</span>-scan for these positions. Conversely, we observed a significant decrease in potency and partial agonism for the <span class="smallcaps smallerCapital">d</span>-Asp<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> analogue <b>14</b> while its Ala replacement had little effect on cAMP production at the rGLP-2R.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> All <span class="smallcaps smallerCapital">d</span>-scan analogues <b>11</b>–<b>30</b> were inactive at both the hGLP-1R (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) and hGCGR (data not shown).</div><div class="NLM_p">Based on the outcome of our <span class="smallcaps smallerCapital">d</span>-scan and the results of the previously reported Ala-scan,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> positions 11 and 16 were selected for further modifications. Amino acids used in position 11 were of both <span class="smallcaps smallerCapital">l</span>- and <span class="smallcaps smallerCapital">d</span>-configurations. For position 16, only <span class="smallcaps smallerCapital">l</span>-amino acids were employed, as the <span class="smallcaps smallerCapital">d</span>-Asn<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> analogue <b>21</b> was considerably (6.8-fold) less potent than <b>6</b>. In addition to the <i>in vitro</i> screening for hGLP-2 receptor potency and selectivity, we also determined CL after intravenous administration to rats.</div><div class="NLM_p">First, the asparagine residue in position 11 was replaced with a variety of natural and unnatural amino acids of both <span class="smallcaps smallerCapital">l</span>- and <span class="smallcaps smallerCapital">d</span>-configuration (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacological Profile of [Gly<sup>2</sup>,Nle<sup>10</sup>,X<sup>11</sup>]hGLP-2 (1−30)-NH<sub>2</sub></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">Structure<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center" char=".">hGLP-2R</th><th class="rowsep1 colsep0" align="center">hGLP-1R</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">Selectivity<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center">Rat iv PK</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">Efficacy (%)</th><th class="colsep0 rowsep0" align="center">hGLP-1R/hGLP-2R</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left" char=".">0.07</td><td class="colsep0 rowsep0" align="left">520</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">7400</td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left" char=".">0.09</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >11000</td><td class="colsep0 rowsep0" align="left">9.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left" char=".">0.22</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >4500</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Dab</td><td class="colsep0 rowsep0" align="left" char=".">0.66</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >1500</td><td class="colsep0 rowsep0" align="left">9.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">His</td><td class="colsep0 rowsep0" align="left" char=".">0.44</td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">680</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-His</td><td class="colsep0 rowsep0" align="left" char=".">0.20</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >5000</td><td class="colsep0 rowsep0" align="left">0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left" char=".">0.15</td><td class="colsep0 rowsep0" align="left">180</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">1200</td><td class="colsep0 rowsep0" align="left">2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Leu</td><td class="colsep0 rowsep0" align="left" char=".">0.31</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >3200</td><td class="colsep0 rowsep0" align="left">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">Ile</td><td class="colsep0 rowsep0" align="left" char=".">0.13</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">840</td><td class="colsep0 rowsep0" align="left">5.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">Hol</td><td class="colsep0 rowsep0" align="left" char=".">0.29</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">87</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">Cha</td><td class="colsep0 rowsep0" align="left" char=".">0.51</td><td class="colsep0 rowsep0" align="left">8.9</td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">0.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">Phe</td><td class="colsep0 rowsep0" align="left" char=".">0.15</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left" char=".">0.09</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1300</td><td class="colsep0 rowsep0" align="left">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">Cpa</td><td class="colsep0 rowsep0" align="left" char=".">0.16</td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">0.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Cpa</td><td class="colsep0 rowsep0" align="left" char=".">0.09</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">86</td><td class="colsep0 rowsep0" align="left">660</td><td class="colsep0 rowsep0" align="left">0.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-2Cpa</td><td class="colsep0 rowsep0" align="left" char=".">0.11</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">900</td><td class="colsep0 rowsep0" align="left">0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-3Cpa</td><td class="colsep0 rowsep0" align="left" char=".">0.11</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left">400</td><td class="colsep0 rowsep0" align="left">0.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Tyr</td><td class="colsep0 rowsep0" align="left" char=".">0.18</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">68</td><td class="colsep0 rowsep0" align="left">170</td><td class="colsep0 rowsep0" align="left">4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Thi</td><td class="colsep0 rowsep0" align="left" char=".">0.10</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">800</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-3Thi</td><td class="colsep0 rowsep0" align="left" char=".">0.09</td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">920</td><td class="colsep0 rowsep0" align="left">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">Trp</td><td class="colsep0 rowsep0" align="left" char=".">0.21</td><td class="colsep0 rowsep0" align="left">56</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">260</td><td class="colsep0 rowsep0" align="left">0.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Trp</td><td class="colsep0 rowsep0" align="left" char=".">0.10</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">400</td><td class="colsep0 rowsep0" align="left">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">Bip</td><td class="colsep0 rowsep0" align="left" char=".">0.18</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Bip</td><td class="colsep0 rowsep0" align="left" char=".">1.9</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">108</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Compounds <b>1</b> and <b>2</b> are the C-terminal acid 33-mer peptides (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Analogue <b>6</b> has Met in position 10.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">EC<sub>50</sub> (hGLP-1R)/EC<sub>50</sub> (hGLP-2R).</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Compounds fully efficacious at the hGLP-2R.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">No agonism up to the highest concentration tested (1000 nM).</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Not tested.</p></div></div></div><div class="NLM_p">Compound <b>31</b>, where the Asn<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> residue was substituted with a positively charged <span class="smallcaps smallerCapital">d</span>-Dab showed a 3-fold loss of potency as compared to <b>6</b>. In most cases, the hydrophobic replacements led to compounds equipotent or slightly more potent than <b>6.</b> However, introduction of residues with bulky hydrophobic side chains resulted in less potent analogues (i.e., Cha, <b>38,</b><span class="smallcaps smallerCapital">d</span>-Bip, <b>51</b>). These modifications also increased the potency of analogues at the hGLP-1R, reducing hGLP-1/hGLP-2 receptor selectivity (e.g., compounds <b>37</b>−<b>39</b>, <b>41</b>). Although we do not know if our GLP-2 analogues bind to the hGLP-1R in exactly the same orientation and register as hGLP-1, it is interesting to note that hGLP-1 has a hydrophilic serine in the equivalent position. The replacement of the hydrophobic residue of L-configuration with its <span class="smallcaps smallerCapital">d</span>-counterpart considerably improved selectivity vs the hGLP-1 receptor and, in the aromatic residues series, also increased the potency at the hGLP-2R by 2-fold (as exemplified by the EC<sub>50</sub> values for compounds <b>40</b>, <b>42</b>−<b>44</b>, <b>46</b>, and <b>47</b>–<b>49</b>, which were in the 0.09–0.11 nM range). Compounds <b>31</b>–<b>51</b> were inactive at the hGCGR (data not shown). One unexpected finding was that all analogues with a lipophilic amino acid (L or D) in position 11 in this series had significantly reduced CL values in rat as compared to those of reference compounds <b>1</b>, <b>2</b>, and <b>6</b>. Within the series, the analogues modified with aromatic residues (<b>33</b>, <b>39</b>–<b>45</b>) and cyclic Cha displayed lower CL (0.32–4.9 mL/min/kg) than analogues with aliphatic residues (<b>34</b>–<b>36</b>) (2.8–5.6 mL/min/kg). Moreover, the size/type of the aromatic ring and the type and the location of substituents in this aromatic ring had a huge impact on CL values in this series. For example, the 4-hydroxy compound <b>45</b> showed relatively high (albeit still lower than <b>2)</b> CL value of 4.9 mL/min/kg. On the other hand, the <span class="smallcaps smallerCapital">d</span>-Cpa compounds <b>42</b>–<b>44</b> displayed CL values in the range of 0.32–0.73 mL/min/kg. The lowest value in this series (0.32 mL/min/kg), about 30 times lower than that of <b>2,</b> was found for the 3-chloro isomer <b>44</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacological Profile of [Gly<sup>2</sup>,Nle<sup>10</sup>,Y<sup>16</sup>]hGLP-2 (1−30)-NH<sub>2</sub></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">Structure<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center" char=".">hGLP-2R</th><th class="rowsep1 colsep0" align="center">hGLP-1R</th><th class="rowsep1 colsep0" align="center">Selectivity<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center">Rat iv PK</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">hGLP-1R/hGLP-2R</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left" char=".">0.07</td><td class="colsep0 rowsep0" align="left">520</td><td class="colsep0 rowsep0" align="left">7400</td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left" char=".">0.09</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >11000</td><td class="colsep0 rowsep0" align="left">9.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left" char=".">0.22</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >4500</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left" char=".">0.10</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >10000</td><td class="colsep0 rowsep0" align="left">0.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">Cha</td><td class="colsep0 rowsep0" align="left" char=".">0.10</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >10000</td><td class="colsep0 rowsep0" align="left">0.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">Phe</td><td class="colsep0 rowsep0" align="left" char=".">0.14</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >7100</td><td class="colsep0 rowsep0" align="left">5.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">Tyr</td><td class="colsep0 rowsep0" align="left" char=".">0.11</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >9000</td><td class="colsep0 rowsep0" align="left">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">Cpa</td><td class="colsep0 rowsep0" align="left" char=".">0.22</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >4500</td><td class="colsep0 rowsep0" align="left">0.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">Thi</td><td class="colsep0 rowsep0" align="left" char=".">0.20</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >5000</td><td class="colsep0 rowsep0" align="left">6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">Aph</td><td class="colsep0 rowsep0" align="left" char=".">0.13</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >7600</td><td class="colsep0 rowsep0" align="left">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">His</td><td class="colsep0 rowsep0" align="left" char=".">0.42</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >2300</td><td class="colsep0 rowsep0" align="left">0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="left">hPhe</td><td class="colsep0 rowsep0" align="left" char=".">0.11</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >9000</td><td class="colsep0 rowsep0" align="left">0.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">1Nal</td><td class="colsep0 rowsep0" align="left" char=".">0.19</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >5200</td><td class="colsep0 rowsep0" align="left">0.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">2Nal</td><td class="colsep0 rowsep0" align="left" char=".">0.13</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >7600</td><td class="colsep0 rowsep0" align="left">0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="left">Trp</td><td class="colsep0 rowsep0" align="left" char=".">0.15</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >6600</td><td class="colsep0 rowsep0" align="left">0.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">Bip</td><td class="colsep0 rowsep0" align="left" char=".">0.35</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >2800</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Analogues <b>1</b> and <b>2</b> are the C-terminal acid 33-mer peptides (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), and compounds <b>1</b>, <b>2</b>, and <b>6</b> have Met in position 10.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">EC<sub>50</sub> (hGLP-1R)/EC<sub>50</sub> (hGLP-2R).</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Compounds fully efficacious at the hGLP-2R.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">No agonism up to the highest concentration tested (1000 nM).</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Not tested.</p></div></div></div><div class="NLM_p">To explore the SAR of position 16, compound <b>6</b> was modified with hydrophobic aliphatic and aromatic residues to yield analogues <b>52</b>–<b>64</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Most of the modifications were well tolerated by the hGLP-2R and resulted in compounds equipotent or up to 2-fold more potent <i>in vitro</i> than <b>6</b>. The aliphatic Leu<sup>16</sup> and Cha<sup>16</sup> analogues were the most potent compounds in this series (EC<sub>50</sub> = 0.10 nM) whereas analogues with heterocyclic His (<b>59</b>) and bulky Bip (<b>64</b>) showed a minor, 2-fold loss in potency as compared to <b>6</b>. Unlike modifications in position 11, changes in position 16 did not have any deteriorating effect on selectivity vs the hGLP-1R as none of the compounds <b>52</b>–<b>64</b> showed any activity at this receptor <i>in vitro</i> up to the maximum concentration tested (1000 nM). The peptides in this series showed no activity at the hGCGR up to 1000 nM (data not shown). A somewhat different PK SAR was seen in this series compared to compounds modified in position 11. Remarkably low CL values were observed for analogues with bulky, hydrophobic side chains, both aliphatic and aromatic (e.g., <b>53</b>, <b>60</b>–<b>63</b>). However, for compounds with an unsubstituted phenyl (<b>54</b>) and 2-thienyl (<b>57</b>) rings, higher CL values were determined. The introduction of various substituents in position 4 of the Phe<sup>16</sup> phenyl ring resulted in compounds with lower CL than the parent analogue <b>54</b>. Rather surprisingly, the His<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> compound <b>59</b> showed the lowest CL (0.13 mL/min/kg) in the series. As it was observed for position 11, replacement of a single amino acid (Asn<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a>) by a lipophilic one reduced the clearance of a 30 amino acid long peptide by a large factor.</div><div class="NLM_p">Modifications in positions 11 (<span class="smallcaps smallerCapital">d</span>-Thi and <span class="smallcaps smallerCapital">d</span>-Phe) and 16 (Leu, Phe, Tyr) that resulted in the most potent and selective analogues <i>in vitro</i> were combined in analogues <b>65</b>–<b>71</b> (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). All compounds turned out to be very potent hGLP-2R agonists <i>in vitro</i> (EC<sub>50</sub> < 0.1 nM). The 2.4-fold loss of potency associated with truncating the GLP-2 molecule from 33 to 30 residues (compound <b>6</b>) was fully compensated by the replacements of the Asn<a onclick="showRef(event, 'ref11 ref16'); return false;" href="javascript:void(0);" class="ref ref11 ref16">(11, 16)</a> residues with the lipophilic amino acids. Compounds <b>65</b>−<b>71</b> displayed a receptor selectivity profile similar to the analogues modified only in position 11 with the notable exemption of those with Tyr<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and the rat GLP-2 analogue <b>71</b>. The modifications in positions 11 and/or 16 appeared to have a somewhat additive effect on CL as extremely low values in the 0.26–0.52 mL/min/kg range were consistently observed for analogues <b>65</b>−<b>71</b>. The combination of the <span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup> residue with Phe<sup>16</sup> or Leu<sup>16</sup> residues resulted in compounds with the most desirable pharmacological profile (equipotent <i>in vitro</i> with <b>1</b>, selective and extremely low-CL in rat).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacological Profile of [Gly<sup>2</sup>,Nle<sup>10</sup>,X<sup>11</sup>,Y<sup>16</sup>]hGLP-2 (1−30)-NH<sub>2</sub></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">Structure<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center" char=".">hGLP-2R</th><th class="rowsep1 colsep0" align="center">hGLP-1R</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">Selectivity<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center">Rat iv PK</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">Efficacy (%)</th><th class="colsep0 rowsep0" align="center">hGLP-1R/hGLP-2R</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left" char=".">0.07</td><td class="colsep0 rowsep0" align="left">520</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">7400</td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left" char=".">0.09</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >11000</td><td class="colsep0 rowsep0" align="left">9.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left" char=".">0.22</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >4500</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left" char=".">0.08</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >12000</td><td class="colsep0 rowsep0" align="left">0.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Phe</td><td class="colsep0 rowsep0" align="left" char=".">0.09</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >11000</td><td class="colsep0 rowsep0" align="left">0.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Tyr</td><td class="colsep0 rowsep0" align="left" char=".">0.07</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">1200</td><td class="colsep0 rowsep0" align="left">0.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Thi</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left" char=".">0.08</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >12000</td><td class="colsep0 rowsep0" align="left">0.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Thi</td><td class="colsep0 rowsep0" align="left">Phe</td><td class="colsep0 rowsep0" align="left" char=".">0.08</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> >12000</td><td class="colsep0 rowsep0" align="left">0.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Thi</td><td class="colsep0 rowsep0" align="left">Tyr</td><td class="colsep0 rowsep0" align="left" char=".">0.07</td><td class="colsep0 rowsep0" align="left">70</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">7000</td><td class="colsep0 rowsep0" align="left">0.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left" char=".">0.04</td><td class="colsep0 rowsep0" align="left">130</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">3200</td><td class="colsep0 rowsep0" align="left">0.49</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Analogues <b>1</b> and <b>2</b> are the C-terminal acid 33-mer peptides (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Compound <b>6</b> has Met in position 10, compound <b>71</b> is a rGLP-2 analogue with Thr in position 19.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">EC<sub>50</sub> (hGLP-1R)/EC<sub>50</sub> (hGLP-2R).</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Compounds fully efficacious at the hGLP-2R.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">No agonism up to the highest concentration tested (1000 nM).</p></div></div></div><div class="NLM_p">Shortening the sequence of <b>2</b> by just three residues (compounds <b>31</b>–<b>71</b>) would have only a minor impact on manufacturing costs if one of these analogues was selected for development. Moreover, CL of the shortened analogue <b>6</b> was more than 2-fold higher than that of <b>2</b> so we explored whether adding back the native C-terminal tripeptide to the best analogues from the 1−30-NH<sub>2</sub> series would result in compounds with even better pharmacological profile than those of peptides <b>65</b>–<b>71</b>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacological Profile of [Gly<sup>2</sup>,Nle<sup>10</sup>,X<sup>11</sup>,Y<sup>16</sup>]hGLP-2 (1−33)-R</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">Structure<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center" char=".">hGLP-2R</th><th class="rowsep1 colsep0" align="center">hGLP-1R</th><th class="rowsep1 colsep0" align="center">Selectivity<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center">Rat iv PK</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">hGLP-1R/hGLP-2R</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left" char=".">0.07</td><td class="colsep0 rowsep0" align="left">520</td><td class="colsep0 rowsep0" align="left">7400</td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left">Asn</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left" char=".">0.09</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >11000</td><td class="colsep0 rowsep0" align="left">9.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left" char=".">0.03</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >33000</td><td class="colsep0 rowsep0" align="left">0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left" char=".">0.03</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >33000</td><td class="colsep0 rowsep0" align="left">0.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Phe</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left" char=".">0.06</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >16000</td><td class="colsep0 rowsep0" align="left">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>75</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Phe</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left" char=".">0.06</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >16000</td><td class="colsep0 rowsep0" align="left">0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>76</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Thi</td><td class="colsep0 rowsep0" align="left">Phe</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left" char=".">0.07</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >14000</td><td class="colsep0 rowsep0" align="left">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>77</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-3Cpa</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left" char=".">0.09</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >11000</td><td class="colsep0 rowsep0" align="left">0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-3Cpa</td><td class="colsep0 rowsep0" align="left">Phe</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left" char=".">0.13</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >7600</td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-3Cpa</td><td class="colsep0 rowsep0" align="left">2-Nal</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left" char=".">0.51</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >1900</td><td class="colsep0 rowsep0" align="left">0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>80</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Thi</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left" char=".">0.05</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >20000</td><td class="colsep0 rowsep0" align="left">0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left">NHEt</td><td class="colsep0 rowsep0" align="left" char=".">0.05</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >20000</td><td class="colsep0 rowsep0" align="left">0.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left">NH-iBu</td><td class="colsep0 rowsep0" align="left" char=".">0.06</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >16000</td><td class="colsep0 rowsep0" align="left">0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>83</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left">NHBn</td><td class="colsep0 rowsep0" align="left" char=".">0.10</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >10000</td><td class="colsep0 rowsep0" align="left">0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left">NH-4Pic</td><td class="colsep0 rowsep0" align="left" char=".">0.04</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >25000</td><td class="colsep0 rowsep0" align="left">0.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left">NH-R<sup>1</sup> <a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left" char=".">0.03</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >33000</td><td class="colsep0 rowsep0" align="left">0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>86</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left">Leu</td><td class="colsep0 rowsep0" align="left">NH-R<sup>2</sup> <a class="ref internalNav" href="#t6fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left" char=".">0.03</td><td class="colsep0 rowsep0" align="left"> >1000<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> >33000</td><td class="colsep0 rowsep0" align="left">0.28</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Compounds <b>1</b> and <b>2</b> have Met in position 10. Compound <b>80</b> is a rat (Thr<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a>) analogue.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">EC<sub>50</sub> (hGLP-1R)/EC<sub>50</sub> (hGLP-2R).</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Compounds fully efficacious at the hGLP-2R.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">No agonism up to the highest concentration tested (1000 nM).</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">R<sup>1</sup> is -((CH<sub>2</sub>)<sub>2</sub>O)<sub>4</sub>-(CH<sub>2</sub>)<sub>2</sub>-CONH<sub>2</sub>.</p></div><div class="footnote" id="t6fn6"><sup>f</sup><p class="last">R<sup>2</sup> is −CH<sub>2</sub>-((CH<sub>2</sub>)<sub>2</sub>O)<sub>3</sub>-(CH<sub>2</sub>)<sub>3</sub>-NHCO-CH<sub>2</sub>-O-CH<sub>2</sub>-CONH<sub>2</sub>.</p></div></div></div><div class="NLM_p">To address that question the full length analogues <b>72</b>–<b>86</b> were designed with the best hydrophobic modifications identified in the 1−30 series. In addition, compounds <b>81</b>–<b>86</b> were synthesized as analogues of <b>73</b> modified with various substituents at the C-terminal amide (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). A majority of the peptides in this series were very potent as hGLP-2R agonists <i>in vitro</i> with the exception of analogue <b>79</b> containing the bulky 2Nal<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> substitution and hydrophobic 3Cpa<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> which was 5 times less potent <i>in vitro</i> than <b>2</b>. Analogues in this subset displayed much improved selectivity vs the hGLP-1R as compared to their 1−30 counterparts. Compounds <b>72</b>−<b>86</b> were also very selective vs, hGCGR (data not shown). The combination of <span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>/Leu<sup>16</sup> resulted in the most potent analogues <i>in vitro</i> and C-terminal amides were as potent as their corresponding C-terminal acids (see <b>72</b> vs <b>73</b> and <b>74</b> vs <b>75</b>). The CL values of the full length analogues was similar or lower than those of the 30-mer peptides. The <i>N</i>-alkyl amides <b>81</b>–<b>83</b> had CL values lower than 0.2 mL/min/kg and the N-benzyl amide <b>83</b> had the lowest CL value in the series (0.10 mL/min/kg). The more polar analogues with short PEG chains at the C-terminus (<b>85</b> and <b>86</b>) had CL values similar to the parent compound <b>73</b>.</div><div class="NLM_p">In general, modifications with hydrophobic residues in just one or two positions (11 and/or 16) in these 33 amino acid long peptides produced remarkable reductions in metabolic clearance in rats, from 9.9 mL/min/kg for the DPP IV stable <b>2</b> to less than 0.3 mL/min/kg for compounds <b>72</b>–<b>80</b>. A variety of strategies to reduce clearance and lengthen half-life of peptides have been described, either by increasing molecular weight to decrease the rate of renal filtration or by facilitating their binding to plasma proteins to reduce their free fraction, which may be subject to proteolysis and renal filtration.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> These strategies require modification of the structure of the peptides; examples include lipidization (i.e., palmitoylation), PEG-ylation and fusion to long half-life polypeptides (e.g., XTEN) and proteins (e.g., albumin, Fc moieties). The singly palmitoylated GLP-1 analogue liraglutide is marketed for the treatment of diabetes mellitus and is suitable for once a day subcutaneous administration.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> A number of compounds described in this work display a PK profile that, if it translates to humans, may allow more convenient dosing than with <b>2</b> or other GLP-2 analogues in clinical development. Remarkably, the decrease in rat clearance in our analogues has been achieved without employing any of the strategies to prolong plasma half-life mentioned above, i.e., without drastically increasing molecular weight and/or adding synthetic complexity.</div><div class="NLM_p">As noted above, the introduction of modifications in just one or two positions in 30- or 33-mer GLP-2 analogues resulted in remarkable reductions in their clearance. We thought it was unlikely that these substitutions would render the peptides highly resistant to proteolysis as point modifications in positions 11 and/or 16 would not be able to prevent enzymatic attack at multiple and very distant potential proteolysis sites, if proteolysis is actually the reason for the high clearance of <b>1</b> and <b>2</b> (but see the discussion on helicity later). The value of the residual clearance in rats for analogues <b>72</b>–<b>86,</b> < 0.3 mL/min/kg, is much lower than the glomerular filtration rate in these animals, about 9 mL/min/kg.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Since the MW of these peptides (<4100) is not sufficiently high to slow down glomerular filtration <i>per se</i>,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> the low total clearance pointed at a reduced free fraction of the peptides in plasma and to plasma protein binding (PPB) as the cause of their low clearance. We therefore tested selected analogues with low CL for PPB in rat plasma using an ultracentrifugation method (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Rat Plasma Protein Binding and Helicity Values for Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">Major Modifications<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">PPB (%)</th><th class="colsep0 rowsep0" align="center">Helicity (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">None</td><td class="colsep0 rowsep0" align="left">66.2</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">58.1</td><td class="colsep0 rowsep0" align="left">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">Phe<sup>11</sup>, C-term NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">N.D.<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>, C-term NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">96.1</td><td class="colsep0 rowsep0" align="left">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">Leu<sup>16</sup>, C-term NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">98.7</td><td class="colsep0 rowsep0" align="left">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>, Leu<sup>16</sup>, C-term NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">97.6</td><td class="colsep0 rowsep0" align="left">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>, Leu<sup>16</sup></td><td class="colsep0 rowsep0" align="left">99.5</td><td class="colsep0 rowsep0" align="left">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>, Leu<sup>16</sup>, C-term NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">99.2</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>, Leu<sup>16</sup>, C-term NHEt</td><td class="colsep0 rowsep0" align="left">N.D.<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>, Leu<sup>16</sup>, C-term NHiBu</td><td class="colsep0 rowsep0" align="left">98.4</td><td class="colsep0 rowsep0" align="left">73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>83</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>, Leu<sup>16</sup>, C-term NHBn</td><td class="colsep0 rowsep0" align="left">N.D.<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe<sup>11</sup>, Leu<sup>16</sup>, C-term NH-4Pic</td><td class="colsep0 rowsep0" align="left">N.D.<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">49</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">All compounds are the Gly<sup>2</sup> analogues except for <b>1</b>. <b>1</b> and <b>2</b> are the Met<sup>10</sup> analogues, and all other compounds are the Nle<sup>10</sup> analogues. <b>1</b>, <b>2</b>, <b>72</b>, <b>73</b>, and <b>81</b>–<b>84</b> are 33-mer peptides, and <b>39</b>, <b>40</b>, <b>52</b>, and <b>65</b> are 30-mer peptides;</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">N.D. = not determined.</p></div></div></div><div class="NLM_p">Surprisingly, whereas <b>1</b> and <b>2</b> exhibited very moderate protein binding, all the compounds with low CL showed extensive PPB (>95%). It appears that the single replacement of Asn either in position 11 (compound <b>40</b>) or 16 (compound <b>52</b>) with a hydrophobic residue is sufficient to cause a significant increase in PPB. Since hormones of the glucagon family have been shown to have considerable helical character in solution<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and some albumin-binding motifs reported in the literature contain multiple helical domains,<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61, 62)</a> we investigated whether the high PPB in our analogues might be attributable to an enhanced helical character as compared to <b>1</b> or <b>2</b>. Selected compounds were evaluated by circular dichroism for their secondary structure in solution at physiological pH and ionic strength. All analogues tested showed higher helical content than <b>1</b> or <b>2</b> in PBS buffer. It can be speculated that the introduction of a lipophilic amino acid in positions 11, 16, or both, might contribute to stabilizing a helical conformation in this segment of the peptide via new hydrophobic interactions. In an α-helix, the side chain of a hydrophobic amino acid in position 11 would be located close to that of Leu<sup>14</sup> and one in position 16 would be in close proximity to the side chain of Ile.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Interestingly, peptides <b>81</b>–<b>84</b> which are C-terminally alkylated analogues of compound <b>73</b> showed particularly high helical content (>50%) in PBS buffer (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, numeric values in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). It is tempting to speculate that a similar set of hydrophobic interactions between the side chain of Ile<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and the C-terminal amide groups might be responsible for this peculiar “capping effect”. However, as there was no clear correlation between helicity and PPB or CL we cannot conclude that the increase in helicity in our analogues is directly responsible for their strong protein binding.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/medium/jm-2015-01909v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. CD spectra of reference peptides <b>1</b>, and <b>2</b>, and compounds <b>73</b> and <b>81</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01909&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on the data presented here and other considerations, compound <b>73</b> was selected for further evaluation. To investigate the effect of its lower clearance and higher plasma protein binding on its <i>in vivo</i> activity, the intestinotrophic activity of analogue <b>73</b> was tested in normal male Sprague–Dawley rats. Compound <b>73,</b> reference <b>2</b>, or vehicle control were injected once daily at doses ranging from 3 to 1000 nmol/kg for 5 days by the subcutaneous route and the wet weight of the small intestine was determined after the final dose. Compounds <b>2</b> and <b>73</b> had similar potency at the rat GLP-2R <i>in vitro</i>, but <b>73</b> achieved a larger increase in small intestinal growth at all doses tested (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a> and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Thus, the decrease in plasma free fraction of <b>73</b> was more than compensated by the decrease in its clearance and consequent increase in half-life relative to <b>2</b> (details will be reported elsewhere), and <b>73</b> appears to be a promising compound for the treatment of conditions requiring intestinotrophic activity.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Comparison of <b>73</b> and <b>2</b> Potency <i>in Vitro</i> in the rGLP-2R Assay and Effect <i>in Vivo</i> in the Small Intestine Growth Stimulation Assay at the Highest Dose Tested</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" char="." /></col><col align="left" char="." /></col><col align="left" /></col><col align="left" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center" char="."><i>In vitro</i> rGLP-2R<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><i>In vivo</i> Rat intestinal growth at dose of 1000 nmol/kg<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center" char=".">Rat iv PK</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">Increase wet weight over vehicle (%)</th><th class="colsep0 rowsep0" align="center">N<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left" char=".">0.08</td><td class="colsep0 rowsep0" align="left" char=".">39.0</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left" char=".">9.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="left" char=".">0.04</td><td class="colsep0 rowsep0" align="left" char=".">61.2</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left" char=".">0.27</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">In vitro potency at the rat GLP-2 receptor.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Compounds were administered once daily for 5 days; see <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">N -= number of rats per compound.</p></div></div></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/medium/jm-2015-01909v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Stimulation of intestinal growth by compounds <b>2</b> (closed bars) and <b>73</b> (open bars) after daily s.c. administrations for 5 days. Small intestine wet weight for each rat was normalized to body weight and expressed as % increase over the mean of a vehicle control group run in the same experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01909&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14724" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14724" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A new series of GLP-2 analogues modified in positions 2, 10, 11, and 16 and at the C-terminus has been designed, synthesized, and evaluated in pharmacological models. The new compounds are potent hGLP-2R agonists and selective vs the related hGLP-1 and hGCG receptors <i>in vitro</i>. Hydrophobic modifications in positions 11 and/or 16 resulted in compounds of extremely low CL in rats, mostly by increasing plasma protein binding. These low CL values were achieved without employing the conjugation strategies typically used to improve the half-life of peptides, such as lipidation, pegylation, or fusion with proteins. Compound <b>73</b> (FE 203799), which showed a promising pharmacological profile including <i>in vivo</i> potency in a rat model, has been selected for clinical development and is being considered as a treatment for gastrointestinal disorders. A comprehensive pharmacological evaluation of the compound will be reported elsewhere.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58003" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58003" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> General</h4><div class="NLM_p">Amino acid derivatives were purchased from Novabiochem, Bachem, and Peptide International and resins were obtained from Novabiochem and Matrix Innovation. Other chemicals and solvents were purchased from Sigma-Aldrich, VWR and Fisher Scientific.</div><div class="NLM_p">Analytical HPLC was performed on a Waters 600 Liquid Chromatograph using a Vydac C<sub>18</sub>, 5 μm, 4.6 × 250 mm column at a flow rate of 2 mL/min. Preparative HPLC was performed on a Waters 2000 Liquid Chromatograph using a C18, 300 Å, 15 μm PrePak 47 × 300 mm cartridge at a flow rate of 100 mL/min. Final purity of analogues was assessed on a 1100 Agilent Liquid Chromatograph as described in <a href="/doi/suppl/10.1021/acs.jmedchem.5b01909/suppl_file/jm5b01909_si_001.pdf" class="ext-link">Supporting Information</a>. Mass spectra were recorded on a Finnigan MAT LCQ spectrometer.</div><div class="NLM_p">Boc-His(Trt)-Gly-Asp(tBu)-Gly-OH (<b>3</b>). The fully protected tetrapeptide was assembled manually by Fmoc chemistry starting from H-Gly-O-2Cl-Trityl resin (Novabiochem, cat # 856053). The couplings were performed with DIC/HOBt using 3-fold excess of amino acid derivatives. The Fmoc protecting group was removed with 20% PIP/DMF. The fully protected tetrapeptide was cleaved from the resin with 30% HIPF/DCM (v/v).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The compound was lyophilized twice from t-butanol and the crude product (about 90% HPLC purity) was used in the subsequent step without purification.</div><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15"> Synthesis of 30-mer (<b>4</b>–<b>71</b>) or 33-mer (<b>73</b>, <b>75</b>–<b>80</b>) peptide primary amides</h5><div class="NLM_p last">The 5−30 or 5−33 fragments were assembled on Rink amide resin by Fmoc chemistry using ABI 433A (Applied Biosystems) or 9050 Plus (Perceptive Biosystems) automatic peptide synthesizers on a 0.25 mmol or a 0.5 mmol scale. The following side chain protecting groups were used for all peptides discussed in this paper: Trt for Gln and Asn, tBu for Glu and Asp, Pbf for Arg, Boc for Lys and Trp. Single HATU-mediated couplings with a 5-fold excess of reagents were used. The 1–4 fragment was subsequently added by a manual, DIC/HOBt-mediated coupling of tetrapeptide <b>3</b> using a 2-fold excess of reagents. The peptides were cleaved with the TFA/H<sub>2</sub>O/TIS 90/6/4 cocktail (2 h). For analogues containing methionine (<b>4–10</b>), 2-mercaptopyridine was added to the cleavage mixture.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16"> Synthesis of 33-mer C-terminal acids (<b>1</b>, <b>2</b>, <b>72</b>, <b>74</b>)</h5><div class="NLM_p last">The 5−33 fragments were assembled on Fmoc-Asp(OtBu)-O-NovaSyn TGT resin (EMD, cat# 856126) using ABI 433A synthesizer. The 1–4 fragment was added manually as described above. To synthesize <b>1</b>, the N-terminal tetrapetide Boc-His(Trt)-Ala-Asp(tBu)-Gly-OH was used instead of <b>3</b>. For methionine-containing peptides (<b>1</b>, <b>2</b>) 2-mercaptopyridine was added to the cleavage mixture.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> Synthesis of 33-mer C-terminal secondary amides (<b>81</b>–<b>84</b>)</h5><div class="NLM_p last">The 1−33 peptide acids were assembled using Fmoc-Asp(OtBu)-O-TGT-NovaSyn resin as described in the previous paragraph. The fully protected analogues were cleaved from the resin with the HIPF/DCM 1/4 (v/v) cocktail,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> the solvents were evaporated and the peptides were precipitated with ethyl ether and separated by filtration. The crude protected analogues were coupled with an appropriate amine using DIC/HOAt in the chloroform/2,2,2-trifluoroethanol 3/1 (v/v) solvent system.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The side-chain protecting groups were removed with the TFA/H<sub>2</sub>O/TIS 90/6/4 (v/v/v) cocktail.</div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> Synthesis of 33-mer C-terminal mini-PEG secondary amides (<b>85</b>, <b>86</b>)</h5><div class="NLM_p last">The compounds were prepared on Rink ChemMatrix resin. The mini-PEG fragments (Fmoc-15-amino-4,7,10,13-tetraoxapentadecanoic acid, EMD, product number 851035, for compound <b>85</b> and O-(N-Fmoc-3-aminopropyl)-O′-(N-diglycolyl-3-aminopropyl)-diethylene glycol, EMD, product number 851031, for compound <b>86</b>, respectively) were coupled using PyBOP/DIPEA in NMP. The resins were subsequently capped with 5% acetic anhydride, 6% 2,4-lutidine in DMF. Fmoc-Asp(OtBu)-OH was then manually added and the resulting resins were transferred to automatic synthesis vessels. The 5–32 fragments were assembled on the ABI 433A synthesizer and the 1–4 fragment was added manually by coupling peptide <b>3</b> using PyBOP/DIEA in NMP. The peptides were cleaved from the resin as described above.</div></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Purification</h4><div class="NLM_p last">The peptides were purified by preparative HPLC in triethylammonium phosphate buffers at pH 2.3 or 7.0. For more complex crude products an additional run in perchlorate buffer at pH 2.3 was performed. The compounds were eluted with a gradient of acetonitrile. The pooled fractions were diluted with at least one volume of water, reloaded on the prep column and eluted with a fast gradient of acetonitrile in 0.1% TFA. The fractions with HPLC purity exceeding 95% were pooled and lyophilized.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Biological methods</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> In vitro receptor assays</h4><div class="NLM_p">The agonist activity and potency of compounds at the rat and human Glucagon-like peptide 2 receptors (rGLP-2R and hGLP-2R) were determined in a transcriptional reporter gene assay (RGA) by transiently transfecting the human or rat GLP-2 receptor expression DNA construct into a human embryonic kidney (HEK-293) cell line in concert with a reporter DNA construct containing intracellular cAMP responsive promoter elements regulating expression of firefly luciferase.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Two days following transfection, cells were exposed to serial dilutions of compounds diluted half-log per dose (concentration range of 0.0003–30 nM), incubated at 37 °C for 5 h, followed by lysis of cells in the presence of luciferin and the total luminescence was measured. Compound <b>1</b> (30 nM) was used as an internal control in each experiment. The data displayed normal variation in individual assays performed.</div><div class="NLM_p last">To determine hGLP-1 receptor selectivity, compounds were tested in a luciferase-based transcriptional reporter assay (RGA) in a HEK-293 cell line stably expressing both the human Glucagon-like peptide 1 (hGLP-1) receptor and a reporter DNA construct containing intracellular cAMP responsive promoter elements. hGLP-1 was used as an internal control for the hGLP-1 receptor assay. To determine hGCG receptor selectivity, compounds were tested in luciferase-based transcriptional reporter gene assays by transiently transfecting the human Glucagon receptor (hGCGR) expression DNA construct into a HEK-293 cell line in concert with a reporter DNA construct containing intracellular cAMP responsive promoter elements. hGlucagon was used as an internal control for the hGCG receptor assay. In both assays compounds were tested in at least three independent experiments. Dose–response curves were analyzed using a one-site, four parameter model from Xlfit (IDBS) and used to estimate EC<sub>50</sub> and efficacy values. Agonist potency is presented as geometric means in nanomol/L (nM) and efficacy is presented as the arithmetic means in percentage of internal control efficacy. Selectivity values are given as ratios of the EC<sub>50</sub> values at the receptor of interest to the corresponding EC<sub>50</sub> values at the hGLP-2R.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> PK studies. Animals</h4><div class="NLM_p last">All animals procedures were approved by the Ferring Research Institute Institutional Animal Care and Use Committee and were in accordance with the <i>Guide for the Care and Use of Laboratory Animals</i> published by the National Research Council. The <b>s</b>ingle-dose pharmacokinetic profiles of GLP-2 analogues were investigated following <i>i.v.</i> administration in male Sprague–Dawley rats (230–300 g). Animals with chronic jugular vein and carotid artery catheters inserted surgically were obtained from Harlan Laboratories Inc. (Indianapolis USA). The rats were given free access to food (18% protein Rodent Diet, Harlan Teklad, Madison USA) and water. They were housed in a conventional animal facility in individually ventilated caging (LabProducts Inc., Seaford USA) with appropriate air flow under controlled environmental conditions (20–22 °C, 12 h light/dark cycle).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Dosing and sampling</h4><div class="NLM_p last">The GLP-2 analogues were dissolved in 25 mM phosphate buffer in water, pH 7.4 (no tonicity adjustment with NaCl). Each rat was given a single dose of 0.2 mg/kg of each test compound in cassette mode through the jugular vein.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Cassettes were constituted of 3 to 6 GLP-2 analogues with each compound at a concentration of 0.2 mg/mL. Blood samples (250 μL) were collected from the carotid artery catheter at nominal times of either 2, 4, 6, 10, 20, 30, 60, 90, and 120 min or 2, 5, 8, 13, 20, 35, 55, 80, 120, 210, and 300 min after administration into prechilled tubes containing K<sub>2</sub>EDTA as anticoagulant. Blood that was drawn from the animal was replaced with an equal volume of saline. The samples were centrifuged at 4 °C and plasma was separated. All samples were immediately frozen on dry ice and stored at −50 °C until further analysis.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Bioanalysis</h4><div class="NLM_p last">The concentrations of GLP-2 analogues in rat plasma were determined using a liquid chromatography tandem mass spectrometry (LC/MS/MS) method. The dynamic range of the assays was 2–4000 ng/mL. Standard and internal standard solutions were prepared in 50% DMSO in acetonitrile. Typically, 40 μL of rat plasma sample was mixed with 20 μL of the internal standard and 100 μL of the crashing solution (50% DMSO in acetonitrile). After shaking for 2 min and centrifugation at 5700 g for 30 min, supernatant was injected into a Jupiter 5 μm 300 Å C18 50 × 2.0 mm HPLC column (Phenomenex, Torrance USA) coupled to a Shimadzu LC-20AD series LC (Shimadzu, Kyoto Japan) system. The analytes were eluted using a gradient of solvent B (solvent A - 0.01% TFA and 1% formic acid in water; solvent B - 0.01% TFA, 1% formic acid and 70% acetonitrile in water) at a flow rate of 0.5 mL/min and detected using an API-4000 triple quadrupole mass spectrometer (Applied Biosystems, Ontario Canada) in the positive electrospray ionization mode. Analyte concentrations were calculated by linear regression analysis using the peak area ratio of analyte to the internal standard on the Applied Biosystems Analyst software version 1.4.2.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> PK data analysis</h4><div class="NLM_p last">PK parameters were calculated using a noncompartmental curve stripping method (PK Solutions 2.0, Summit Research Services, Ashland, USA). The area under the plasma concentration–time curve to infinity (AUC<sub>∞</sub>) was calculated by combining the area under the curve to the last time point (AUC<sub>0-t</sub>) with the extrapolated AUC value of the terminal phase. Body weight normalized CL values (mL/min/kg) were calculated as dose divided by AUC<sub>(0-∞)</sub> and rat body weight.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Determination of rat plasma protein binding</h4><div class="NLM_p last">Rat plasma protein binding (PPB) analysis was performed by an ultracentrifugation (UC) method. Briefly, 5 μL of a 20–100 mg/mL solution of the GLP-2 analogue in DMSO was added to a 1 mL Sorvall polycarbonate thick-walled UC tube (Fisher Scientific, product number 45237) containing 495 μL of rat plasma to a final peptide concentration of 200–1000 ng/mL. The peptide plasma mixture was incubated at 37 °C for 15 min in a Sorvall S140-AT 35° fixed angle rotor, and then spun at 120,000 rpm (773,000 xg) for 30 min at 37 °C in a Sorvall MX150 microultracentrifuge (Asheville NC, USA). After centrifugation, a 50 μL sample in the middle layer of the UC tube was collected at the 300 μL volume meniscus level with a 250 μL pipettor tip. The compound concentrations in the collected sample was quantified immediately by the LC/MS/MS method described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Each compound was assayed in quadruplicate. The percentage of binding was calculated as<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/jm-2015-01909v_m001.gif" alt="" /></img></span>Where Ci is the initial concentration of peptide and <i>Cm</i> is the concentration of peptide remaining in the middle layer after ultracentrifugation.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Rat intestinal growth assay</h4><div class="NLM_p last">Male Sprague–Dawley rats (Harlan, Indianapolis) (body weight 235–275 g) were housed in a controlled environment with free access to food and water. On the first day of experimentation animals were randomly assigned to treatment groups (typically n = 6 per treatment) with doses standardized by body weight. Compounds or vehicle (1 mL/kg) were administered by s.c. bolus injection, once daily at approximately the same time of day for five consecutive days. Animals were weighed at the beginning of each day of dosing to determine dose volumes and to track body weight. Animals were euthanized after dosing on the final day (96 h after the first dose), the gastrointestinal tract was excised and the small intestine was carefully dissected. Intestines were flushed with saline to expel contents. Excess saline was removed and the wet weight of intestines was recorded.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Dosing solutions</h4><div class="NLM_p last">Peptides were dissolved in 25 mM phosphate buffer, pH 7.4. On the first day of experimentation, compounds were formulated at concentrations allowing administration of the desired dose in a volume of 1 mL per kg of animal body weight (3–1000 nmol/mL), and stored at 4 °C over the course of the experiment.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Data calculation and statistical analysis</h4><div class="NLM_p last">For each animal, wet weight of the intestine was normalized to body weight and percent increase over the mean of the vehicle group run in the same experiment was calculated. Data from multiple experiments were combined and data for each treatment are expressed as mean with SEM. For statistical comparisons, data were analyzed by ANOVA followed by Student–Newman–Keuls method for <i>post hoc</i> comparisons. Differences between groups were considered to be statistically significant at <i>p</i> < 0.05.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01909">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01909" class="ext-link">10.1021/acs.jmedchem.5b01909</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><i>In vitro,</i> PK, PPB, and helicity data with statistical parameters, protocol for helicity determinations, and physiochemical properties of analogues <b>1</b>, <b>2</b>, and <b>4</b>–<b>86</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01909/suppl_file/jm5b01909_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01909/suppl_file/jm5b01909_si_001.pdf">jm5b01909_si_001.pdf (100.06 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01909" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23322" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23322" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kazimierz Wiśniewski</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e0ab819a898d8985929aceb789938e898597938b89a086859292898e87ce838f8d"><span class="__cf_email__" data-cfemail="480329322125212d3a32661f213b26212d3f3b2321082e2d3a3a21262f662b2725">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Javier Sueiras-Diaz</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guangcheng Jiang</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Galyean</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Lu</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dorain Thompson</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yung-Chih Wang</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Glenn Croston</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Posch</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Diane M. Hargrove</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Halina Wiśniewska</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Régent Laporte</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John J. Dwyer</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Qi</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karthik Srinivasan</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Hartwig</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicky Ferdyan</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Monica Mares</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Kraus</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sudarkodi Alagarsamy</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre J. M. Rivière</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudio D. Schteingart</span> - <span class="hlFld-Affiliation affiliation">Ferring
Research Institute Inc., 4245 Sorrento
Valley Boulevard, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d90e5567-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Marlene Brown and Karina Mena for their excellent technical assistance. We also wish to thank Leslie Callejas-Dominguez, Erin La, D. Scott Rey, and Jeannine Toy for their assistance in implementing the rat intestinal growth assay and Denise Riedl for auditing the data and critical reading of the manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i32" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i32"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i33" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i33"> Abbreviations Used</h2><tr><td class="NLM_term">Aph</td><td class="NLM_def"><p class="first last">β-(4-aminophenyl)alanine</p></td></tr><tr><td class="NLM_term">Bip</td><td class="NLM_def"><p class="first last">β-(4,4′-biphenyl)alanine</p></td></tr><tr><td class="NLM_term">Cha</td><td class="NLM_def"><p class="first last">β-cyclohexylalanine</p></td></tr><tr><td class="NLM_term">Cpa</td><td class="NLM_def"><p class="first last">β-(4-chlorophenyl)alanine</p></td></tr><tr><td class="NLM_term">2Cpa</td><td class="NLM_def"><p class="first last">β-(2-chlorophenyl)alanine</p></td></tr><tr><td class="NLM_term">3Cpa</td><td class="NLM_def"><p class="first last">β-(3-chlorophenyl)alanine</p></td></tr><tr><td class="NLM_term">Dab</td><td class="NLM_def"><p class="first last">2,4-diaminobutyric acid</p></td></tr><tr><td class="NLM_term">Dcpm</td><td class="NLM_def"><p class="first last">dicyclopropylmethyl</p></td></tr><tr><td class="NLM_term">Dmb</td><td class="NLM_def"><p class="first last">2,4-dimethoxybenzyl</p></td></tr><tr><td class="NLM_term">DPP IV</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase IV</p></td></tr><tr><td class="NLM_term">GLP-1R</td><td class="NLM_def"><p class="first last">GLP-1 receptor</p></td></tr><tr><td class="NLM_term">GLP-2R</td><td class="NLM_def"><p class="first last">GLP-2 receptor</p></td></tr><tr><td class="NLM_term">hGCGR</td><td class="NLM_def"><p class="first last">human glucagon receptor</p></td></tr><tr><td class="NLM_term">Hmb</td><td class="NLM_def"><p class="first last">2-hydroxy-4-methoxybenzyl</p></td></tr><tr><td class="NLM_term">Hol</td><td class="NLM_def"><p class="first last">homoleucine</p></td></tr><tr><td class="NLM_term">1Nal</td><td class="NLM_def"><p class="first last">β-(1-naphtyl)alanine</p></td></tr><tr><td class="NLM_term">2Nal</td><td class="NLM_def"><p class="first last">β-(2-naphtyl)alanine</p></td></tr><tr><td class="NLM_term">4Pic</td><td class="NLM_def"><p class="first last">4-picolyl (4-pyridinylmethyl)</p></td></tr><tr><td class="NLM_term">RGA</td><td class="NLM_def"><p class="first last">reporter gene assay</p></td></tr><tr><td class="NLM_term">rGLP-2R</td><td class="NLM_def"><p class="first last">rat GLP-2 receptor</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">Thi</td><td class="NLM_def"><p class="first last">β-(2-thienyl)alanine</p></td></tr><tr><td class="NLM_term">3Thi</td><td class="NLM_def"><p class="first last">β-(3-thienyl)alanine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 67 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Wideman, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covey, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. J.</span><span> </span><span class="NLM_article-title">A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2744</span><span class="NLM_x">–</span> <span class="NLM_lpage">2752</span><span class="refDoi"> DOI: 10.2337/db07-0563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.2337%2Fdb07-0563" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2007&pages=2744-2752&author=R.+D.+Widemanauthor=S.+D.+Coveyauthor=G.+C.+Webbauthor=D.+J.+Druckerauthor=T.+J.+Kieffer&title=A+switch+from+prohormone+convertase+%28PC%29-2+to+PC1%2F3+expression+in+transplanted+alpha-cells+is+accompanied+by+differential+processing+of+proglucagon+and+improved+glucose+homeostasis+in+mice&doi=10.2337%2Fdb07-0563"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2337%2Fdb07-0563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb07-0563%26sid%3Dliteratum%253Aachs%26aulast%3DWideman%26aufirst%3DR.%2BD.%26aulast%3DCovey%26aufirst%3DS.%2BD.%26aulast%3DWebb%26aufirst%3DG.%2BC.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DKieffer%26aufirst%3DT.%2BJ.%26atitle%3DA%2520switch%2520from%2520prohormone%2520convertase%2520%2528PC%2529-2%2520to%2520PC1%252F3%2520expression%2520in%2520transplanted%2520alpha-cells%2520is%2520accompanied%2520by%2520differential%2520processing%2520of%2520proglucagon%2520and%2520improved%2520glucose%2520homeostasis%2520in%2520mice%26jtitle%3DDiabetes%26date%3D2007%26volume%3D56%26spage%3D2744%26epage%3D2752%26doi%3D10.2337%2Fdb07-0563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Buhl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thim, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kofod, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orskov, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Naturally occurring products of proglucagon 111–160 in the porcine and human small intestine</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">8621</span><span class="NLM_x">–</span> <span class="NLM_lpage">8624</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1988&pages=8621-8624&author=T.+Buhlauthor=L.+Thimauthor=H.+Kofodauthor=C.+Orskovauthor=H.+Harlingauthor=J.+J.+Holst&title=Naturally+occurring+products+of+proglucagon+111%E2%80%93160+in+the+porcine+and+human+small+intestine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DThim%26aufirst%3DL.%26aulast%3DKofod%26aufirst%3DH.%26aulast%3DOrskov%26aufirst%3DC.%26aulast%3DHarling%26aufirst%3DH.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DNaturally%2520occurring%2520products%2520of%2520proglucagon%2520111%25E2%2580%2593160%2520in%2520the%2520porcine%2520and%2520human%2520small%2520intestine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1988%26volume%3D263%26spage%3D8621%26epage%3D8624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Munroe, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kooshesh, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizkalla, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demchyshyn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamboj, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumner-Smith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crivici, A.</span><span> </span><span class="NLM_article-title">Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">1569</span><span class="NLM_x">–</span> <span class="NLM_lpage">1573</span><span class="refDoi"> DOI: 10.1073/pnas.96.4.1569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1073%2Fpnas.96.4.1569" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=1569-1573&author=D.+G.+Munroeauthor=A.+K.+Guptaauthor=F.+Koosheshauthor=T.+B.+Vyasauthor=G.+Rizkallaauthor=H.+Wangauthor=L.+Demchyshynauthor=Z.+J.+Yangauthor=R.+K.+Kambojauthor=H.+Chenauthor=K.+McCallumauthor=M.+Sumner-Smithauthor=D.+J.+Druckerauthor=A.+Crivici&title=Prototypic+G+protein-coupled+receptor+for+the+intestinotrophic+factor+glucagon-like+peptide+2&doi=10.1073%2Fpnas.96.4.1569"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.4.1569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.4.1569%26sid%3Dliteratum%253Aachs%26aulast%3DMunroe%26aufirst%3DD.%2BG.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DKooshesh%26aufirst%3DF.%26aulast%3DVyas%26aufirst%3DT.%2BB.%26aulast%3DRizkalla%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DDemchyshyn%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DZ.%2BJ.%26aulast%3DKamboj%26aufirst%3DR.%2BK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMcCallum%26aufirst%3DK.%26aulast%3DSumner-Smith%26aufirst%3DM.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DCrivici%26aufirst%3DA.%26atitle%3DPrototypic%2520G%2520protein-coupled%2520receptor%2520for%2520the%2520intestinotrophic%2520factor%2520glucagon-like%2520peptide%25202%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D1569%26epage%3D1573%26doi%3D10.1073%2Fpnas.96.4.1569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Pedersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brix, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunddal, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenkilde, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orskov, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine</span> <span class="citation_source-journal">Peptides</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.1016/j.peptides.2015.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2Fj.peptides.2015.02.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=20-28&author=J.+Pedersenauthor=N.+B.+Pedersenauthor=S.+W.+Brixauthor=K.+V.+Grunddalauthor=M.+M.+Rosenkildeauthor=B.+Hartmannauthor=C.+Orskovauthor=S.+S.+Poulsenauthor=J.+J.+Holst&title=The+glucagon-like+peptide+2+receptor+is+expressed+in+enteric+neurons+and+not+in+the+epithelium+of+the+intestine&doi=10.1016%2Fj.peptides.2015.02.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2015.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2015.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DJ.%26aulast%3DPedersen%26aufirst%3DN.%2BB.%26aulast%3DBrix%26aufirst%3DS.%2BW.%26aulast%3DGrunddal%26aufirst%3DK.%2BV.%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26aulast%3DHartmann%26aufirst%3DB.%26aulast%3DOrskov%26aufirst%3DC.%26aulast%3DPoulsen%26aufirst%3DS.%2BS.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520glucagon-like%2520peptide%25202%2520receptor%2520is%2520expressed%2520in%2520enteric%2520neurons%2520and%2520not%2520in%2520the%2520epithelium%2520of%2520the%2520intestine%26jtitle%3DPeptides%26date%3D2015%26volume%3D67%26spage%3D20%26epage%3D28%26doi%3D10.1016%2Fj.peptides.2015.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 2</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">1759</span><span class="NLM_x">–</span> <span class="NLM_lpage">1764</span><span class="refDoi"> DOI: 10.1210/jcem.86.4.7386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1210%2Fjcem.86.4.7386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=11297614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVCksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2001&pages=1759-1764&author=D.+J.+Drucker&title=Glucagon-like+peptide+2&doi=10.1210%2Fjcem.86.4.7386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 2</span></div><div class="casAuthors">Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1759-1764</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review with 81 refs.  Glucagon-like peptide 2 (GLP-2) is a 33 amino acid peptide-encoded carboxyterminal to the sequence of GLP-1 in the proglucagon gene.  Both GLP-1 and GLP-2 are secreted from gut endocrine cells and promote nutrient absorption through distinct mechanisms of action.  GLP-2 regulates gastric motility, gastric acid secretion, intestinal hexose transport, and increases the barrier function of the gut epithelium.  GLP-2 significantly enhances the surface area of the mucosal epithelium via stimulation of crypt cell proliferation and inhibition of apoptosis in the enterocyte and crypt compartments.  The cytoprotective and reparative effects of GLP-2 are evident in rodent models of exptl. intestinal injury.  GLP-2 reduces mortality and decreases mucosal injury, cytokine expression, and bacterial septicemia in the setting of small and large bowel inflammation.  GLP-2 also enhances nutrient absorption and gut adaptation in rodents or humans with short bowel syndrome.  The actions of GLP-2 are transduced by the GLP-2 receptor, a G protein-coupled receptor expressed in gut endocrine cells of the stomach, small bowel, and colon.  Activation of GLP-2 receptor signaling in heterologous cells promotes resistance to apoptotic injury in vitro.  The cytoprotective, reparative, and energy-retentive properties of GLP-2 suggests that GLP-2 may potentially be useful for the treatment of human disorders characterized by injury and/or dysfunction of the intestinal mucosal epithelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzFyysyDV6erVg90H21EOLACvtfcHk0lg2HCXMolw4UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVCksL0%253D&md5=bea3fcff269a4b6955383fe7204d7e02</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1210%2Fjcem.86.4.7386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.86.4.7386%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DGlucagon-like%2520peptide%25202%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2001%26volume%3D86%26spage%3D1759%26epage%3D1764%26doi%3D10.1210%2Fjcem.86.4.7386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2</span> <span class="citation_source-journal">Regul. Pept.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/S0167-0115(00)00185-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2FS0167-0115%2800%2900185-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=11033052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntF2htbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2000&pages=45-51&author=J.+J.+Holst&title=Gut+hormones+as+pharmaceuticals.+From+enteroglucagon+to+GLP-1+and+GLP-2&doi=10.1016%2FS0167-0115%2800%2900185-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2</span></div><div class="casAuthors">Holst, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">45-51</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 77 refs. is given on the glucagon-like peptides of the gut and their physiol. and pharmacol. potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2tDt8Jc8Co7Vg90H21EOLACvtfcHk0lg2HCXMolw4UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntF2htbs%253D&md5=af90fb08baa95a2cdecb59e55b1b2870</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0167-0115%2800%2900185-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-0115%252800%252900185-3%26sid%3Dliteratum%253Aachs%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DGut%2520hormones%2520as%2520pharmaceuticals.%2520From%2520enteroglucagon%2520to%2520GLP-1%2520and%2520GLP-2%26jtitle%3DRegul.%2520Pept.%26date%3D2000%26volume%3D93%26spage%3D45%26epage%3D51%26doi%3D10.1016%2FS0167-0115%2800%2900185-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Estall, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2</span> <span class="citation_source-journal">Annu. Rev. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span><span class="refDoi"> DOI: 10.1146/annurev.nutr.26.061505.111223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1146%2Fannurev.nutr.26.061505.111223" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=391-411&author=J.+L.+Estallauthor=D.+J.+Drucker&title=Glucagon-like+peptide-2&doi=10.1146%2Fannurev.nutr.26.061505.111223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1146%2Fannurev.nutr.26.061505.111223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.nutr.26.061505.111223%26sid%3Dliteratum%253Aachs%26aulast%3DEstall%26aufirst%3DJ.%2BL.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DGlucagon-like%2520peptide-2%26jtitle%3DAnnu.%2520Rev.%2520Nutr.%26date%3D2006%26volume%3D26%26spage%3D391%26epage%3D411%26doi%3D10.1146%2Fannurev.nutr.26.061505.111223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wallis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forbes, A.</span><span> </span><span class="NLM_article-title">Review article: Glucagon-like peptide 2--current applications and future directions</span> <span class="citation_source-journal">Aliment. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.1111/j.1365-2036.2006.03193.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1111%2Fj.1365-2036.2006.03193.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=17217448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Glurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=365-372&author=K.+Wallisauthor=J.+R.+Waltersauthor=A.+Forbes&title=Review+article%3A+Glucagon-like+peptide+2%2D%2Dcurrent+applications+and+future+directions&doi=10.1111%2Fj.1365-2036.2006.03193.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Review article: glucagon-like peptide 2 - current applications and future directions</span></div><div class="casAuthors">Wallis, K.; Walters, J. R. F.; Forbes, A.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">365-372</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide 2 (GLP-2) is an important peptide growth factor secreted from the human intestine.  The trophic properties of GLP-2 are very specific to the gut where it is pivotal in the regulation of mucosal morphol., function and integrity.  This review details the current understanding of the mol. biol. of GLP-2, its mechanisms of action and physiol. properties.  A major focus is the discussion of recent clin. data evaluating the use of GLP-2 as a therapeutic agent.  Relevant articles were identified using Medline searches and from the ref. lists of key papers.  In the treatment of short bowel syndrome, GLP-2 has been shown to be highly effective in improving fluid absorption.  In Crohn's disease, GLP-2 is superior to placebo in the induction of remission.  Early data also suggest that the effects of GLP-2 on bone metab. can provide a new treatment approach for patients with osteoporosis.  In the future, the pos. effects of GLP-2 on intestinal barrier function, splanchnic perfusion and mucosal healing could be utilized to expand its therapeutic application to other causes of intestinal injury.  However, important safety aspects need to be considered when using this potent growth-promoting agent for a long term.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOfM-8VKLCp7Vg90H21EOLACvtfcHk0lh3Pgo8Oby1TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Glurg%253D&md5=51c699d29898a231b644fbf753b6bb9e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2036.2006.03193.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2036.2006.03193.x%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DK.%26aulast%3DWalters%26aufirst%3DJ.%2BR.%26aulast%3DForbes%26aufirst%3DA.%26atitle%3DReview%2520article%253A%2520Glucagon-like%2520peptide%25202--current%2520applications%2520and%2520future%2520directions%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2007%26volume%3D25%26spage%3D365%26epage%3D372%26doi%3D10.1111%2Fj.1365-2036.2006.03193.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Thulesen, J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator</span> <span class="citation_source-journal">Curr. Protein Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span><span class="refDoi"> DOI: 10.2174/1389203043486946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.2174%2F1389203043486946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=14965320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVCmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=51-65&author=J.+Thulesen&title=Glucagon-like+peptide+2+%28GLP-2%29%2C+an+intestinotrophic+mediator&doi=10.2174%2F1389203043486946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator</span></div><div class="casAuthors">Thulesen, J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Protein and Peptide Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-65</span>CODEN:
                <span class="NLM_cas:coden">CPPSCM</span>;
        ISSN:<span class="NLM_cas:issn">1389-2037</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide 2 (GLP-2) is a newly discovered gastrointestinal peptide with 33% sequence homol. to glucagon.  GLP-2 has attracted interest because of its potent intestinotrophic endocrine/paracrine actions.  The peptide, consisting of 33 amino acids, results from expression of the glucagon gene in the enteroendocrine L-cells of the intestinal mucosa, from where it is released mainly in response to luminal contact with unabsorbed nutrients.  In addn. to mucosal growth, GLP-2 enhances activities of several intestinal brush-border enzymes, and it delays gastric transit, thereby increasing the intestinal capacity for nutrient absorption.  Thus, it appears that GLP-2 serves to ensure an optimal intestinal capacity.  The physiol. responses following exogenous administration of GLP-2 have been intensely investigated, and these appear to be rather specific for the gut, which is concordant with the localization of the GLP-2 receptor.  In addn., treatment with GLP-2 in exptl. animal models of several enteropathies indicates that GLP-2 ameliorates most of the obsd. intestinal abnormalities in these conditions.  Following secretion to the blood stream, the intact peptide is degraded rather rapidly by an aminopeptidase.  To circumvent the rapid and widespread metab. of intact GLP-2, degrdn.-resistant synthetic GLP-2 analogs have been developed together with other approaches, such as inhibition of the GLP-2 degrading enzyme.  This is of particular interest with respect to developing GLP-2 into a useful therapeutic agent in conditions with compromised intestinal function, since the first clin. trial has already indicated the potential of GLP-2 treatment in patients with short bowel syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxoJuIHb_JB7Vg90H21EOLACvtfcHk0lh3Pgo8Oby1TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVCmt70%253D&md5=f78a264eb5a30f5830600a5b0741c553</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F1389203043486946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389203043486946%26sid%3Dliteratum%253Aachs%26aulast%3DThulesen%26aufirst%3DJ.%26atitle%3DGlucagon-like%2520peptide%25202%2520%2528GLP-2%2529%252C%2520an%2520intestinotrophic%2520mediator%26jtitle%3DCurr.%2520Protein%2520Pept.%2520Sci.%26date%3D2004%26volume%3D5%26spage%3D51%26epage%3D65%26doi%3D10.2174%2F1389203043486946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusta, B.</span><span> </span><span class="NLM_article-title">Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2</span> <span class="citation_source-journal">Annu. Rev. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span><span class="refDoi"> DOI: 10.1146/annurev-physiol-021113-170317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1146%2Fannurev-physiol-021113-170317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=24161075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVCmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=561-583&author=D.+J.+Druckerauthor=B.+Yusta&title=Physiology+and+pharmacology+of+the+enteroendocrine+hormone+glucagon-like+peptide-2&doi=10.1146%2Fannurev-physiol-021113-170317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2</span></div><div class="casAuthors">Drucker, Daniel J.; Yusta, Bernardo</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">561-583</span>CODEN:
                <span class="NLM_cas:coden">ARPHAD</span>;
        ISSN:<span class="NLM_cas:issn">0066-4278</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid proglucagon-derived peptide secreted from enteroendocrine L cells.  GLP-2 circulates at low basal levels in the fasting period, and plasma levels rise rapidly after food ingestion.  Renal clearance and enzymic inactivation control the elimination of bioactive GLP-2.  GLP-2 increases mesenteric blood flow and activates proabsorptive pathways in the gut, facilitating nutrient absorption.  GLP-2 also enhances gut barrier function and induces proliferative and cytoprotective pathways in the small bowel.  The actions of GLP-2 are transduced via a single G protein-coupled receptor (GLP-2R), expressed predominantly within the gastrointestinal tract.  Disruption of GLP-2R signaling increases susceptibility to gut injury and impairs the adaptive mucosal response to refeeding.  Sustained augmentation of GLP-2R signaling reduces the requirement for parenteral nutrition in human subjects with short-bowel syndrome.  Hence GLP-2 integrates nutrient-derived signals to optimize mucosal integrity and energy absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol4vDm4UO_zrVg90H21EOLACvtfcHk0lh3Pgo8Oby1TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVCmtro%253D&md5=fa17b789eb9ec08042186b1d89d143a4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1146%2Fannurev-physiol-021113-170317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-physiol-021113-170317%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DYusta%26aufirst%3DB.%26atitle%3DPhysiology%2520and%2520pharmacology%2520of%2520the%2520enteroendocrine%2520hormone%2520glucagon-like%2520peptide-2%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2014%26volume%3D76%26spage%3D561%26epage%3D583%26doi%3D10.1146%2Fannurev-physiol-021113-170317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asa, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span> </span><span class="NLM_article-title">Induction of intestinal epithelial proliferation by glucagon-like peptide 2</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">7911</span><span class="NLM_x">–</span> <span class="NLM_lpage">7916</span><span class="refDoi"> DOI: 10.1073/pnas.93.15.7911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1073%2Fpnas.93.15.7911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=8755576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaK28XksFSrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=7911-7916&author=D.+J.+Druckerauthor=P.+Erlichauthor=S.+L.+Asaauthor=P.+L.+Brubaker&title=Induction+of+intestinal+epithelial+proliferation+by+glucagon-like+peptide+2&doi=10.1073%2Fpnas.93.15.7911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of intestinal epithelial proliferation by glucagon-like peptide 2</span></div><div class="casAuthors">Drucker, Daniel J.; Ehrlich, Peter; Asa, Sylvia L.; Brubaker, Patrical L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7911-7916</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Injury, inflammation, or resection of the small intestine results in severe compromise of intestinal function.  Nevertheless, therapeutic strategies for enhancing growth and repair of the intestinal mucosal epithelium are currently not available.  We demonstrate that nude mice bearing s.c. proglucagon-producing tumors exhibit marked proliferation of the small intestinal epithelium.  The factor responsible for inducing intestinal proliferation was identified as glucagon-like peptide 2 (GLP-2), a 33-amino acid peptide with no previously ascribed biol. function.  GLP-2 stimulated crypt cell proliferation and consistently induced a marked increase in bowel wt. and villus growth of the jejunum and ileum that was evident within 4 days after initiation of GLP-2 administration.  These observations define a novel biol. role for GLP-2 as an intestinal-derived peptide stimulator of small bowel epithelial proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo49R9X6QMYXLVg90H21EOLACvtfcHk0ljkU9Q9B0gScQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFSrtbw%253D&md5=5c75a93928611978a52f2ef00ee32088</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.15.7911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.15.7911%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DErlich%26aufirst%3DP.%26aulast%3DAsa%26aufirst%3DS.%2BL.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26atitle%3DInduction%2520of%2520intestinal%2520epithelial%2520proliferation%2520by%2520glucagon-like%2520peptide%25202%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D7911%26epage%3D7916%26doi%3D10.1073%2Fpnas.93.15.7911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Tsai, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asa, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Intestinal growth-promoting properties of glucagon-like peptide-2 in mice</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">E77</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1997&pages=E77-84&author=C.+H.+Tsaiauthor=M.+Hillauthor=S.+L.+Asaauthor=P.+L.+Brubakerauthor=D.+J.+Drucker&title=Intestinal+growth-promoting+properties+of+glucagon-like+peptide-2+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DC.%2BH.%26aulast%3DHill%26aufirst%3DM.%26aulast%3DAsa%26aufirst%3DS.%2BL.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DIntestinal%2520growth-promoting%2520properties%2520of%2520glucagon-like%2520peptide-2%2520in%2520mice%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1997%26volume%3D273%26spage%3DE77%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Meier, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nauck, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinze, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetze, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulut, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallwitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1053/j.gastro.2005.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1053%2Fj.gastro.2005.10.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2006&pages=44-54&author=J.+J.+Meierauthor=M.+A.+Nauckauthor=A.+Pottauthor=K.+Heinzeauthor=O.+Goetzeauthor=K.+Bulutauthor=W.+E.+Schmidtauthor=B.+Gallwitzauthor=J.+J.+Holst&title=Glucagon-like+peptide+2+stimulates+glucagon+secretion%2C+enhances+lipid+absorption%2C+and+inhibits+gastric+acid+secretion+in+humans&doi=10.1053%2Fj.gastro.2005.10.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2005.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2005.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26aulast%3DNauck%26aufirst%3DM.%2BA.%26aulast%3DPott%26aufirst%3DA.%26aulast%3DHeinze%26aufirst%3DK.%26aulast%3DGoetze%26aufirst%3DO.%26aulast%3DBulut%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DW.%2BE.%26aulast%3DGallwitz%26aufirst%3DB.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DGlucagon-like%2520peptide%25202%2520stimulates%2520glucagon%2520secretion%252C%2520enhances%2520lipid%2520absorption%252C%2520and%2520inhibits%2520gastric%2520acid%2520secretion%2520in%2520humans%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D130%26spage%3D44%26epage%3D54%26doi%3D10.1053%2Fj.gastro.2005.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hsieh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longuet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maida, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahrami, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adeli, K.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">997</span><span class="NLM_x">–</span> <span class="NLM_lpage">1005</span><span class="refDoi"> DOI: 10.1053/j.gastro.2009.05.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1053%2Fj.gastro.2009.05.051" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=997-1005&author=J.+Hsiehauthor=C.+Longuetauthor=A.+Maidaauthor=J.+Bahramiauthor=E.+Xuauthor=C.+L.+Bakerauthor=P.+L.+Brubakerauthor=D.+J.+Druckerauthor=K.+Adeli&title=Glucagon-like+peptide-2+increases+intestinal+lipid+absorption+and+chylomicron+production+via+CD36&doi=10.1053%2Fj.gastro.2009.05.051"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2009.05.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2009.05.051%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DJ.%26aulast%3DLonguet%26aufirst%3DC.%26aulast%3DMaida%26aufirst%3DA.%26aulast%3DBahrami%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DE.%26aulast%3DBaker%26aufirst%3DC.%2BL.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DAdeli%26aufirst%3DK.%26atitle%3DGlucagon-like%2520peptide-2%2520increases%2520intestinal%2520lipid%2520absorption%2520and%2520chylomicron%2520production%2520via%2520CD36%26jtitle%3DGastroenterology%26date%3D2009%26volume%3D137%26spage%3D997%26epage%3D1005%26doi%3D10.1053%2Fj.gastro.2009.05.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Bremholm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henriksen, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2 increases mesenteric blood flow in humans</span> <span class="citation_source-journal">Scand. J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">319</span><span class="refDoi"> DOI: 10.1080/00365520802538195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1080%2F00365520802538195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=19005872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1equr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=314-319&author=L.+Bremholmauthor=M.+Hornumauthor=B.+M.+Henriksenauthor=S.+Larsenauthor=J.+J.+Holst&title=Glucagon-like+peptide-2+increases+mesenteric+blood+flow+in+humans&doi=10.1080%2F00365520802538195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide-2 increases mesenteric blood flow in humans</span></div><div class="casAuthors">Bremholm, Lasse; Hornum, Mads; Henriksen, Birthe Merete; Larsen, Steen; Holst, Jens Juul</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-319</span>CODEN:
                <span class="NLM_cas:coden">SJGRA4</span>;
        ISSN:<span class="NLM_cas:issn">0036-5521</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Mesenteric blood flow is believed to be influenced by digestion and absorption of ingested macronutrients.  We hypothesized that the intestinotrophic hormone, GLP-2 (glucagons-like peptide 2), may be involved in the regulation of mesenteric blood flow.  Changes in mesenteric blood flow were measured by Doppler ultrasound scanning of the superior mesenteric artery (SMA).  The aim of the study was to demonstrate the influence of GLP-2 on this flow, expressed as changes in resistance index (RI).  A homogeneous group of 10 fasting healthy volunteers completed a 2-day trial.  On day 1, a std. meal was given, and RI measured in the SMA.  On day 2, GLP-2 was infused i.v. at rates of 0.5, 1.0 and 2.0 pmol/kg/min over 3×45 min sepd. by a 15-20 min rest period.  After a further 15-20 min of rest, 450 nmol synthetic GLP-2 was given s.c..  RI in the SMA was measured before, during and after the meal and GLP-2 infusions.  After i.v. infusion of GLP-2, the following decreases in RI were obsd.: 0.5 pmol/kg/min: 2.7% (range 0-6.3%), 1.0 pmol/kg/min: 6.7% (range 0.4-15.9%), 2.0 pmol/kg/min: 15.3% (range 9.6-22.7%) p<0.00802.  When given s.c., GLP-2 elicited a max. av. change in RI of 15.6% (range 5.0-28.1%).  The std. meal elicited a 14.7% (range 8.8-21.6%) change, p<0.020 There was a similar change in RI over time (0-90 min) after a std. meal and after s.c. GLP-2, p<0.005.  Our study showed a significant assocn. between i.v. and s.c. administration of synthetic GLP-2 and changes in mesenteric blood flow.  An exponential dose-response relationship was obsd. after i.v. infusion.  The meal-induced changes in mesenteric blood flow over time were similar to those obtained by s.c. GLP-2.  Thus, our results support the hypothesis that GLP-2 is an important regulator of mesenteric blood flow.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6NX4dU8aOeLVg90H21EOLACvtfcHk0ljkU9Q9B0gScQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1equr8%253D&md5=5a317c3a06e002ae57421ff1ce433ac1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1080%2F00365520802538195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00365520802538195%26sid%3Dliteratum%253Aachs%26aulast%3DBremholm%26aufirst%3DL.%26aulast%3DHornum%26aufirst%3DM.%26aulast%3DHenriksen%26aufirst%3DB.%2BM.%26aulast%3DLarsen%26aufirst%3DS.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DGlucagon-like%2520peptide-2%2520increases%2520mesenteric%2520blood%2520flow%2520in%2520humans%26jtitle%3DScand.%2520J.%2520Gastroenterol.%26date%3D2009%26volume%3D44%26spage%3D314%26epage%3D319%26doi%3D10.1080%2F00365520802538195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Stephens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoll, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottrell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helmrath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrin, D. G.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in tpn-fed neonatal piglets</span> <span class="citation_source-journal">Am. J. Physiol. Regul. Integr. Comp. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">R283</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span><span class="refDoi"> DOI: 10.1152/ajpregu.00588.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1152%2Fajpregu.00588.2005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2006&pages=R283-289&author=J.+Stephensauthor=B.+Stollauthor=J.+Cottrellauthor=X.+Changauthor=M.+Helmrathauthor=D.+G.+Burrin&title=Glucagon-like+peptide-2+acutely+increases+proximal+small+intestinal+blood+flow+in+tpn-fed+neonatal+piglets&doi=10.1152%2Fajpregu.00588.2005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1152%2Fajpregu.00588.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpregu.00588.2005%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DJ.%26aulast%3DStoll%26aufirst%3DB.%26aulast%3DCottrell%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DX.%26aulast%3DHelmrath%26aufirst%3DM.%26aulast%3DBurrin%26aufirst%3DD.%2BG.%26atitle%3DGlucagon-like%2520peptide-2%2520acutely%2520increases%2520proximal%2520small%2520intestinal%2520blood%2520flow%2520in%2520tpn-fed%2520neonatal%2520piglets%26jtitle%3DAm.%2520J.%2520Physiol.%2520Regul.%2520Integr.%2520Comp.%2520Physiol.%26date%3D2006%26volume%3D290%26spage%3DR283%26epage%3D289%26doi%3D10.1152%2Fajpregu.00588.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Nagell, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wettergren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortensen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1</span> <span class="citation_source-journal">Scand. J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">358</span><span class="refDoi"> DOI: 10.1080/00365520410004424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1080%2F00365520410004424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=15125467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFCnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2004&pages=353-358&author=C.+F.+Nagellauthor=A.+Wettergrenauthor=J.+F.+Pedersenauthor=D.+Mortensenauthor=J.+J.+Holst&title=Glucagon-like+peptide-2+inhibits+antral+emptying+in+man%2C+but+is+not+as+potent+as+glucagon-like+peptide-1&doi=10.1080%2F00365520410004424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1</span></div><div class="casAuthors">Nagell, C. F.; Wettergren, A.; Pedersen, J. F.; Mortensen, D.; Holst, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-358</span>CODEN:
                <span class="NLM_cas:coden">SJGRA4</span>;
        ISSN:<span class="NLM_cas:issn">0036-5521</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis</span>)
        </div><div class="casAbstract">GLP-1 (glucagon-like peptide-1) and GLP-2 (glucagon-like peptide-2) are released in equimolar amts. in response to meal ingestion.  GLP-1 inhibits gastric emptying and reduces postprandial gastric and exocrine pancreatic secretion and may play a physiol. regulatory role in controlling appetite and energy intake in humans.  The role of GLP-2 is more uncertain.  Based on the results of animal studies, it was suggested that GLP-2 may induce intestinal epithelial growth and inhibit gastric motility.  The aim of this study was to det. to what extent GLP-2 alone or together with GLP-1 inhibits gastric emptying and the sensation of hunger in man.  Eight healthy volunteers were tested in a double-blind, placebo-controlled fashion.  Antral emptying of a liq. meal and hunger ratings were detd. using ultrasound technol. and visual analog scales scoring during infusions of saline, GLP-2 (0.5, and 1.0 pmol kg body wt min), GLP-1 (0.5 pmol kg body wt min) or GLP-1 and GLP-2 (0.5 pmol kg body wt min).  The GLP-2 infusions resulted in a dose-dependent increase in antral emptying time (35%; ns and 75%; P = 0.049) compared to saline, but GLP-2 was less potent than GLP-1, which increased the antral emptying time by 192% (P < 0.001).  Addn. of GLP-2 to the GLP-1 infusion did not alter the antral emptying time compared with GLP-1 alone.  The GLP-1 infusion decreased the sensation of hunger compared with saline (P = 0.023), whereas the 2 GLP-2 infusions had no significant effect.  Addn. of GLP-2 to the GLP-1 infusion did not decrease the sensation of hunger further.  Both GLP-1 and GLP-2 inhibit antral emptying in man, but GLP-1 is more potent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmDASIseiU8rVg90H21EOLACvtfcHk0ljdPmHQHxxyGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFCnt7o%253D&md5=302b23d3dc4da159f5ecd969ed994099</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F00365520410004424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00365520410004424%26sid%3Dliteratum%253Aachs%26aulast%3DNagell%26aufirst%3DC.%2BF.%26aulast%3DWettergren%26aufirst%3DA.%26aulast%3DPedersen%26aufirst%3DJ.%2BF.%26aulast%3DMortensen%26aufirst%3DD.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DGlucagon-like%2520peptide-2%2520inhibits%2520antral%2520emptying%2520in%2520man%252C%2520but%2520is%2520not%2520as%2520potent%2520as%2520glucagon-like%2520peptide-1%26jtitle%3DScand.%2520J.%2520Gastroenterol.%26date%3D2004%26volume%3D39%26spage%3D353%26epage%3D358%26doi%3D10.1080%2F00365520410004424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sigalet, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaji, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharkey, K. A.</span><span> </span><span class="NLM_article-title">Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2</span> <span class="citation_source-journal">Am. J. Physiol. Gastrointest. Liver Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">293</span><span class="NLM_x">, </span> <span class="NLM_fpage">G211</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1152/ajpgi.00530.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1152%2Fajpgi.00530.2006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2007&pages=G211-221&author=D.+L.+Sigaletauthor=L.+E.+Wallaceauthor=J.+J.+Holstauthor=G.+R.+Martinauthor=T.+Kajiauthor=H.+Tanakaauthor=K.+A.+Sharkey&title=Enteric+neural+pathways+mediate+the+anti-inflammatory+actions+of+glucagon-like+peptide+2&doi=10.1152%2Fajpgi.00530.2006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.00530.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.00530.2006%26sid%3Dliteratum%253Aachs%26aulast%3DSigalet%26aufirst%3DD.%2BL.%26aulast%3DWallace%26aufirst%3DL.%2BE.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DG.%2BR.%26aulast%3DKaji%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DSharkey%26aufirst%3DK.%2BA.%26atitle%3DEnteric%2520neural%2520pathways%2520mediate%2520the%2520anti-inflammatory%2520actions%2520of%2520glucagon-like%2520peptide%25202%26jtitle%3DAm.%2520J.%2520Physiol.%2520Gastrointest.%2520Liver%2520Physiol.%26date%3D2007%26volume%3D293%26spage%3DG211%26epage%3D221%26doi%3D10.1152%2Fajpgi.00530.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Alavi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palazzo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, R.</span><span> </span><span class="NLM_article-title">Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2</span> <span class="citation_source-journal">J. Pediatr. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">851</span><span class="refDoi"> DOI: 10.1053/jpsu.2000.6861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1053%2Fjpsu.2000.6861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10873024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADC%252BD3cvps1Kitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=847-851&author=K.+Alaviauthor=M.+Z.+Schwartzauthor=J.+P.+Palazzoauthor=R.+Prasad&title=Treatment+of+inflammatory+bowel+disease+in+a+rodent+model+with+the+intestinal+growth+factor+glucagon-like+peptide-2&doi=10.1053%2Fjpsu.2000.6861"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2</span></div><div class="casAuthors">Alavi K; Schwartz M Z; Palazzo J P; Prasad R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pediatric surgery</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">847-51</span>
        ISSN:<span class="NLM_cas:issn">0022-3468</span>.
    </div><div class="casAbstract">BACKGROUND/PURPOSE:  Microinjection of a Fisher (F344) rat zygote with human HLA-B27 and beta2-microglobulin genes induces spontaneous chronic gastrointestinal (GI) inflammation similar to lesions seen in patients with inflammatory bowel disease (IBD).  This study was designed to evaluate the potential therapeutic benefit of GLP-2, an intestinal growth factor, in this transgenic rat model of IBD.  METHODS:  Five F344 (control) and 10 HLA-B27 (on a F344 background) rats at 25 weeks of age were used.  Rats were divided into the following 3 groups: group 1, F344 rats, no treatment (n = 5); group 2, HLA-B27, no treatment (n = 5); and group 3, HLA-B27, treated with a 14-day systemic infusion (via the jugular vein) of GLP-2 at 50 microg/kg/d (n = 5).  After infusion, all rats underwent laparotomy, and the intestine from the ligament of Treitz to the rectum was harvested.  Total mucosal damage (percent surface area) was measured using image analysis software (Sigmascan 2.0).  Microscopic analysis was performed by a blinded reviewer and scored as follows: 0, no inflammation; 1, mild inflammation; 2, moderate inflammation; and 3, severe inflammation.  Colonic mucosal total RNA was assayed for tumor necrosis factor alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-2 (IL-2), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), internal standard, mRNA by reverse transcriptase polymerase chain reaction.  Statistical analysis was performed using analysis of variance (ANOVA) and expressed as mean +/- SEM.  RESULTS:  Normal F344 rats did not show evidence of gross or histological lesions in the small or large intestine.  GLP-2 reduced total mucosal damage from 9.0% +/- 0.7% in group 2 to 0.9% +/- 0.5% in group 3 (P < .01).  The histological lesion score was reduced from 7.0 +/- 0.6 in group 2 to 4.4 +/- 0.8 in group 3 (P < .01).  Furthermore, GLP-2 reduced the mean band intensity (MBI) of TNF-alpha (0.4 +/- 0.04 in group 2 to 0 in group 3, P < .01) and IFN-gamma (0.3 +/- 0.02 in group 2 to 0 in group 3, P < .01).  CONCLUSIONS:  These data show for the first time that GLP-2 significantly reduces gross (90% decrease) and histological (40% decrease) lesions in this rat model of IBD.  This is further supported by a significant decrease in gene expression of the inflammatory mediators TNF-alpha (100% decrease) and IFN-gamma (100% decrease).  These data suggest a potential therapeutic role for GLP-2 in IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvBDi0Vltjy1MGsG_HTXYFfW6udTcc2eZclOzJCtddubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvps1Kitg%253D%253D&md5=e0ab22e4f8badab5a90945d71b6c9e62</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1053%2Fjpsu.2000.6861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fjpsu.2000.6861%26sid%3Dliteratum%253Aachs%26aulast%3DAlavi%26aufirst%3DK.%26aulast%3DSchwartz%26aufirst%3DM.%2BZ.%26aulast%3DPalazzo%26aufirst%3DJ.%2BP.%26aulast%3DPrasad%26aufirst%3DR.%26atitle%3DTreatment%2520of%2520inflammatory%2520bowel%2520disease%2520in%2520a%2520rodent%2520model%2520with%2520the%2520intestinal%2520growth%2520factor%2520glucagon-like%2520peptide-2%26jtitle%3DJ.%2520Pediatr.%2520Surg.%26date%3D2000%26volume%3D35%26spage%3D847%26epage%3D851%26doi%3D10.1053%2Fjpsu.2000.6861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Hartmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harr, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeppesen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojdemann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortensen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">In vivo and in vitro degradation of glucagon-like peptide-2 in humans</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">2884</span><span class="NLM_x">–</span> <span class="NLM_lpage">2888</span><span class="refDoi"> DOI: 10.1210/jcem.85.8.6717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1210%2Fjcem.85.8.6717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10946898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnslahsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2000&pages=2884-2888&author=B.+Hartmannauthor=M.+B.+Harrauthor=P.+B.+Jeppesenauthor=M.+Wojdemannauthor=C.+F.+Deaconauthor=P.+B.+Mortensenauthor=J.+J.+Holst&title=In+vivo+and+in+vitro+degradation+of+glucagon-like+peptide-2+in+humans&doi=10.1210%2Fjcem.85.8.6717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo and in vitro degradation of glucagon-like peptide-2 in humans</span></div><div class="casAuthors">Hartmann, Bolette; Harr, Mette B.; Jeppesen, Palle B.; Wojdemann, Morten; Deacon, Carolyn F.; Mortensen, Per B.; Holst, Jens J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2884-2888</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Glucagon-like peptide-2 (GLP-2), an intestinal product of glucagon gene expression which induces intestinal growth in mice, has been proposed as a treatment for intestinal insufficiency.  GLP-2 is metabolized extensively by dipeptidyl peptidase IV (DPP-IV) in rats, but less is known about its fate in humans.  Therefore, GLP-2 metab. was investigated in healthy volunteers after (1) a 500-Cal mixed meal (n = 6), (2) iv infusion of synthetic human GLP-2 (0.8 pmol/kg/min; n = 8), (3) a s.c. bolus injection (400 μg; n = 9), and (4) in vitro incubation in plasma and blood (1000 pmol/L; n = 4) .  GLP-2 concns. were detd. by N-terminal RIA measuring only intact GLP-2, side-viewing RIA measuring intact and degraded forms [e.g. GLP-2-(3-33) arising from DPP-IV degrdn.], and high performance liq. chromatog. (HPLC).  Meal ingestion elevated plasma GLP-2 (intact, 16 ± 3 to 73 ± 10 pmol/L at 90 min), and HPLC revealed two immunoreactive components: intact GLP-2 (57 ± 2%) and GLP-2-(3-33).  GLP-2 infusion increased plasma levels [intact, 9 ± 4 to 131 ± 11 pmol/L; total, 23 ± 7 to 350 ± 18 pmol/L; the differences represent GLP-2-(3-33)].  The elimination t1/2 values were 7.2 ± 2 min (intact GLP-2) and 27.4 ± 5.4 min [GLP-2-(3-33)], and MCRs were 6.8 ± 0.6 and 1.9 ± 0.3 mL/kg/min, resp.  S.c. injection increased intact GLP-2 to maximally 1493 ± 250 pmol/L at 45 min, whereas total GLP-2 increased to 2793 ± 477 pmol/L at 90 min.  At 60 min, plasma contained 69 ± 1% intact GLP-2.  In vitro the t1/2 values were 8.0 ± 1.5 h (plasma) and 3.3 ± 0.3 h (blood).  GLP-2-(3-33) was the only degrdn. product identified by HPLC, and a DPP-IV inhibitor abolished the degrdn. of GLP-2 in vitro.  We conclude that GLP-2 is extensively degraded to GLP-2-(3-33) in humans, presumably by DPP-IV.  Nevertheless, 69% remains intact 1 h after GLP-2 injection, supporting the possibility of s.c. use in patients with intestinal insufficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoezfRJnBcJG7Vg90H21EOLACvtfcHk0liLoeEBxRGaQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnslahsb4%253D&md5=4e9dd22c8d3ff5f5e0301162ad60dee8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1210%2Fjcem.85.8.6717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.85.8.6717%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DB.%26aulast%3DHarr%26aufirst%3DM.%2BB.%26aulast%3DJeppesen%26aufirst%3DP.%2BB.%26aulast%3DWojdemann%26aufirst%3DM.%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26aulast%3DMortensen%26aufirst%3DP.%2BB.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DIn%2520vivo%2520and%2520in%2520vitro%2520degradation%2520of%2520glucagon-like%2520peptide-2%2520in%2520humans%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2000%26volume%3D85%26spage%3D2884%26epage%3D2888%26doi%3D10.1210%2Fjcem.85.8.6717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crivici, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumner-Smith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeForest, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span> </span><span class="NLM_article-title">Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span><span class="refDoi"> DOI: 10.1038/nbt0797-673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1038%2Fnbt0797-673" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1997&pages=673-677&author=D.+J.+Druckerauthor=Q.+Shiauthor=A.+Criviciauthor=M.+Sumner-Smithauthor=W.+Tavaresauthor=M.+Hillauthor=L.+DeForestauthor=S.+Cooperauthor=P.+L.+Brubaker&title=Regulation+of+the+biological+activity+of+glucagon-like+peptide+2+in+vivo+by+dipeptidyl+peptidase+IV&doi=10.1038%2Fnbt0797-673"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt0797-673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0797-673%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DCrivici%26aufirst%3DA.%26aulast%3DSumner-Smith%26aufirst%3DM.%26aulast%3DTavares%26aufirst%3DW.%26aulast%3DHill%26aufirst%3DM.%26aulast%3DDeForest%26aufirst%3DL.%26aulast%3DCooper%26aufirst%3DS.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26atitle%3DRegulation%2520of%2520the%2520biological%2520activity%2520of%2520glucagon-like%2520peptide%25202%2520in%2520vivo%2520by%2520dipeptidyl%2520peptidase%2520IV%26jtitle%3DNat.%2520Biotechnol.%26date%3D1997%26volume%3D15%26spage%3D673%26epage%3D677%26doi%3D10.1038%2Fnbt0797-673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Thulesen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastrup, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissow, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeppesen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orskov, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, S. S.</span><span> </span><span class="NLM_article-title">The truncated metabolite GLP-2 (3–33) interacts with the GLP-2 receptor as a partial agonist</span> <span class="citation_source-journal">Regul. Pept.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1016/S0167-0115(01)00316-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2FS0167-0115%2801%2900316-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=11738243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovVCjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2002&pages=9-15&author=J.+Thulesenauthor=L.+B.+Knudsenauthor=B.+Hartmannauthor=S.+Hastrupauthor=H.+Kissowauthor=P.+B.+Jeppesenauthor=C.+Orskovauthor=J.+J.+Holstauthor=S.+S.+Poulsen&title=The+truncated+metabolite+GLP-2+%283%E2%80%9333%29+interacts+with+the+GLP-2+receptor+as+a+partial+agonist&doi=10.1016%2FS0167-0115%2801%2900316-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist</span></div><div class="casAuthors">Thulesen, Jesper; Knudsen, Lotte Bjerre; Hartmann, Bolette; Hastrup, Sven; Kissow, Hannelouise; Jeppesen, Palle Bekker; Orskov, Cathrine; Holst, Jens Juul; Poulsen, Steen Seier</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-15</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The therapeutic potential of the intestinotrophic mediator glucagon-like peptide-2 (1-33) [GLP-2 (1-33)] has increased interest in the pharmacokinetics of the peptide.  This study was undertaken to investigate whether the primary degrdn. product GLP-2 (3-33) interacts with the GLP-2 receptor.  Functional (cAMP) and binding in vitro studies were carried out in cells expressing the transfected human GLP-2 receptor.  Furthermore, a biol. response of GLP-2 (3-33) was tested in vivo.  Mice were allocated to groups treated for 10 days (twice daily) with: (1) 5 μg GLP-2 (1-33), (2) 25 μg GLP-2 (3-33), (3) 5 μg GLP-2 (1-33) + 100 μg GLP-2 (3-33), or (4) 5 μg GLP-2 (1-33) + 500 μg GLP-2 (3-33).  The intestine was investigated for growth changes.  GLP-2 (3-33) bound to the GLP-2 receptor with a binding affinity of 7.5% of that of GLP-2 (1-33).  The cAMP accumulation was stimulated with an efficacy of 15% and a potency more than two orders of magnitude lower than that of GLP-2 (1-33).  Increasing doses of GLP-2 (3-33) (10-7-10-5 M) caused a shift to the right in the dose-response curve of GLP-2 (1-33).  Treatment of mice with either GLP-2 (1-33) or (3-33) induced significant growth responses in both the small and large intestines, but the response induced by GLP-2 (3-33) was much smaller.  Co-administration of 500 μg of GLP-2 (3-33) and 5 μg GLP-2 (1-33) resulted in a growth response that was smaller than that of 5 μg GLP-2 (1-33) alone.  Consistent with the obsd. in vivo activities, our functional studies and binding data indicate that GLP-2 (3-33) acts as a partial agonist with potential competitive antagonistic properties on the GLP-2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbdvWbDih5a7Vg90H21EOLACvtfcHk0ljDnaikAp-efA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovVCjt74%253D&md5=9b363b142168519ca7be07aac37ee47e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0167-0115%2801%2900316-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-0115%252801%252900316-0%26sid%3Dliteratum%253Aachs%26aulast%3DThulesen%26aufirst%3DJ.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DHartmann%26aufirst%3DB.%26aulast%3DHastrup%26aufirst%3DS.%26aulast%3DKissow%26aufirst%3DH.%26aulast%3DJeppesen%26aufirst%3DP.%2BB.%26aulast%3DOrskov%26aufirst%3DC.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DPoulsen%26aufirst%3DS.%2BS.%26atitle%3DThe%2520truncated%2520metabolite%2520GLP-2%2520%25283%25E2%2580%259333%2529%2520interacts%2520with%2520the%2520GLP-2%2520receptor%2520as%2520a%2520partial%2520agonist%26jtitle%3DRegul.%2520Pept.%26date%3D2002%26volume%3D103%26spage%3D9%26epage%3D15%26doi%3D10.1016%2FS0167-0115%2801%2900316-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Larsen, B. D.; Petersen, Y. M.</span><span> </span><span class="NLM_article-title">Selective glucagon-like-peptide-2 (GLP-2) analogues</span>. WO2008056155,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=B.+D.+Larsen&author=Y.+M.+Petersen&title=Selective+glucagon-like-peptide-2+%28GLP-2%29+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DB.%2BD.%26atitle%3DSelective%2520glucagon-like-peptide-2%2520%2528GLP-2%2529%2520analogues%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Just, R.; Bovbjerg, K. L.; Riber, D.; Russel, W. S.</span><span> </span><span class="NLM_article-title">Glucagon-like-peptide-2 (GLP-2) analogues</span>. WO2013164484,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Just&author=K.+L.+Bovbjerg&author=D.+Riber&author=W.+S.+Russel&title=Glucagon-like-peptide-2+%28GLP-2%29+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJust%26aufirst%3DR.%26atitle%3DGlucagon-like-peptide-2%2520%2528GLP-2%2529%2520analogues%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeForest, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span> </span><span class="NLM_article-title">Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">G1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1997&pages=G1252-1262&author=D.+J.+Druckerauthor=L.+DeForestauthor=P.+L.+Brubaker&title=Intestinal+response+to+growth+factors+administered+alone+or+in+combination+with+human+%5BGly2%5Dglucagon-like+peptide+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DDeForest%26aufirst%3DL.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26atitle%3DIntestinal%2520response%2520to%2520growth%2520factors%2520administered%2520alone%2520or%2520in%2520combination%2520with%2520human%2520%255BGly2%255Dglucagon-like%2520peptide%25202%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1997%26volume%3D273%26spage%3DG1252%26epage%3D1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Boushey, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusta, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">E937</span><span class="NLM_x">–</span> <span class="NLM_lpage">947</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1999&pages=E937-947&author=R.+P.+Bousheyauthor=B.+Yustaauthor=D.+J.+Drucker&title=Glucagon-like+peptide+2+decreases+mortality+and+reduces+the+severity+of+indomethacin-induced+murine+enteritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoushey%26aufirst%3DR.%2BP.%26aulast%3DYusta%26aufirst%3DB.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DGlucagon-like%2520peptide%25202%2520decreases%2520mortality%2520and%2520reduces%2520the%2520severity%2520of%2520indomethacin-induced%2520murine%2520enteritis%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1999%26volume%3D277%26spage%3DE937%26epage%3D947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Scott, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNaughton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meddings, J. B.</span><span> </span><span class="NLM_article-title">GLP-2 augments the adaptive response to massive intestinal resection in rat</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">G911</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1998&pages=G911-921&author=R.+B.+Scottauthor=D.+Kirkauthor=W.+K.+MacNaughtonauthor=J.+B.+Meddings&title=GLP-2+augments+the+adaptive+response+to+massive+intestinal+resection+in+rat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DR.%2BB.%26aulast%3DKirk%26aufirst%3DD.%26aulast%3DMacNaughton%26aufirst%3DW.%2BK.%26aulast%3DMeddings%26aufirst%3DJ.%2BB.%26atitle%3DGLP-2%2520augments%2520the%2520adaptive%2520response%2520to%2520massive%2520intestinal%2520resection%2520in%2520rat%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1998%26volume%3D275%26spage%3DG911%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Washizawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Openo, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegler, T. R.</span><span> </span><span class="NLM_article-title">Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats</span> <span class="citation_source-journal">JPEN, J. Parenter. Enteral Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span><span class="refDoi"> DOI: 10.1177/0148607104028006399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1177%2F0148607104028006399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=15568286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVGgtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2004&pages=399-409&author=N.+Washizawaauthor=L.+H.+Guauthor=L.+Guauthor=K.+P.+Openoauthor=D.+P.+Jonesauthor=T.+R.+Ziegler&title=Comparative+effects+of+glucagon-like+peptide-2+%28GLP-2%29%2C+growth+hormone+%28GH%29%2C+and+keratinocyte+growth+factor+%28KGF%29+on+markers+of+gut+adaptation+after+massive+small+bowel+resection+in+rats&doi=10.1177%2F0148607104028006399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats</span></div><div class="casAuthors">Washizawa, Naohiro; Gu, Li H.; Gu, Liang; Openo, Kyle P.; Jones, Dean P.; Ziegler, Thomas R.</div><div class="citationInfo"><span class="NLM_cas:title">JPEN, Journal of Parenteral and Enteral Nutrition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">399-409</span>CODEN:
                <span class="NLM_cas:coden">JPENDU</span>;
        ISSN:<span class="NLM_cas:issn">0148-6071</span>.
    
            (<span class="NLM_cas:orgname">American Society for Parenteral and Enteral Nutrition</span>)
        </div><div class="casAbstract">Administration of specific growth factors exert gut-trophic effects in animal models of massive small bowel resection (SBR); however, little comparative data are available.  The authors' aim was to compare effects of a human glucagon-like peptide-2 (GLP-2) analog, recombinant growth hormone (GH) and recombinant keratinocyte growth factor (KGF) on jejunal, ileal, and colonic growth and functional indexes after 80% SBR in rats.  Thirty-seven male rats underwent small bowel transection (sham operation) with s.c. saline administration (control; Tx-S) or 80% midjejuno-ileal resection (Rx) and treatment with either s.c. saline (Rx-S), GLP-2 at 0.2 mg/kg/d (Rx-GLP-2), GH at 3.0 mg/kg/d (Rx-GH), or KGF at 3.0 mg/kg/d (Rx-KGF) for 7 days.  All groups were pair-fed to intake of Rx-S rats.  Gut mucosal cell growth indexes (wet wt., DNA and protein content, villus height, crypt depth, and total mucosal height) were measured.  Expression of the cytoprotective trefoil peptide TFF3 was detd. by Western blot.  Gut mucosal concns. of the tripeptide glutathione (L-glutamyl-L-cysteinyl-glycine) and glutathione disulfide (GSSG) were measured by HPLC and the glutathione/GSSG ratio calcd.  SBR increased adaptive growth indexes in jejunal, ileal, and colonic mucosa.  GLP-2 treatment increased jejunal villus height and jejunal total mucosal height compared with effects of resection alone or resection with GH or KGF treatment.  Both GH and KGF modestly increased colonic crypt depth after SBR.  SBR did not affect small bowel or colonic goblet cell no. or TFF3 expression; however, goblet cell no. and TFF3 expression in both small bowel and colon were markedly up-regulated by KGF treatment and unaffected by GLP-2 and GH.  SBR oxidized the ileal and colonic mucosal glutathione/GSSG redox pools.  GLP-2 treatment after SBR increased the glutathione/GSSG ratio in jejunum, whereas KGF had an intermediate effect.  In addn., GLP-2 (but not GH or KGF) prevented the SBR-induced oxidn. of the glutathione/GSSG pools in both ileum and colon.  Thus, GLP-2 exerts superior trophic effects on jejunal growth and also improves mucosal glutathione redox status throughout the bowel after massive SBR in rats.  Both GH and KGF increase colonic mucosal growth in this model.  KGF alone potently increases gut mucosal goblet cell no. and expression of the cytoprotective trefoil peptide TFF3.  The differential effects of GLP-2, GH and KGF administration in this model of short bowel syndrome suggest that individual therapy with these growth factors may not be an adequate strategy to maximally improve adaptive gut mucosal growth and cytoprotection after massive small intestinal resection.  Future research should address the use of these agents in combination in short bowel syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsuJQpGLkTsLVg90H21EOLACvtfcHk0lguGzQl3CNxPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVGgtLrK&md5=4b25f18d2621053dccefbcaae9630b05</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1177%2F0148607104028006399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0148607104028006399%26sid%3Dliteratum%253Aachs%26aulast%3DWashizawa%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DL.%2BH.%26aulast%3DGu%26aufirst%3DL.%26aulast%3DOpeno%26aufirst%3DK.%2BP.%26aulast%3DJones%26aufirst%3DD.%2BP.%26aulast%3DZiegler%26aufirst%3DT.%2BR.%26atitle%3DComparative%2520effects%2520of%2520glucagon-like%2520peptide-2%2520%2528GLP-2%2529%252C%2520growth%2520hormone%2520%2528GH%2529%252C%2520and%2520keratinocyte%2520growth%2520factor%2520%2528KGF%2529%2520on%2520markers%2520of%2520gut%2520adaptation%2520after%2520massive%2520small%2520bowel%2520resection%2520in%2520rats%26jtitle%3DJPEN%252C%2520J.%2520Parenter.%2520Enteral%2520Nutr.%26date%3D2004%26volume%3D28%26spage%3D399%26epage%3D409%26doi%3D10.1177%2F0148607104028006399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Tavakkolizadeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kormi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seifert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edelman, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinner, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whang, E. E.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 2: A new treatment for chemotherapy-induced enteritis</span> <span class="citation_source-journal">J. Surg. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1006/jsre.2000.5917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1006%2Fjsre.2000.5917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10816354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjt1ansLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2000&pages=77-82&author=A.+Tavakkolizadehauthor=R.+Shenauthor=P.+Abrahamauthor=N.+Kormiauthor=P.+Seifertauthor=E.+R.+Edelmanauthor=D.+O.+Jacobsauthor=M.+J.+Zinnerauthor=S.+W.+Ashleyauthor=E.+E.+Whang&title=Glucagon-like+peptide+2%3A+A+new+treatment+for+chemotherapy-induced+enteritis&doi=10.1006%2Fjsre.2000.5917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like Peptide 2: A New Treatment for Chemotherapy-Induced Enteritis</span></div><div class="casAuthors">Tavakkolizadeh, A.; Shen, R.; Abraham, P.; Kormi, N.; Seifert, P.; Edelman, E. R.; Jacobs, D. O.; Zinner, M. J.; Ashley, S. W.; Whang, E. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-82</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Background.  Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models.  The authors hypothesized that GLP-2 administration would be beneficial in chemotherapy-induced enteritis either by preventing injury or by promoting recovery.  Material and methods.  Rats received no drug (control), chemotherapy alone [5-fluorouracil (5-FU), 190 mg/kg, i.p.] (Chemo), 5-FU followed by 3 days of GLP-2 analog (ALX-0600, 0.1 μg, s.c. twice daily) (CH-G), or GLP-2 analog for 6 days prior to 5-FU and for 3 days afterward (G-CH-G).  Animals were pair fed.  Rats received 5-bromo-2-deoxyuridine (Br-dU, 50 mg/kg, 2.5 h prior to sacrifice on Day 3 postchemotherapy) for immunohistochem. assessment of cellular proliferation.  Results.  Chemotherapy induced significant redns. in body wt., villus height, and crypt depth compared with controls.  Intestinal wet wt., villus height, and crypt depth were significantly higher for the CH-G group compared with the Chemo group.  The CH-G group also showed a significant improvement in villus height compared with the G-CH-G group.  Crypt depth, but not jejunal wet wt. or villus height, was significantly improved in the G-CH-G group compared with the Chemo group.  The percentage of Br-dU-labeled cells in the intestinal crypts did not differ among the groups.  Conclusions.  These results suggest, for the first time, that GLP-2 treatment initiated after chemotherapy administration enhances intestinal recovery.  In contrast, GLP-2 treatment initiated prior to chemotherapy administration to prevent injury has less beneficial effect.  GLP-2 administration may be beneficial to patients suffering from chemotherapy-induced enteritis.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrccfqZiB86Z7Vg90H21EOLACvtfcHk0li939QhN1aqgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjt1ansLw%253D&md5=0662220d0c9469725d05c979f923adf9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1006%2Fjsre.2000.5917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjsre.2000.5917%26sid%3Dliteratum%253Aachs%26aulast%3DTavakkolizadeh%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DAbraham%26aufirst%3DP.%26aulast%3DKormi%26aufirst%3DN.%26aulast%3DSeifert%26aufirst%3DP.%26aulast%3DEdelman%26aufirst%3DE.%2BR.%26aulast%3DJacobs%26aufirst%3DD.%2BO.%26aulast%3DZinner%26aufirst%3DM.%2BJ.%26aulast%3DAshley%26aufirst%3DS.%2BW.%26aulast%3DWhang%26aufirst%3DE.%2BE.%26atitle%3DGlucagon-like%2520peptide%25202%253A%2520A%2520new%2520treatment%2520for%2520chemotherapy-induced%2520enteritis%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2000%26volume%3D91%26spage%3D77%26epage%3D82%26doi%3D10.1006%2Fjsre.2000.5917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Boushey, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusta, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">687</span><span class="NLM_x">–</span> <span class="NLM_lpage">693</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=687-693&author=R.+P.+Bousheyauthor=B.+Yustaauthor=D.+J.+Drucker&title=Glucagon-like+peptide+%28GLP%29-2+reduces+chemotherapy-associated+mortality+and+enhances+cell+survival+in+cells+expressing+a+transfected+GLP-2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoushey%26aufirst%3DR.%2BP.%26aulast%3DYusta%26aufirst%3DB.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DGlucagon-like%2520peptide%2520%2528GLP%2529-2%2520reduces%2520chemotherapy-associated%2520mortality%2520and%2520enhances%2520cell%2520survival%2520in%2520cells%2520expressing%2520a%2520transfected%2520GLP-2%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D687%26epage%3D693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Torres, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thim, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milliat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vozenin-Brotons, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, U. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahnfelt-Ronne, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourhis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benderitter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francois, A.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat</span> <span class="citation_source-journal">Int. J. Radiat. Oncol., Biol., Phys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1563</span><span class="NLM_x">–</span> <span class="NLM_lpage">1571</span><span class="refDoi"> DOI: 10.1016/j.ijrobp.2007.08.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2Fj.ijrobp.2007.08.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=18035212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlCrs7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2007&pages=1563-1571&author=S.+Torresauthor=L.+Thimauthor=F.+Milliatauthor=M.+C.+Vozenin-Brotonsauthor=U.+B.+Olsenauthor=I.+Ahnfelt-Ronneauthor=J.+Bourhisauthor=M.+Benderitterauthor=A.+Francois&title=Glucagon-like+peptide-2+improves+both+acute+and+late+experimental+radiation+enteritis+in+the+rat&doi=10.1016%2Fj.ijrobp.2007.08.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat</span></div><div class="casAuthors">Torres, Sandra; Thim, Lars; Milliat, Fabien; Vozenin-Brotons, Marie-Catherine; Olsen, Ulfe Bang; Ahnfelt-Ronne, Ian; Bourhis, Jean; Benderitter, Marc; Francois, Agnes</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Oncology, Biology, Physics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1563-1571</span>CODEN:
                <span class="NLM_cas:coden">IOBPD3</span>;
        ISSN:<span class="NLM_cas:issn">0360-3016</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Acute and/or chronic radiation enteritis can develop after radiotherapy for pelvic cancers.  Exptl. and clin. observations have provided evidence of a role played by acute mucosal disruption in the appearance of late effects.  The therapeutic potential of acute administration of glucagon-like peptide-2 (GLP-2) against acute and chronic intestinal injury was investigated in this study.  Intestinal segments were surgically exteriorized and exposed to 16.7 or 19 Gy x-rays.  The rats were treated once daily with vehicle or a protease-resistant GLP-2 deriv. for 14 days before irradn., with or without 7 days of GLP-2 after treatment.  Macroscopic and microscopic observations were made 2 and 15 wk after radiation exposure.  In the control animals, GLP-2 induced an increase in intestinal mucosal mass, along with an increase in villus height and crypt depth.  GLP-2 administration before and after irradn. completely prevented the acute radiation-induced mucosal ulcerations obsd. after exposure to 16.7 Gy.  GLP-2 treatment strikingly reduced the late radiation damage obsd. after 19 Gy irradn.  Microscopic observations revealed an improved organization of the intestinal wall and an efficient wound healing process, esp. in the smooth muscle layers.  GLP-2 has a clear therapeutic potential against both acute and chronic radiation enteritis.  This therapeutic effect is mediated through an increased mucosal mass before tissue injury and the stimulation of still unknown mechanisms of tissue response to radiation damage.  Although these preliminary results still need to be confirmed, GLP-2 might be a way to limit patient discomfort during radiotherapy and reduce the risk of consequential late effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqVBLw2jTXT7Vg90H21EOLACvtfcHk0li939QhN1aqgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlCrs7jL&md5=914f882451bd5854541f36baedcde411</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ijrobp.2007.08.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijrobp.2007.08.051%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DS.%26aulast%3DThim%26aufirst%3DL.%26aulast%3DMilliat%26aufirst%3DF.%26aulast%3DVozenin-Brotons%26aufirst%3DM.%2BC.%26aulast%3DOlsen%26aufirst%3DU.%2BB.%26aulast%3DAhnfelt-Ronne%26aufirst%3DI.%26aulast%3DBourhis%26aufirst%3DJ.%26aulast%3DBenderitter%26aufirst%3DM.%26aulast%3DFrancois%26aufirst%3DA.%26atitle%3DGlucagon-like%2520peptide-2%2520improves%2520both%2520acute%2520and%2520late%2520experimental%2520radiation%2520enteritis%2520in%2520the%2520rat%26jtitle%3DInt.%2520J.%2520Radiat.%2520Oncol.%252C%2520Biol.%252C%2520Phys.%26date%3D2007%26volume%3D69%26spage%3D1563%26epage%3D1571%26doi%3D10.1016%2Fj.ijrobp.2007.08.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">DaCambra, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusta, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumner-Smith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crivici, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span> </span><span class="NLM_article-title">Structural determinants for activity of glucagon-like peptide-2</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">8888</span><span class="NLM_x">–</span> <span class="NLM_lpage">8894</span><span class="refDoi"> DOI: 10.1021/bi000497p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi000497p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=8888-8894&author=M.+P.+DaCambraauthor=B.+Yustaauthor=M.+Sumner-Smithauthor=A.+Criviciauthor=D.+J.+Druckerauthor=P.+L.+Brubaker&title=Structural+determinants+for+activity+of+glucagon-like+peptide-2&doi=10.1021%2Fbi000497p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fbi000497p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi000497p%26sid%3Dliteratum%253Aachs%26aulast%3DDaCambra%26aufirst%3DM.%2BP.%26aulast%3DYusta%26aufirst%3DB.%26aulast%3DSumner-Smith%26aufirst%3DM.%26aulast%3DCrivici%26aufirst%3DA.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26atitle%3DStructural%2520determinants%2520for%2520activity%2520of%2520glucagon-like%2520peptide-2%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D8888%26epage%3D8894%26doi%3D10.1021%2Fbi000497p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Venneti, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewage, C. M.</span><span> </span><span class="NLM_article-title">Conformational and molecular interaction studies of glucagon-like peptide-2 with its N-terminal extracellular receptor domain</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">585</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1016/j.febslet.2010.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2Fj.febslet.2010.12.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=585&publication_year=2011&pages=346-352&author=K.+C.+Vennetiauthor=C.+M.+Hewage&title=Conformational+and+molecular+interaction+studies+of+glucagon-like+peptide-2+with+its+N-terminal+extracellular+receptor+domain&doi=10.1016%2Fj.febslet.2010.12.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2010.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2010.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DVenneti%26aufirst%3DK.%2BC.%26aulast%3DHewage%26aufirst%3DC.%2BM.%26atitle%3DConformational%2520and%2520molecular%2520interaction%2520studies%2520of%2520glucagon-like%2520peptide-2%2520with%2520its%2520N-terminal%2520extracellular%2520receptor%2520domain%26jtitle%3DFEBS%2520Lett.%26date%3D2011%26volume%3D585%26spage%3D346%26epage%3D352%26doi%3D10.1016%2Fj.febslet.2010.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Marier, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beliveau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouksassi, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesavan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahir, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caminis, J.</span><span> </span><span class="NLM_article-title">Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1289</span><span class="NLM_x">–</span> <span class="NLM_lpage">1299</span><span class="refDoi"> DOI: 10.1177/0091270008320605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1177%2F0091270008320605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=18974283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlyrs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=1289-1299&author=J.+F.+Marierauthor=M.+Beliveauauthor=M.+S.+Mouksassiauthor=P.+Shawauthor=J.+Cyranauthor=J.+Kesavanauthor=J.+Wallensauthor=H.+Zahirauthor=D.+Wellsauthor=J.+Caminis&title=Pharmacokinetics%2C+safety%2C+and+tolerability+of+teduglutide%2C+a+glucagon-like+peptide-2+%28GLP-2%29+analog%2C+following+multiple+ascending+subcutaneous+administrations+in+healthy+subjects&doi=10.1177%2F0091270008320605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects</span></div><div class="casAuthors">Marier, Jean-Francois; Beliveau, Martin; Mouksassi, Mohamad-Samer; Shaw, Paula; Cyran, Jane; Kesavan, Jothi; Wallens, John; Zahir, Hamim; Wells, David; Caminis, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1289-1299</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, is currently being evaluated for the treatment of short-bowel syndrome, Crohn's disease, and other gastrointestinal disorders.  The pharmacokinetics, safety, and tolerability of teduglutide in healthy subjects (N = 64) were assessed following daily s.c. administrations for 8 days in a double-blinded, randomized, placebo-controlled, ascending-dose study.  Teduglutide treatments were administered as a 50-mg/mL (10, 15, 20, 25, 30, 50, and 80 mg) or 20-mg/mL (20 mg) formulation.  Blood samples were collected on days 1 and 8, and plasma concns. of teduglutide were measured using a liq. chromatog./tandem mass spectrometry method.  Mean systemic exposures to teduglutide were very similar on days 1 and 8, suggesting minimal, if any, accumulation following once-daily repeated administrations.  The apparent clearance of teduglutide following administration of the 50-mg/mL formulation was const. over the dose range, with mean values in male and female subjects of 0.155 and 0.159 L/h/kg, resp.  Peak plasma concns. and total exposure of teduglutide after s.c. injection of a 20-mg/mL formulation (1.0 mL) were approx. 15% and 78% higher than those obsd. with the 50-mg/mL formulation (0.4 mL), resp.  Teduglutide treatments were safe and well tolerated.  All but 1 adverse event was assessed as mild or moderate in severity.  No relationship between teduglutide treatments and frequency of adverse events was obsd., with the exception of injection site pain, which increased as a function of dose and injected vol.  Results from the current study will assist in the dose selection in future efficacy studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfwvOVdhK00LVg90H21EOLACvtfcHk0livXaVFdGYMng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlyrs7bP&md5=3355be2323958e3f2bc5081c67af6557</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1177%2F0091270008320605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270008320605%26sid%3Dliteratum%253Aachs%26aulast%3DMarier%26aufirst%3DJ.%2BF.%26aulast%3DBeliveau%26aufirst%3DM.%26aulast%3DMouksassi%26aufirst%3DM.%2BS.%26aulast%3DShaw%26aufirst%3DP.%26aulast%3DCyran%26aufirst%3DJ.%26aulast%3DKesavan%26aufirst%3DJ.%26aulast%3DWallens%26aufirst%3DJ.%26aulast%3DZahir%26aufirst%3DH.%26aulast%3DWells%26aufirst%3DD.%26aulast%3DCaminis%26aufirst%3DJ.%26atitle%3DPharmacokinetics%252C%2520safety%252C%2520and%2520tolerability%2520of%2520teduglutide%252C%2520a%2520glucagon-like%2520peptide-2%2520%2528GLP-2%2529%2520analog%252C%2520following%2520multiple%2520ascending%2520subcutaneous%2520administrations%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D1289%26epage%3D1299%26doi%3D10.1177%2F0091270008320605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Jeppesen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilroy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertkiewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allard, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Keefe, S. J.</span><span> </span><span class="NLM_article-title">Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">902</span><span class="NLM_x">–</span> <span class="NLM_lpage">914</span><span class="refDoi"> DOI: 10.1136/gut.2010.218271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1136%2Fgut.2010.218271" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=902-914&author=P.+B.+Jeppesenauthor=R.+Gilroyauthor=M.+Pertkiewiczauthor=J.+P.+Allardauthor=B.+Messingauthor=S.+J.+O%E2%80%99Keefe&title=Randomised+placebo-controlled+trial+of+teduglutide+in+reducing+parenteral+nutrition+and%2For+intravenous+fluid+requirements+in+patients+with+short+bowel+syndrome&doi=10.1136%2Fgut.2010.218271"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1136%2Fgut.2010.218271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.2010.218271%26sid%3Dliteratum%253Aachs%26aulast%3DJeppesen%26aufirst%3DP.%2BB.%26aulast%3DGilroy%26aufirst%3DR.%26aulast%3DPertkiewicz%26aufirst%3DM.%26aulast%3DAllard%26aufirst%3DJ.%2BP.%26aulast%3DMessing%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DS.%2BJ.%26atitle%3DRandomised%2520placebo-controlled%2520trial%2520of%2520teduglutide%2520in%2520reducing%2520parenteral%2520nutrition%2520and%252For%2520intravenous%2520fluid%2520requirements%2520in%2520patients%2520with%2520short%2520bowel%2520syndrome%26jtitle%3DGut%26date%3D2011%26volume%3D60%26spage%3D902%26epage%3D914%26doi%3D10.1136%2Fgut.2010.218271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Vipperla, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Keefe, S. J.</span><span> </span><span class="NLM_article-title">Targeted therapy of short-bowel syndrome with teduglutide: The new kid on the block</span> <span class="citation_source-journal">Clin. Exp. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">495</span><span class="refDoi"> DOI: 10.2147/CEG.S42665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.2147%2FCEG.S42665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=25525380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADC%252BC2MvhtVKnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=489-495&author=K.+Vipperlaauthor=S.+J.+O%E2%80%99Keefe&title=Targeted+therapy+of+short-bowel+syndrome+with+teduglutide%3A+The+new+kid+on+the+block&doi=10.2147%2FCEG.S42665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block</span></div><div class="casAuthors">Vipperla Kishore; O'Keefe Stephen J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and experimental gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">489-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Extensive intestinal resection impairs the absorptive capacity and results in short-bowel syndrome-associated intestinal failure (SBS-IF), when fluid, electrolyte, acid-base, micro-, and macronutrient homeostasis cannot be maintained on a conventional oral diet.  Several factors, including the length and site of the resected intestine, anatomical conformation of the remnant bowel, and the degree of postresection intestinal adaptation determine the disease severity.  While mild SBS patients achieve nutritional autonomy with dietary modification (eg, hyperphagia, small frequent meals, and oral rehydration fluids), those with moderate-to-severe disease may develop SBS-IF and become dependent on parenteral support (PS) in the form of intravenous fluids and/or nutrition for sustenance of life.  SBS-IF is a chronic debilitating disease associated with a poor quality of life, and carries significant morbidity and health care costs.  Medical management of SBS-IF is primarily focused on individually tailored symptomatic treatment strategies, such as antisecretory and antidiarrheal agents to mitigate fluid losses, and PS.  However, PS administration is associated with potentially life-threatening complications, such as central venous thromboses, bloodstream infections, and liver disease.  In pursuit of a targeted therapy to augment intestinal adaptation, research over the past 2 decades has identified glucagon-like peptide, an intestinotrophic gut peptide that has been shown to enhance intestinal absorptive capacity by causing an increase in the villus length, crypt depth, and mesenteric blood flow and by decreasing gastrointestinal motility and secretions.  Teduglutide, a recombinant analog of glucagon-like peptide-2, is the first targeted therapeutic agent to gain approval for use in adult SBS-IF.  Teduglutide was shown to result in significant (20%-100%) reduction in PS-volume requirement and have a satisfactory safety profile in three randomized control trials.  Further research is warranted to see if reduction in PS dependency translates to improved quality of life and reduced PS-associated complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3dPpQYTDtzxOk4JA3soTqfW6udTcc2eZScF_Z8ycLerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvhtVKnsw%253D%253D&md5=bae90c8939596fbea0040ea8bca119fa</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2147%2FCEG.S42665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCEG.S42665%26sid%3Dliteratum%253Aachs%26aulast%3DVipperla%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DS.%2BJ.%26atitle%3DTargeted%2520therapy%2520of%2520short-bowel%2520syndrome%2520with%2520teduglutide%253A%2520The%2520new%2520kid%2520on%2520the%2520block%26jtitle%3DClin.%2520Exp.%2520Gastroenterol.%26date%3D2014%26volume%3D7%26spage%3D489%26epage%3D495%26doi%3D10.2147%2FCEG.S42665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Jeppesen, P. B.</span><span> </span><span class="NLM_article-title">Teduglutide for the treatment of short bowel syndrome</span> <span class="citation_source-journal">Drugs Today (Barc)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">614</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=24191254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADC%252BC2c7jtVynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=599-614&author=P.+B.+Jeppesen&title=Teduglutide+for+the+treatment+of+short+bowel+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Teduglutide for the treatment of short bowel syndrome</span></div><div class="casAuthors">Jeppesen P B</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">599-614</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Glucagon-like peptide 2 (GLP-2) decreases gastric and intestinal motility, reduces gastric secretions, promotes intestinal growth and improves post-resection structural and functional adaptation in short bowel syndrome (SBS).  Teduglutide, an analogue of GLP-2, has a prolonged half-life and provides intestinotrophic effects with once-daily subcutaneous injection in patients with SBS.  This monograph reviews the preclinical and clinical data that provide the scientific rationale for the use of teduglutide in this orphan condition.  Teduglutide increases intestinal absorption and diminishes the need for parenteral support in patients with SBS.  The adverse event profile is consistent with the underlying disease and the known mechanism of action of teduglutide.  Following its positive regulatory review and approval by the European Medicines Agency and the U.S.  Food and Drug Administration in 2012, teduglutide has moved from the research setting to clinical practice, offering a new treatment paradigm for this burdensome and potentially life-threatening condition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR89KumefERg4NpW7w2tapOfW6udTcc2eZScF_Z8ycLerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7jtVynug%253D%253D&md5=959ebcca6adcacfdd718825485c904d3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJeppesen%26aufirst%3DP.%2BB.%26atitle%3DTeduglutide%2520for%2520the%2520treatment%2520of%2520short%2520bowel%2520syndrome%26jtitle%3DDrugs%2520Today%2520%2528Barc%2529%26date%3D2013%26volume%3D49%26spage%3D599%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Naberhuis, J. K.; Tappenden, K. A.</span><span> </span><span class="NLM_article-title">Teduglutide for safe reduction of parenteral nutrient and/or fluid requirements in adults: A systematic review</span>.  <span class="citation_source-journal">JPEN, J. Parenter. Enteral Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span>. [Online early access]. DOI: <span class="refDoi"> DOI: 10.1177/0148607115582063</span> . Published Online: April 16, 2015.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1177%2F0148607115582063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+K.+Naberhuis&author=K.+A.+Tappenden&title=Teduglutide+for+safe+reduction+of+parenteral+nutrient+and%2For+fluid+requirements+in+adults%3A+A+systematic+review&doi=10.1177%2F0148607115582063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1177%2F0148607115582063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0148607115582063%26sid%3Dliteratum%253Aachs%26aulast%3DNaberhuis%26aufirst%3DJ.%2BK.%26atitle%3DTeduglutide%2520for%2520safe%2520reduction%2520of%2520parenteral%2520nutrient%2520and%252For%2520fluid%2520requirements%2520in%2520adults%253A%2520A%2520systematic%2520review%26jtitle%3DJPEN%252C%2520J.%2520Parenter.%2520Enteral%2520Nutr.%26date%3D2015%26doi%3D10.1177%2F0148607115582063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Seidner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youssef, N. N.</span><span> </span><span class="NLM_article-title">Effect of teduglutide, a glucagon-like peptide 2 analog, on citrulline levels in patients with short bowel syndrome in two phase III randomized trials</span> <span class="citation_source-journal">Clin. Transl. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e93</span><span class="refDoi"> DOI: 10.1038/ctg.2015.15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1038%2Fctg.2015.15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=26111125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOmtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=e93&author=D.+L.+Seidnerauthor=F.+Jolyauthor=N.+N.+Youssef&title=Effect+of+teduglutide%2C+a+glucagon-like+peptide+2+analog%2C+on+citrulline+levels+in+patients+with+short+bowel+syndrome+in+two+phase+III+randomized+trials&doi=10.1038%2Fctg.2015.15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials</span></div><div class="casAuthors">Seidner, Douglas L.; Joly, Francisca; Youssef, Nader N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e93</span>CODEN:
                <span class="NLM_cas:coden">CTGLAG</span>;
        ISSN:<span class="NLM_cas:issn">2155-384X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objectives: In clin. trials, treatment with the glucagon-like peptide 2 analog teduglutide was assocd. with improved fluid and nutrient absorption and increased intestinal villus height and crypt depth in patients with short bowel syndrome (SBS).  Plasma citrulline, an amino acid produced by enterocytes, is considered a measure of enterocyte mass.  This anal. assessed changes in plasma citrulline levels in patients with SBS in 2 phase III clin. studies of teduglutide.  Methods: Both teduglutide studies (0.05 or 0.10 mg/kg/day in CL0600-004 and 0.05 mg/kg/day in CL0600-020) were phase III, 24-wk, double-blind, and placebo controlled.  Plasma citrulline levels were analyzed and validated by liq. chromatog. coupled to tandem mass spectrometry.  Results: In both the CL0600-004 and CL0600-020 studies, change in mean plasma citrulline concns. at Week 24 vs. baseline was significantly greater with teduglutide compared with placebo (10.9 (0.05-mg/kg/day dose) and 15.7 (0.10-mg/kg/day dose) vs. 2.0 μmol/L and 20.6 vs. 0.7 μmol/L, resp., for each study (P≤0.0001 for each comparison with placebo)).  Teduglutide treatment was assocd. with redns. from baseline in PS (parenteral support) vol. requirements; however, a significant correlation between PS redn. and increase in plasma citrulline at Week 24 was obsd. in only one out of the three teduglutide treatment groups.  Conclusions: In 2 phase III studies, patients receiving teduglutide had significant increases in plasma citrulline at Week 24 compared with patients receiving placebo.  Increases in plasma citrulline concns. likely reflect enterocyte mass expansion, but no clear correlation was detected between change in plasma citrulline and change in weekly PS vol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZN_z0fYksrLVg90H21EOLACvtfcHk0lg9ii7tvTpsaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOmtrfI&md5=906c3c54a4d82ee596b75f39b7c2cc68</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fctg.2015.15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fctg.2015.15%26sid%3Dliteratum%253Aachs%26aulast%3DSeidner%26aufirst%3DD.%2BL.%26aulast%3DJoly%26aufirst%3DF.%26aulast%3DYoussef%26aufirst%3DN.%2BN.%26atitle%3DEffect%2520of%2520teduglutide%252C%2520a%2520glucagon-like%2520peptide%25202%2520analog%252C%2520on%2520citrulline%2520levels%2520in%2520patients%2520with%2520short%2520bowel%2520syndrome%2520in%2520two%2520phase%2520III%2520randomized%2520trials%26jtitle%3DClin.%2520Transl.%2520Gastroenterol.%26date%3D2015%26volume%3D6%26spage%3De93%26doi%3D10.1038%2Fctg.2015.15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Buchman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou-Assi, S. G.</span><span> </span><span class="NLM_article-title">Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn’s disease</span> <span class="citation_source-journal">Inflamm. Bowel Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">962</span><span class="NLM_x">–</span> <span class="NLM_lpage">973</span><span class="refDoi"> DOI: 10.1002/ibd.21117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fibd.21117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=19821509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADC%252BC3czjvFejsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=962-973&author=A.+L.+Buchmanauthor=S.+Katzauthor=J.+C.+Fangauthor=C.+N.+Bernsteinauthor=S.+G.+Abou-Assi&title=Teduglutide%2C+a+novel+mucosally+active+analog+of+glucagon-like+peptide-2+%28GLP-2%29+for+the+treatment+of+moderate+to+severe+Crohn%E2%80%99s+disease&doi=10.1002%2Fibd.21117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease</span></div><div class="casAuthors">Buchman Alan L; Katz Seymour; Fang John C; Bernstein Charles N; Abou-Assi Souheil G</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">962-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Teduglutide, an analog of glucagon-like peptide-2 (GLP-2), is associated with trophic effects on gut mucosa.  Its role in the treatment of active Crohn's disease (CD) was assessed in a pilot, randomized, placebo-controlled, double-blinded, dose-ranging study.  METHODS:  Subjects with moderate-to-severe CD were randomized 1:1:1:1 to placebo or 1 of 3 doses of teduglutide (0.05, 0.10, or 0.20 mg/kg daily) delivered as a daily subcutaneous injection for 8 weeks.  The primary outcome measure was the percentage of subjects in each group that responded to treatment, defined as a decrease in Crohn's Disease Activity Index (CDAI) score to <150 or a decrease of > 100 points.  At week 8 there was an optional 12-week open-label period of treatment with teduglutide 0.10 mg/kg/d.  RESULTS:  One hundred subjects were enrolled and 71 completed the study.  The mean baseline CDAI score was 290.8 +/- 57.6 and was similar across groups.  There were numerically higher response and remission rates in all teduglutide-treated groups as compared with placebo, although the percentage of subjects who achieved a clinical response or remission was more substantial, and seen as early as week 2 of treatment in the highest dose (0.2 mg/kg/d) group (44% response and 32% remission versus 32% response and 20% remission in the placebo group).  Of subjects who had not achieved remission during the 8-week placebo-controlled phase in the higher-dose group, 50% achieved remission during the more prolonged, open-label treatment phase.  Plasma citrulline was similar across groups at baseline, but increased substantially over time in all teduglutide groups when compared with placebo at week 8.  Adverse events were not different between placebo and active treatment groups.  CONCLUSIONS:  Teduglutide is a novel and potentially effective therapy for inducing remission and mucosal healing in patients with active moderate-to-severe CD.  Further clinical investigation of this growth factor is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSp9OMg9pT7OIhLSh9fo81bfW6udTcc2eYbh6ITCadnnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czjvFejsw%253D%253D&md5=c86ed439b08e2bdcd72e3ba427fbb48e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fibd.21117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fibd.21117%26sid%3Dliteratum%253Aachs%26aulast%3DBuchman%26aufirst%3DA.%2BL.%26aulast%3DKatz%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DJ.%2BC.%26aulast%3DBernstein%26aufirst%3DC.%2BN.%26aulast%3DAbou-Assi%26aufirst%3DS.%2BG.%26atitle%3DTeduglutide%252C%2520a%2520novel%2520mucosally%2520active%2520analog%2520of%2520glucagon-like%2520peptide-2%2520%2528GLP-2%2529%2520for%2520the%2520treatment%2520of%2520moderate%2520to%2520severe%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2010%26volume%3D16%26spage%3D962%26epage%3D973%26doi%3D10.1002%2Fibd.21117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Larsen, B. D.; Petersen, Y. M.; Ebbehoej, K.</span><span> </span><span class="NLM_article-title">Glucagon-like-peptide-2 (GLP-2) analogues</span>. WO2006117565,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=B.+D.+Larsen&author=Y.+M.+Petersen&author=K.+Ebbehoej&title=Glucagon-like-peptide-2+%28GLP-2%29+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DB.%2BD.%26atitle%3DGlucagon-like-peptide-2%2520%2528GLP-2%2529%2520analogues%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Schon, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisfaludy, L.</span><span> </span><span class="NLM_article-title">Formation of aminosuccinyl peptides during acidolytic deprotection followed by their transformation to piperazine-2,5-dione derivatives in neutral media</span> <span class="citation_source-journal">Int. J. Pept. Protein Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.1111/j.1399-3011.1979.tb01960.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1111%2Fj.1399-3011.1979.tb01960.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=43840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaL3cXhvFyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1979&pages=485-494&author=I.+Schonauthor=L.+Kisfaludy&title=Formation+of+aminosuccinyl+peptides+during+acidolytic+deprotection+followed+by+their+transformation+to+piperazine-2%2C5-dione+derivatives+in+neutral+media&doi=10.1111%2Fj.1399-3011.1979.tb01960.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Formation of aminosuccinyl peptides during acidolytic deprotection followed by their transformation to piperazine-2,5-dione derivatives in neutral media</span></div><div class="casAuthors">Schon, Istvan; Kisfaludy, Lajos</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-94</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">The acidolytic deblocking of Me3CO2C-Leu-Asp(OCMe3)-Phe-NH2 by prolonged treatment with 4N HCl/HOAc gave succinimide peptide I, which was partially transformed to piperazinedione II during purifn. by column chromatog. on silica gel in neutral media.  The study of succinimide formation for different reaction conditions and for several aspartic acid-contg. peptides showed that succinimides were formed in strongly acidic media from aspartyl peptides contg. a free β-carboxyl group.  II did not form in CF3CO2H.  For tripeptides contg. Asp in position 2, the influence of the C-terminal residue was greater than that of the N-terminal residue on both the rate of formation of succinimide and its further transformation to the piperazinedione deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqscjf_fPhEi7Vg90H21EOLACvtfcHk0lg9ii7tvTpsaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhvFyktro%253D&md5=340da5ae65fb5d3b8fc6428d215e5388</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1979.tb01960.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1979.tb01960.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchon%26aufirst%3DI.%26aulast%3DKisfaludy%26aufirst%3DL.%26atitle%3DFormation%2520of%2520aminosuccinyl%2520peptides%2520during%2520acidolytic%2520deprotection%2520followed%2520by%2520their%2520transformation%2520to%2520piperazine-2%252C5-dione%2520derivatives%2520in%2520neutral%2520media%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1979%26volume%3D14%26spage%3D485%26epage%3D494%26doi%3D10.1111%2Fj.1399-3011.1979.tb01960.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Suli-Vargha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ilas, J.</span><span> </span><span class="NLM_article-title">1,4-diazepine-2,5-dione ring formation during solid phase synthesis of peptides containing aspartic acid beta -benzyl ester</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span><span class="refDoi"> DOI: 10.1002/psc.885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=17853501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=742-748&author=H.+Suli-Varghaauthor=G.+Schlosserauthor=J.+Ilas&title=1%2C4-diazepine-2%2C5-dione+ring+formation+during+solid+phase+synthesis+of+peptides+containing+aspartic+acid+beta+-benzyl+ester&doi=10.1002%2Fpsc.885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">1,4-Diazepine-2,5-dione ring formation during solid phase synthesis of peptides containing aspartic acid β-benzyl ester</span></div><div class="casAuthors">Suli-Vargha, Helga; Schlosser, Gitta; Ilas, Janez</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">742-748</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The Fmoc-based SPPS of H-Xaa-Asp(OBzl)-Yaa-Gly-NH2 sequences results in side reactions yielding not only aspartimide peptides and piperidide derivs., but also 1,4-diazepine-2,5-dione-peptides.  Evidence is presented to show that the 1,4-diazepine-2,5-dione deriv. is formed from the aspartimide peptide.  The rate of this ring transformation depends primarily on the tendency to aspartimide and piperidide formation, which is influenced by the nature of the amino acid following the aspartic acid β-benzyl ester (Xaa).  However the bulkiness of the amino acid side chain preceding the aspartic acid β-benzyl ester (Yaa) is also important.  Under certain conditions the 1,4-diazepine-2,5-dione peptide deriv. may even be formed dominantly, which is a highly undesirable side reaction in peptide synthesis, but which provides a new way for the synthesis of diazepine peptide derivs. with targeted biol. or pharmacol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr167YjGN7ELbVg90H21EOLACvtfcHk0lhMaUzGONo5ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktbrL&md5=38aed3967e09a28cb36e536f195c4114</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fpsc.885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.885%26sid%3Dliteratum%253Aachs%26aulast%3DSuli-Vargha%26aufirst%3DH.%26aulast%3DSchlosser%26aufirst%3DG.%26aulast%3DIlas%26aufirst%3DJ.%26atitle%3D1%252C4-diazepine-2%252C5-dione%2520ring%2520formation%2520during%2520solid%2520phase%2520synthesis%2520of%2520peptides%2520containing%2520aspartic%2520acid%2520beta%2520-benzyl%2520ester%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2007%26volume%3D13%26spage%3D742%26epage%3D748%26doi%3D10.1002%2Fpsc.885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Mergler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, F.</span><span> </span><span class="NLM_article-title">The aspartimide problem in Fmoc-based SPPS. Part III</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">650</span><span class="NLM_x">–</span> <span class="NLM_lpage">657</span><span class="refDoi"> DOI: 10.1002/psc.668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=15849777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFygsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=650-657&author=M.+Merglerauthor=F.+Dick&title=The+aspartimide+problem+in+Fmoc-based+SPPS.+Part+III&doi=10.1002%2Fpsc.668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The aspartimide problem in Fmoc-based SPPS. Part III</span></div><div class="casAuthors">Mergler, M.; Dick, F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">650-657</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A newly developed Fmoc-Asp deriv., Fmoc-Asp β-(2,3,4-trimethyl-pent-3-yl) ester (Fmoc = 9-fluorenylmethyloxycarbonyl), has been tried in the Fmoc-based SPPS of H-Val-Lys-Asp-Xaa-Tyr-Ile-OH, a well-established peptide model for studying base-catalyzed aspartimide formation.  When synthesizing the hexapeptide incorporating Gly, Arg(Pbf), Asn(Mtt), Asp(OtBu) or Cys(Acm) for Xaa, considerable amts. of aspartimide-related byproducts were to be expected.  The Asp3 β-carboxy protecting group and the duration of exposure to bases were varied.  Byproduct formation could be reduced by incorporation of the new Asp deriv. more efficiently than by introducing the less bulky Asp(OMpe).  Significant improvements were obsd. in cases of prolonged contact with piperidine or DBU.  Both β-carboxy protecting groups were superior to the std. Asp(OtBu) which was also included in this study, but the addnl. stabilization gained by our new protecting group was valuable esp. in syntheses of long peptides or difficult sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoht36BP3nB7bVg90H21EOLACvtfcHk0lhMaUzGONo5ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFygsLrM&md5=42458f1c5fb2429da9d07c925fa2f190</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fpsc.668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.668%26sid%3Dliteratum%253Aachs%26aulast%3DMergler%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DF.%26atitle%3DThe%2520aspartimide%2520problem%2520in%2520Fmoc-based%2520SPPS.%2520Part%2520III%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2005%26volume%3D11%26spage%3D650%26epage%3D657%26doi%3D10.1002%2Fpsc.668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Mergler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sax, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahelin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vorherr, T.</span><span> </span><span class="NLM_article-title">The aspartimide problem in Fmoc-based SPPS. Part II</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">518</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1002/psc.473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=12952393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1Wjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=518-526&author=M.+Merglerauthor=F.+Dickauthor=B.+Saxauthor=C.+Stahelinauthor=T.+Vorherr&title=The+aspartimide+problem+in+Fmoc-based+SPPS.+Part+II&doi=10.1002%2Fpsc.473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The aspartimide problem in Fmoc-based SPPS. Part II</span></div><div class="casAuthors">Mergler, M.; Dick, F.; Sax, B.; Staehelin, C.; Vorherr, T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">518-526</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The sequence dependence of base-catalyzed aspartimide formation during Fmoc-based SPPS (Fmoc = 9-fluorenylmethyloxycarbonyl) was systematically studied employing the peptide models H-Val-Lys-Asp-Xaa-Tyr-Ile-OH.  The extent of formation of aspartimide and related byproducts was detd. by RP-HPLC.  Considerable amts. of byproducts were formed in the case of Xaa = Asp(OtBu), Arg(Pbf), Asn(Mtt), Cys(Acm) and unprotected Thr.  Aspartimide formation could be diminished by incorporation of Asp(OMpe) or by employing milder methods for Fmoc cleavage, e.g. hexamethyleneimine/N-methylpyrrolidine/HOBt/NMP/DMSO 4:50:4:71:71 (vol./vol./w/vol./vol.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru4Fttj0z8J7Vg90H21EOLACvtfcHk0lgDLcn9UbRoMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1Wjsbk%253D&md5=3bd78007418963ed009af0fc220c9143</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fpsc.473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.473%26sid%3Dliteratum%253Aachs%26aulast%3DMergler%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DF.%26aulast%3DSax%26aufirst%3DB.%26aulast%3DStahelin%26aufirst%3DC.%26aulast%3DVorherr%26aufirst%3DT.%26atitle%3DThe%2520aspartimide%2520problem%2520in%2520Fmoc-based%2520SPPS.%2520Part%2520II%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2003%26volume%3D9%26spage%3D518%26epage%3D526%26doi%3D10.1002%2Fpsc.473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Mergler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sax, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vorherr, T.</span><span> </span><span class="NLM_article-title">The aspartimide problem in Fmoc-based SPPS. Part I</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1002/psc.430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=12587881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht12qtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=36-46&author=M.+Merglerauthor=F.+Dickauthor=B.+Saxauthor=P.+Weilerauthor=T.+Vorherr&title=The+aspartimide+problem+in+Fmoc-based+SPPS.+Part+I&doi=10.1002%2Fpsc.430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The aspartimide problem in Fmoc-based SPPS. Part I</span></div><div class="casAuthors">Mergler, M.; Dick, F.; Sax, B.; Weiler, P.; Vorherr, T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-46</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A variety of Asp β-carboxy protecting groups, Hmb backbone protection and a range of Fmoc cleavage protocols have been employed in the syntheses of the model hexapeptide H-VKDGYI-OH to investigate the aspartimide problem in more detail.  The extent of formation of aspartimide and aspartimide-related byproducts was detd. by RP-HPLC.  This study included three new Fmoc-Asp-OH derivs.: the β-(4-pyridyldiphenylmethyl) and β-(9-phenylfluoren-9-yl) esters and the orthoester Fmoc-β-(4-methyl-2,6,7-trioxabicyclo[2.2.2]oct-1-yl)alanine.  3-Methylpent-3-yl protection of the Asp side chain resulted in significant improvements with respect to aspartimide formation.  Complete suppression was achieved using the combination OtBu side chain protection and Hmb backbone protection for the preceding Gly residue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFzqypZqV6AbVg90H21EOLACvtfcHk0lgDLcn9UbRoMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht12qtbo%253D&md5=0622d6d24a4c4bf78e7b6ccbe86e3bc6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fpsc.430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.430%26sid%3Dliteratum%253Aachs%26aulast%3DMergler%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DF.%26aulast%3DSax%26aufirst%3DB.%26aulast%3DWeiler%26aufirst%3DP.%26aulast%3DVorherr%26aufirst%3DT.%26atitle%3DThe%2520aspartimide%2520problem%2520in%2520Fmoc-based%2520SPPS.%2520Part%2520I%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2003%26volume%3D9%26spage%3D36%26epage%3D46%26doi%3D10.1002%2Fpsc.430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Lauer, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, G. B.</span><span> </span><span class="NLM_article-title">Sequence dependence of aspartimide formation during 9-fluorenylmethoxycarbonyl solid-phase peptide synthesis</span> <span class="citation_source-journal">Lett. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span><span class="refDoi"> DOI: 10.1007/BF00117955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1007%2FBF00117955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaK2MXkvFyqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1995&pages=197-205&author=J.+L.+Lauerauthor=C.+G.+Fieldsauthor=G.+B.+Fields&title=Sequence+dependence+of+aspartimide+formation+during+9-fluorenylmethoxycarbonyl+solid-phase+peptide+synthesis&doi=10.1007%2FBF00117955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence dependence of aspartimide formation during 9-fluorenylmethoxycarbonyl solid-phase peptide synthesis</span></div><div class="casAuthors">Lauer, Janelle L.; Fields, Cynthia G.; Fields, Gregg B.</div><div class="citationInfo"><span class="NLM_cas:title">Letters in Peptide Science</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">197-205</span>CODEN:
                <span class="NLM_cas:coden">LPSCEM</span>;
        ISSN:<span class="NLM_cas:issn">0929-5666</span>.
    </div><div class="casAbstract">The authors have examd. the sequence dependence of aspartimide formation during 9-fluorenylmethoxycarbonyl (Fmoc)-based solid-phase synthesis of the peptide Bz-Val-Lys(Boc)-Asp(OtBu)-X-Tyr(tBu)-Ile-OH [Boc = tert-butoxycarbonyl, tBu = tert-butyl; X = (protected) amino acid residue].  The extent of aspartimide formation and subsequent conversion to the α- or β-piperidide was characterized and quantitated by anal. reversed-phase HPLC and fast atom bombardment mass spectrometry.  Aspartimide formation occurred for X = Arg(Pmc), Asn(Trt), Asp(OtBu), Cys(Acm), Gly, Ser, Thr, and Thr(tBu) (Pmc = 2,2,5,7,8-pentamthylchroman-6-sulfonyl, Trt = trityl, Acm = acetamidomethyl).  No single approach was found that could inhibit this side reaction for all sequences.  The most effective combinations, in general, for minimization of aspartimide formation were (i) tert-Bu side-chain protection of aspartate, piperidine for removal of the Fmoc group, and either 1-hydroxybenzotriazole or 2,4-dinitrophenol as an additive to the piperidine soln.; or (ii) 1-adamantyl side-chain protection of aspartate and DBU for removal of the Fmoc group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS626dukxJwLVg90H21EOLACvtfcHk0lgDLcn9UbRoMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvFyqsrk%253D&md5=61de60c8979c01616bfac2cce4443460</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2FBF00117955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00117955%26sid%3Dliteratum%253Aachs%26aulast%3DLauer%26aufirst%3DJ.%2BL.%26aulast%3DFields%26aufirst%3DC.%2BG.%26aulast%3DFields%26aufirst%3DG.%2BB.%26atitle%3DSequence%2520dependence%2520of%2520aspartimide%2520formation%2520during%25209-fluorenylmethoxycarbonyl%2520solid-phase%2520peptide%2520synthesis%26jtitle%3DLett.%2520Pept.%2520Sci.%26date%3D1995%26volume%3D1%26spage%3D197%26epage%3D205%26doi%3D10.1007%2FBF00117955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Wade, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tregear, G. W.</span><span> </span><span class="NLM_article-title">Base-induced side reactions in fmoc-solid phase peptide synthesis: Minimization by use of piperazine as N-alpha deprotection reagent</span> <span class="citation_source-journal">Lett. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1007/BF02443569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1007%2FBF02443569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkslOrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=107-112&author=J.+D.+Wadeauthor=M.+N.+Mathieuauthor=M.+Macrisauthor=G.+W.+Tregear&title=Base-induced+side+reactions+in+fmoc-solid+phase+peptide+synthesis%3A+Minimization+by+use+of+piperazine+as+N-alpha+deprotection+reagent&doi=10.1007%2FBF02443569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Base-induced side reactions in Fmoc-solid phase peptide synthesis: minimization by use of piperazine as Nα-deprotection reagent</span></div><div class="casAuthors">Wade, John D.; Mathieu, Marc N.; Macris, Mary; Tregear, Geoffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Letters in Peptide Science</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-112</span>CODEN:
                <span class="NLM_cas:coden">LPSCEM</span>;
        ISSN:<span class="NLM_cas:issn">0929-5666</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">Base-induced aspartimide (cyclic imide) and subsequent base adduct formation in the Fmoc-based solid-phase synthesis of sensitive peptide sequences are serious side reactions that are difficult to both anticipate and control.  The effect of extended treatment of piperazine as an Nα-Fmoc deprotection reagent on two sensitive peptide sequences, H-Val-Lys-Asp-Gly-Tyr-Ile-OH and H-Leu-Thr-Glu-Asp-Asn-Lys-OH, was examd.  For comparison, other bases were also investigated, including piperidine, 1-hydroxypiperidine, tetrabutylammonium fluoride (TBAF), and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).  The results showed that all bases induced varying degrees of both aspartimide and, in some cases, base adduct formation, although piperazine caused the least side reaction.  Use of N-(2-hydroxy-4-methoxybenzyl) (Hmb) peptide backbone amide protection was confirmed to confer complete protection against side reaction.  In the absence of such protection, for all bases, the use of 1-hydroxybenzotriazole (HOBt) as additive had some, but not complete, beneficial effect in further reducing side reaction.  Best results were obtained with piperazine contg. 0.1M of HOBt, indicating that this reagent merits serious consideration for Nα-deprotection in the Fmoc-solid phase synthesis of base-sensitive sequences.  A further advantage of this reagent is that it causes little racemization of resin-bound C-terminal cysteine, an occasionally serious base-mediated problem in Fmoc-solid phase assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKjq3YLF6mSrVg90H21EOLACvtfcHk0li_mwjQJG3zeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkslOrt7c%253D&md5=43112d82e771f9dd8a93413ad4578dd4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2FBF02443569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02443569%26sid%3Dliteratum%253Aachs%26aulast%3DWade%26aufirst%3DJ.%2BD.%26aulast%3DMathieu%26aufirst%3DM.%2BN.%26aulast%3DMacris%26aufirst%3DM.%26aulast%3DTregear%26aufirst%3DG.%2BW.%26atitle%3DBase-induced%2520side%2520reactions%2520in%2520fmoc-solid%2520phase%2520peptide%2520synthesis%253A%2520Minimization%2520by%2520use%2520of%2520piperazine%2520as%2520N-alpha%2520deprotection%2520reagent%26jtitle%3DLett.%2520Pept.%2520Sci.%26date%3D2000%26volume%3D7%26spage%3D107%26epage%3D112%26doi%3D10.1007%2FBF02443569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Okada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, K.</span><span> </span><span class="NLM_article-title">Synthesis of beta −1- and beta −2-adamantyl aspartates and their evaluation for peptide synthesis</span> <span class="citation_source-journal">J. Chem. Soc., Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_fpage">1532</span><span class="NLM_x">–</span> <span class="NLM_lpage">1534</span><span class="refDoi"> DOI: 10.1039/C39870001532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1039%2FC39870001532" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&pages=1532-1534&author=Y.+Okadaauthor=S.+Iguchiauthor=K.+Kawasaki&title=Synthesis+of+beta+%E2%88%921-+and+beta+%E2%88%922-adamantyl+aspartates+and+their+evaluation+for+peptide+synthesis&doi=10.1039%2FC39870001532"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1039%2FC39870001532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC39870001532%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DIguchi%26aufirst%3DS.%26aulast%3DKawasaki%26aufirst%3DK.%26atitle%3DSynthesis%2520of%2520beta%2520%25E2%2588%25921-%2520and%2520beta%2520%25E2%2588%25922-adamantyl%2520aspartates%2520and%2520their%2520evaluation%2520for%2520peptide%2520synthesis%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1987%26spage%3D1532%26epage%3D1534%26doi%3D10.1039%2FC39870001532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Karlstrom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unden, A.</span><span> </span><span class="NLM_article-title">Design of protecting groups for the beta-carboxylic group of aspartic acid that minimize base-catalyzed aspartimide formation</span> <span class="citation_source-journal">Int. J. Pept. Protein Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span><span class="refDoi"> DOI: 10.1111/j.1399-3011.1996.tb00846.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1111%2Fj.1399-3011.1996.tb00846.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=8919050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADyaK2s%252FnvV2htw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1996&pages=305-311&author=A.+Karlstromauthor=A.+Unden&title=Design+of+protecting+groups+for+the+beta-carboxylic+group+of+aspartic+acid+that+minimize+base-catalyzed+aspartimide+formation&doi=10.1111%2Fj.1399-3011.1996.tb00846.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Design of protecting groups for the beta-carboxylic group of aspartic acid that minimize base-catalyzed aspartimide formation</span></div><div class="casAuthors">Karlstrom A; Unden A</div><div class="citationInfo"><span class="NLM_cas:title">International journal of peptide and protein research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-11</span>
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">With the objectives of developing new protecting groups for the beta-carboxyl group of aspartic acid that are resistant to base-catalyzed aspartimide formation and of evaluating the importance of sterical factors in the design of such protecting groups, four new alkyl ester derivatives of aspartic acid were synthesized.  The beta-3-pentyl, beta-4-heptyl, beta-2,6-dimethyl-4-heptyl and the recently described beta-2,4-dimethyl-3-pentyl esters of Boc-aspartic acid were incorporated into model peptides, and the resin-bound protected peptides were treated with 20% piperidine for 10 h.  The levels of aspartimide-related side products were compared with the previously reported beta-cyclohexyl, beta-menthyl and beta-2-adamantyl esters of aspartic acid.  The results show that bulky, acyclic, aliphatic protecting groups (in particular the 2,4-dimethyl-3-pentyl ester) are significantly more resistant to base-catalyzed aspartimide formation than comparably rigid cyclic alkyl esters that under the same reaction conditions form several-fold more aspartimide-related side products.  Using elevated temperatures to overcome difficult couplings leads to the formation of significant amounts of aspartimide when aspartic acid is protected with the cyclohexyl group, but the 2,4-dimethyl-3-pentyl protecting group offers excellent protection under these conditions.  The use of the 2,4-dimethyl-3-pentyl protecting group will allow the use of orthogonally removable base-labile protecting groups in Boc chemistry and suggests a design of protecting groups for other nucleophile-sensitive trifunctional amino acids in both Boc and Fmoc chemistry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4-8FHcUthGoJKJbLTgsvCfW6udTcc2ealEP3tUC4KULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252FnvV2htw%253D%253D&md5=a6a761589e2b6648ee4c098a7cc83585</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1996.tb00846.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1996.tb00846.x%26sid%3Dliteratum%253Aachs%26aulast%3DKarlstrom%26aufirst%3DA.%26aulast%3DUnden%26aufirst%3DA.%26atitle%3DDesign%2520of%2520protecting%2520groups%2520for%2520the%2520beta-carboxylic%2520group%2520of%2520aspartic%2520acid%2520that%2520minimize%2520base-catalyzed%2520aspartimide%2520formation%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1996%26volume%3D48%26spage%3D305%26epage%3D311%26doi%3D10.1111%2Fj.1399-3011.1996.tb00846.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Quibell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peckman, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span> </span><span class="NLM_article-title">Suppression of piperidine-mediated side product formation for Asp(OBut)-containing peptides by the use of N-(2-hydroxy-4-methoxybenzyl) (Hmb) backbone amide protection</span> <span class="citation_source-journal">J. Chem. Soc., Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_fpage">2343</span><span class="NLM_x">–</span> <span class="NLM_lpage">2344</span><span class="refDoi"> DOI: 10.1039/c39940002343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1039%2Fc39940002343" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&pages=2343-2344&author=M.+Quibellauthor=D.+Owenauthor=L.+C.+Peckmanauthor=T.+Johnson&title=Suppression+of+piperidine-mediated+side+product+formation+for+Asp%28OBut%29-containing+peptides+by+the+use+of+N-%282-hydroxy-4-methoxybenzyl%29+%28Hmb%29+backbone+amide+protection&doi=10.1039%2Fc39940002343"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2Fc39940002343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39940002343%26sid%3Dliteratum%253Aachs%26aulast%3DQuibell%26aufirst%3DM.%26aulast%3DOwen%26aufirst%3DD.%26aulast%3DPeckman%26aufirst%3DL.%2BC.%26aulast%3DJohnson%26aufirst%3DT.%26atitle%3DSuppression%2520of%2520piperidine-mediated%2520side%2520product%2520formation%2520for%2520Asp%2528OBut%2529-containing%2520peptides%2520by%2520the%2520use%2520of%2520N-%25282-hydroxy-4-methoxybenzyl%2529%2520%2528Hmb%2529%2520backbone%2520amide%2520protection%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1994%26spage%3D2343%26epage%3D2344%26doi%3D10.1039%2Fc39940002343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Cardona, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberle, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barthelemy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beythien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneeberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keyte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. D.</span><span> </span><span class="NLM_article-title">Application of Dmb-dipeptides in the Fmoc SPPS of difficult and aspartimide-prone sequences</span> <span class="citation_source-journal">Int. J. Pept. Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span><span class="refDoi"> DOI: 10.1007/s10989-008-9154-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1007%2Fs10989-008-9154-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1aisLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=285-292&author=V.+Cardonaauthor=I.+Eberleauthor=S.+Barthelemyauthor=J.+Beythienauthor=B.+Doernerauthor=P.+Schneebergerauthor=J.+Keyteauthor=P.+D.+White&title=Application+of+Dmb-dipeptides+in+the+Fmoc+SPPS+of+difficult+and+aspartimide-prone+sequences&doi=10.1007%2Fs10989-008-9154-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Application of DMB-dipeptides in the Fmoc SPPS of difficult and aspartimide-prone sequences</span></div><div class="casAuthors">Cardona, V.; Eberle, I.; Barthelemy, S.; Beythien, J.; Doerner, B.; Schneeberger, P.; Keyte, J.; White, P. D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide Research and Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">285-292</span>CODEN:
                <span class="NLM_cas:coden">IJPRFC</span>;
        ISSN:<span class="NLM_cas:issn">1573-3149</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Mutter's pseudoproline dipeptides and Sheppard's Hmb (Hmb = 2-hydroxy-4-methoxy-1-methylbenzene) derivs. are powerful tools for enhancing synthetic efficiency in Fmoc SPPS (Fmoc = 9-fluorenylmethoxycarbonyl, SPPS = solid phase peptide synthesis).  They work by exploiting the natural propensity of N-alkyl amino acids to disrupt the formation of the secondary structures during peptide assembly.  Their use results in better and more predictable acylation and deprotection kinetics, enhanced reaction rates, and improved yields of crude products.  However, these approaches have certain limitations: pseudoproline dipeptides can only be used for sequences contg. serine or threonine, and the coupling of the amino acid following the Hmb residue can be extremely difficult.  To alleviate some of these shortcomings, we have prepd. a range of Fmoc-Aaa-(Dmb)Gly-OH (Dmb = 2,4-dimethoxy-1-methylbenzene) dipeptides and tested their efficacy in the synthesis of a no. of challenging hydrophobic peptides.  We also compared the efficiency of N-Dmb against N-Hmb backbone protection in preventing aspartimide formation in the Fmoc SPPS of peptides contg. the Asp-Gly sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkMA-kRWfVc7Vg90H21EOLACvtfcHk0lhh1FeFwpVa8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1aisLfE&md5=1d2e632730d47e0a835723956c9d7a6e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs10989-008-9154-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10989-008-9154-z%26sid%3Dliteratum%253Aachs%26aulast%3DCardona%26aufirst%3DV.%26aulast%3DEberle%26aufirst%3DI.%26aulast%3DBarthelemy%26aufirst%3DS.%26aulast%3DBeythien%26aufirst%3DJ.%26aulast%3DDoerner%26aufirst%3DB.%26aulast%3DSchneeberger%26aufirst%3DP.%26aulast%3DKeyte%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DP.%2BD.%26atitle%3DApplication%2520of%2520Dmb-dipeptides%2520in%2520the%2520Fmoc%2520SPPS%2520of%2520difficult%2520and%2520aspartimide-prone%2520sequences%26jtitle%3DInt.%2520J.%2520Pept.%2520Res.%2520Ther.%26date%3D2008%26volume%3D14%26spage%3D285%26epage%3D292%26doi%3D10.1007%2Fs10989-008-9154-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Röder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henklein, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisshoff, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mugge, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patzel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpino Louis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henklein, P.</span><span> </span><span class="NLM_article-title">On the use of N-dicyclopropylmethyl aspartyl-glycine synthone for backbone amide protection</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1002/psc.1196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.1196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=19924731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADC%252BD1Mfjtl2nsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=65-70&author=R.+R%C3%B6derauthor=P.+Henkleinauthor=H.+Weisshoffauthor=C.+Muggeauthor=M.+Patzelauthor=U.+Schubertauthor=A.+Carpino+Louisauthor=P.+Henklein&title=On+the+use+of+N-dicyclopropylmethyl+aspartyl-glycine+synthone+for+backbone+amide+protection&doi=10.1002%2Fpsc.1196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">On the use of N-dicyclopropylmethyl aspartyl-glycine synthone for backbone amide protection</span></div><div class="casAuthors">Roder Rene; Henklein Petra; Weisshoff Hardy; Mugge Clemens; Patzel Michael; Schubert Ulrich; Carpino Louis A; Henklein Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of peptide science : an official publication of the European Peptide Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To prevent aspartimide formation and related side products in Asp-Xaa, particularly Asp-Gly-containing peptides, usually the 2-hydroxy-4-methoxybenzyl (Hmb) backbone amide protection is applied for peptide synthesis according to the Fmoc-protocols.  In the present study, the usefulness of the recently proposed acid-labile dicyclopropylmethyl (Dcpm) protectant was analyzed.  Despite the significant steric hindrance of this bulky group, N-terminal H-(Dcpm)Gly-peptides are quantitatively acylated by potent acylating agents, and alternatively the dipeptide Fmoc-Asp(OtBu)-(Dcpm)Gly-OH derivative can be used as a building block.  In contrast to the Hmb group, Dcpm is inert toward acylations, but is readily removed in the acid deprotection and resin-cleavage step.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTptinzJq0hujAyhZbj3lKdfW6udTcc2eYDSwBxa7kIOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mfjtl2nsg%253D%253D&md5=3b1b61bb08df66b94361f4dae1afdbdc</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fpsc.1196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.1196%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6der%26aufirst%3DR.%26aulast%3DHenklein%26aufirst%3DP.%26aulast%3DWeisshoff%26aufirst%3DH.%26aulast%3DMugge%26aufirst%3DC.%26aulast%3DPatzel%26aufirst%3DM.%26aulast%3DSchubert%26aufirst%3DU.%26aulast%3DCarpino%2BLouis%26aufirst%3DA.%26aulast%3DHenklein%26aufirst%3DP.%26atitle%3DOn%2520the%2520use%2520of%2520N-dicyclopropylmethyl%2520aspartyl-glycine%2520synthone%2520for%2520backbone%2520amide%2520protection%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2010%26volume%3D16%26spage%3D65%26epage%3D70%26doi%3D10.1002%2Fpsc.1196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Barlos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatzi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stavropoulos, G.</span><span> </span><span class="NLM_article-title">2-chlorotrityl chloride resin. Studies on anchoring of Fmoc-amino acids and peptide cleavage</span> <span class="citation_source-journal">Int. J. Pept. Protein Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">520</span><span class="refDoi"> DOI: 10.1111/j.1399-3011.1991.tb00769.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1111%2Fj.1399-3011.1991.tb00769.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1917309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaK3MXltFGjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1991&pages=513-520&author=K.+Barlosauthor=O.+Chatziauthor=D.+Gatosauthor=G.+Stavropoulos&title=2-chlorotrityl+chloride+resin.+Studies+on+anchoring+of+Fmoc-amino+acids+and+peptide+cleavage&doi=10.1111%2Fj.1399-3011.1991.tb00769.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">2-Chlorotrityl chloride resin.  Studies on anchoring of Fmoc-aminio acids and peptide cleavage</span></div><div class="casAuthors">Barlos, Kleomenis; Chatzi, Olga; Gatos, Dimitrios; Stavropoulos, George</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">513-20</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">The esterification of 2-chlorotrityl chloride resin with 9-fluorenylmethoxycarbonyl (Fmoc) amino acids in the presence of EtN(CHMe2)2 is studied under various conditions.  High esterification yields are obtained using 0.6 equiv. Fmoc-amino acid/mmol resin in CH2Cl2 or ClCH2CH2Cl in 25 min at room temp.  The reaction proceeds without byproduct formation even in the case of Fmoc-Asn-OH and Fmoc-Gln-OH.  The quant. and easy cleavage of amino acids and peptides from 2-chlorotrityl resin using AcOH/CF3CH2OH/CH2Cl2 mixts. is accomplished within 15-60 min at room temp. while tert-Bu type protecting groups remain unaffected.  Under these exceptionally mild conditions, 2-chlorotrityl cations generated during the cleavage of amino acids and peptides from resin do not attack the nucleophilic side chains of tryptophan, methionine, and tyrosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ5Em66XBXF7Vg90H21EOLACvtfcHk0lhh1FeFwpVa8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXltFGjur4%253D&md5=2ac32b2f179e3b9e2a4977b6d7fa0aaa</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1991.tb00769.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1991.tb00769.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarlos%26aufirst%3DK.%26aulast%3DChatzi%26aufirst%3DO.%26aulast%3DGatos%26aufirst%3DD.%26aulast%3DStavropoulos%26aufirst%3DG.%26atitle%3D2-chlorotrityl%2520chloride%2520resin.%2520Studies%2520on%2520anchoring%2520of%2520Fmoc-amino%2520acids%2520and%2520peptide%2520cleavage%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1991%26volume%3D37%26spage%3D513%26epage%3D520%26doi%3D10.1111%2Fj.1399-3011.1991.tb00769.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Yamazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagaya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terauchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukumoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takase, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukahara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagakawa, J.</span><span> </span><span class="NLM_article-title">A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists</span> <span class="citation_source-journal">Biomed. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.2220/biomedres.34.129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.2220%2Fbiomedres.34.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=23782746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVart7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=129-136&author=K.+Yamazakiauthor=T.+Kagayaauthor=M.+Watanabeauthor=H.+Terauchiauthor=D.+Iidaauthor=H.+Fukumotoauthor=S.+Suzukiauthor=T.+Araiauthor=M.+Aokiauthor=K.+Takaseauthor=T.+Seikiauthor=K.+Tsukaharaauthor=J.+Nagakawa&title=A+novel+truncated+glucagon-like+peptide+2+%28GLP-2%29+as+a+tool+for+analyzing+GLP-2+receptor+agonists&doi=10.2220%2Fbiomedres.34.129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists</span></div><div class="casAuthors">Yamazaki, Kazuto; Kagaya, Takaki; Watanabe, Misako; Terauchi, Hiroki; Iida, Daisuke; Fukumoto, Hironori; Suzuki, Shuichi; Arai, Tohru; Aoki, Mika; Takase, Kazuma; Seiki, Takashi; Tsukahara, Kappei; Nagakawa, Junichi</div><div class="citationInfo"><span class="NLM_cas:title">Biomedical Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">129-136</span>CODEN:
                <span class="NLM_cas:coden">BRESD5</span>;
        ISSN:<span class="NLM_cas:issn">0388-6107</span>.
    
            (<span class="NLM_cas:orgname">Biomedical Research Press</span>)
        </div><div class="casAbstract">Glucagon-like peptide 2 (GLP-2) is an intestinotropic peptide that binds to GLP-2 receptor (GLP-2R), a class-B G protein-coupled receptor.  The GLP-2R antagonist GLP-2(3-33) has relatively high partial agonistic activity, and there are as yet no ideal known potent GLP-2R antagonists.  We therefore prepd. several truncated forms of human GLP-2 and characterized them by binding and reporter assays to find antagonists more potent than GLP-2(3-33).  We found that GLP-2(11-33) was the most potent orthosteric GLP-2R antagonist, with binding activity almost equal to those of GLP-2 and GLP-2(3-33) and weaker intrinsic agonistic activity than GLP-2(3-33).  GLP-2(11-33) retained weak agonistic activity toward human, cynomolgus monkey, dog, and Syrian hamster GLP-2Rs.  However, it had no agonistic activity toward rat GLP-2R.  GLP-2(11-33) potentiated the agonistic activity of an ago-allosteric modulator of GLP-2R, compd. 1 (N-[1-(2,5-dichlorothiophen-3-yl)-2-(phenylsulfanyl)ethylidene]hydroxylamine), synergistically toward human GLP-2R.  In the case of rat GLP-2R, GLP-2(11-33) decreased the agonistic activity of compd. 1, although GLP-2 and GLP-2(3-33) increased this activity additively.  These findings suggest that the binding sites of the ago-allosteric modulator and GLP-2 overlap, at least in rat GLP-2R.  GLP-2(11-33) is a novel, useful tool for analyzing the mode of action of agonists and ago-allosteric modulators of GLP-2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSIbf14scXjrVg90H21EOLACvtfcHk0lgJbpPuK4V2Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVart7rF&md5=f7ec5629c9d425e19cfc44b613eab564</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2220%2Fbiomedres.34.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2220%252Fbiomedres.34.129%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DKagaya%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DTerauchi%26aufirst%3DH.%26aulast%3DIida%26aufirst%3DD.%26aulast%3DFukumoto%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DArai%26aufirst%3DT.%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DTakase%26aufirst%3DK.%26aulast%3DSeiki%26aufirst%3DT.%26aulast%3DTsukahara%26aufirst%3DK.%26aulast%3DNagakawa%26aufirst%3DJ.%26atitle%3DA%2520novel%2520truncated%2520glucagon-like%2520peptide%25202%2520%2528GLP-2%2529%2520as%2520a%2520tool%2520for%2520analyzing%2520GLP-2%2520receptor%2520agonists%26jtitle%3DBiomed.%2520Res.%26date%3D2013%26volume%3D34%26spage%3D129%26epage%3D136%26doi%3D10.2220%2Fbiomedres.34.129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Goke, R.; Hareter, A.; Vahl, T.; Bode, H.-P.; Hoffmann, E.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-1 receptor in relation to its ligand</span>. In  <span class="citation_source-book">The insulinotropic gut hormone glucagon-like peptide-1</span>; <span class="NLM_contrib-group">Fehmann, H. C.; Goke, B.</span>, Eds.; <span class="NLM_publisher-name">Karger</span>: <span class="NLM_publisher-loc">Basel</span>,<span class="NLM_x"> </span><span class="NLM_year">1997</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=85-104&author=R.+Goke&author=A.+Hareter&author=T.+Vahl&author=H.-P.+Bode&author=E.+Hoffmannauthor=H.+C.+Fehmann&author=B.+Goke&title=The+insulinotropic+gut+hormone+glucagon-like+peptide-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGoke%26aufirst%3DR.%26atitle%3DGlucagon-like%2520peptide-1%2520receptor%2520in%2520relation%2520to%2520its%2520ligand%26btitle%3DThe%2520insulinotropic%2520gut%2520hormone%2520glucagon-like%2520peptide-1%26aulast%3DFehmann%26aufirst%3DH.%2BC.%26pub%3DKarger%26date%3D1997%26spage%3D85%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Pollaro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinis, C.</span><span> </span><span class="NLM_article-title">Strategies to prolong the plasma residence time of peptide drugs</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1039/c0md00111b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1039%2Fc0md00111b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeku7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=319-324&author=L.+Pollaroauthor=C.+Heinis&title=Strategies+to+prolong+the+plasma+residence+time+of+peptide+drugs&doi=10.1039%2Fc0md00111b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to prolong the plasma residence time of peptide drugs</span></div><div class="casAuthors">Pollaro, Lisa; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-324</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Peptides are an attractive class of mols. for the development of therapeutics because they combine unique properties such as high binding affinity, excellent target specificity, low toxicity and a relatively small mass.  However, the short in vivo half-life of peptides which is typically only a few minutes had hampered the development of a larger no. of peptide leads into drugs.  The main reasons for the fast elimination of peptides from the circulation are enzymic degrdn. and/or fast renal clearance.  To prolong the half-life of peptides, their proteolytic stability can be improved by chem. modification strategies and the rate of clearance can be reduced by conjugating the peptides to mols. that prevent their elimination through the kidney.  In this article the authors review the latter class of strategies that aims at prolonging the in vivo plasma residence time of peptides.  Techniques including peptide drug linkage to large polymers, fusion to long-lived proteins such as albumin or the Fc fragment of Ig and conjugation to small mol. albumin-binding tags are discussed and the peptide-conjugate half-lives achieved are compared.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-bQjUGU2Y6LVg90H21EOLACvtfcHk0lgJbpPuK4V2Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeku7%252FJ&md5=03e0faa35f4ce24670ae6c59861b883a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1039%2Fc0md00111b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0md00111b%26sid%3Dliteratum%253Aachs%26aulast%3DPollaro%26aufirst%3DL.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DStrategies%2520to%2520prolong%2520the%2520plasma%2520residence%2520time%2520of%2520peptide%2520drugs%26jtitle%3DMedChemComm%26date%3D2010%26volume%3D1%26spage%3D319%26epage%3D324%26doi%3D10.1039%2Fc0md00111b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Neumiller, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R. K.</span><span> </span><span class="NLM_article-title">Liraglutide: A once-daily incretin mimetic for the treatment of type 2 diabetes mellitus</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1444</span><span class="refDoi"> DOI: 10.1345/aph.1M134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1345%2Faph.1M134" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2009&pages=1433-1444&author=J.+J.+Neumillerauthor=R.+K.+Campbell&title=Liraglutide%3A+A+once-daily+incretin+mimetic+for+the+treatment+of+type+2+diabetes+mellitus&doi=10.1345%2Faph.1M134"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1345%2Faph.1M134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1M134%26sid%3Dliteratum%253Aachs%26aulast%3DNeumiller%26aufirst%3DJ.%2BJ.%26aulast%3DCampbell%26aufirst%3DR.%2BK.%26atitle%3DLiraglutide%253A%2520A%2520once-daily%2520incretin%2520mimetic%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2009%26volume%3D43%26spage%3D1433%26epage%3D1444%26doi%3D10.1345%2Faph.1M134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Ahmed, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balment, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, N.</span><span> </span><span class="NLM_article-title">Renal action of acute chloroquine and paracetamol administration in the anesthetized, fluid-balanced rat</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">478</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span><span class="refDoi"> DOI: 10.1124/jpet.103.051037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1124%2Fjpet.103.051037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=12721325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlslGltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=478-483&author=M.+H.+Ahmedauthor=R.+J.+Balmentauthor=N.+Ashton&title=Renal+action+of+acute+chloroquine+and+paracetamol+administration+in+the+anesthetized%2C+fluid-balanced+rat&doi=10.1124%2Fjpet.103.051037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Renal action of acute chloroquine and paracetamol administration in the anesthetized, fluid-balanced rat</span></div><div class="casAuthors">Ahmed, Mohamed H.; Balment, Richard J.; Ashton, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">478-483</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Chloroquine induces diuresis, natriuresis, and an increase in glomerular filtration rate (GFR) in the rat.  These responses are modified in rats with analgesic nephropathy induced by long-term paracetamol (acetaminophen) administration.  Here, the effects of acute paracetamol treatment on renal function and the response to chloroquine are reported.  Under intraval anesthesia (100 mg/kg) male Sprague-Dawley rats were infused with 2.5% dextrose for 3 h.  After a control hour, they received either vehicle, chloroquine (0.04 mg/h), paracetamol (priming dose of 210 mg/kg followed by 110 mg/kg/h) or chloroquine and paracetamol over the next hour.  Compared with vehicle, chloroquine infusion resulted in increases in GFR (2.4 vs. 4.8 mL/min), urine flow (4.2 vs. 10.4 mL/h), and sodium excretion (47.7 vs. 171.2 μmol/h) and a redn. in urine osmolality (223.2 vs. 121.7 mOsM/kg).  Paracetamol reduced sodium excretion but had no effect on urine flow, GFR, or urine osmolality.  When combined, paracetamol blocked the chloroquine-induced diuresis (3.9 mL/h) and natriuresis (22.6 μmol/h), attenuated the increase in glomerular filtration rate (3.5 mL/min), and raised urine osmolality (280.0 mOsM/kg).  The differing effects of acute and long-term paracetamol treatment on basal and chloroquine-mediated renal function suggest that the length of prior exposure to paracetamol, and thus the presence of analgesic nephropathy, is an important determinant of the renal response to chloroquine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCJVbDf1XFAbVg90H21EOLACvtfcHk0lhKmNRC5JHg5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlslGltLo%253D&md5=d83aeeaa384f1a488f53181cc1a7ae1e</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.051037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.051037%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DM.%2BH.%26aulast%3DBalment%26aufirst%3DR.%2BJ.%26aulast%3DAshton%26aufirst%3DN.%26atitle%3DRenal%2520action%2520of%2520acute%2520chloroquine%2520and%2520paracetamol%2520administration%2520in%2520the%2520anesthetized%252C%2520fluid-balanced%2520rat%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26spage%3D478%26epage%3D483%26doi%3D10.1124%2Fjpet.103.051037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Bailon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, C. Y.</span><span> </span><span class="NLM_article-title">PEG-modified biopharmaceuticals</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span><span class="refDoi"> DOI: 10.1517/17425240802650568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1517%2F17425240802650568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=19236204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktVahsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=1-16&author=P.+Bailonauthor=C.+Y.+Won&title=PEG-modified+biopharmaceuticals&doi=10.1517%2F17425240802650568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">PEG-modified biopharmaceuticals</span></div><div class="casAuthors">Bailon, Pascal; Won, Chee-Youb</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Delivery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-16</span>CODEN:
                <span class="NLM_cas:coden">EODDAW</span>;
        ISSN:<span class="NLM_cas:issn">1742-5247</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  PEGylation is a process in which one or more units of chem. activated polyethylene glycol reacts with a biomol., usually a protein, peptide, small mol. or oligonucleotide, creating a putative new mol. entity possessing physicochem. and physiol. characteristics that are distinct from its predecessor mols.  In recent years, PEGylation has been used not only as a drug delivery technol. but used also as a drug modification technol. to transform existing biopharmaceuticals clin. more efficacious than before their PEGylation.  PEGylation bestows several useful properties upon the native mol., resulting in improved pharmacokinetic and pharmacodynamic properties, which in turn enable the native mol. to achieve max. clin. potency.  In addn., PEGylation results in sustained clin. response with minimal dose and less frequency of dosing, leading to improved quality of life via increased patient compliance and reduced cost.  During the course of development of various pegylated protein therapeutics, several new insights have been gained.  This review article focuses on the approaches, strategies and the utilization of modern PEGylation concepts in the design and development of well-characterized pegylated protein therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf5II9oQ0hJLVg90H21EOLACvtfcHk0lhKmNRC5JHg5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktVahsw%253D%253D&md5=acb7ff4e9a7e77a6135f47be428a46bf</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1517%2F17425240802650568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425240802650568%26sid%3Dliteratum%253Aachs%26aulast%3DBailon%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DC.%2BY.%26atitle%3DPEG-modified%2520biopharmaceuticals%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2009%26volume%3D6%26spage%3D1%26epage%3D16%26doi%3D10.1517%2F17425240802650568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Jonsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dogan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herne, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahmsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nygren, P. A.</span><span> </span><span class="NLM_article-title">Engineering of a femtomolar affinity binding protein to human serum albumin</span> <span class="citation_source-journal">Protein Eng., Des. Sel.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">527</span><span class="refDoi"> DOI: 10.1093/protein/gzn028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1093%2Fprotein%2Fgzn028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=18499681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslGhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=515-527&author=A.+Jonssonauthor=J.+Doganauthor=N.+Herneauthor=L.+Abrahmsenauthor=P.+A.+Nygren&title=Engineering+of+a+femtomolar+affinity+binding+protein+to+human+serum+albumin&doi=10.1093%2Fprotein%2Fgzn028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering of a femtomolar affinity binding protein to human serum albumin</span></div><div class="casAuthors">Jonsson, Andreas; Dogan, Jakob; Herne, Nina; Abrahmsen, Lars; Nygren, Per-Aake</div><div class="citationInfo"><span class="NLM_cas:title">Protein Engineering, Design & Selection</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">515-527</span>CODEN:
                <span class="NLM_cas:coden">PEDSBR</span>;
        ISSN:<span class="NLM_cas:issn">1741-0126</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">We describe the development of a novel serum albumin binding protein showing an extremely high affinity (KD) for HSA in the femtomolar range.  Using a naturally occurring 46-residue three-helix bundle albumin binding domain (ABD) of nanomolar affinity for HSA as template, 15 residues were targeted for a combinatorial protein engineering strategy to identify variants showing improved HSA affinities.  Sequencing of 55 unique phage display-selected clones showed a strong bias for wild-type residues at nine positions, whereas various changes were obsd. at other positions, including charge shifts.  Addnl., a few non-designed substitutions appeared.  On the basis of the sequences of 12 variants showing high overall binding affinities and slow dissocn. rate kinetics, a set of seven-second generation' variants were constructed.  One variant denoted ABD035 displaying wild-type-like secondary structure content and excellent thermal denaturation/renaturation properties showed an apparent affinity for HSA in the range of 50-500 fM, corresponding to several orders of magnitude improvement compared with the wild-type domain.  The ABD035 variant also showed an improved affinity toward serum albumin from a no. of other species, and a capture expt. involving human serum indicated that the selectivity for serum albumin had not been compromised from the affinity engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdDKnGtvKyWbVg90H21EOLACvtfcHk0lhKmNRC5JHg5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslGhu70%253D&md5=ef527a653ec09e553ee2aaa4ea7b5358</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2Fgzn028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252Fgzn028%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DA.%26aulast%3DDogan%26aufirst%3DJ.%26aulast%3DHerne%26aufirst%3DN.%26aulast%3DAbrahmsen%26aufirst%3DL.%26aulast%3DNygren%26aufirst%3DP.%2BA.%26atitle%3DEngineering%2520of%2520a%2520femtomolar%2520affinity%2520binding%2520protein%2520to%2520human%2520serum%2520albumin%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D2008%26volume%3D21%26spage%3D515%26epage%3D527%26doi%3D10.1093%2Fprotein%2Fgzn028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Nilvebrant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hober, S.</span><span> </span><span class="NLM_article-title">The albumin-binding domain as a scaffold for protein engineering</span> <span class="citation_source-journal">Comput. Struct. Biotechnol. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e201303009</span><span class="refDoi"> DOI: 10.5936/csbj.201303009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.5936%2Fcsbj.201303009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=24688717" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=e201303009&author=J.+Nilvebrantauthor=S.+Hober&title=The+albumin-binding+domain+as+a+scaffold+for+protein+engineering&doi=10.5936%2Fcsbj.201303009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.5936%2Fcsbj.201303009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5936%252Fcsbj.201303009%26sid%3Dliteratum%253Aachs%26aulast%3DNilvebrant%26aufirst%3DJ.%26aulast%3DHober%26aufirst%3DS.%26atitle%3DThe%2520albumin-binding%2520domain%2520as%2520a%2520scaffold%2520for%2520protein%2520engineering%26jtitle%3DComput.%2520Struct.%2520Biotechnol.%2520J.%26date%3D2013%26volume%3D6%26spage%3De201303009%26doi%3D10.5936%2Fcsbj.201303009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Bollhagen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmiedberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grell, E.</span><span> </span><span class="NLM_article-title">A new reagent for the cleavage of fully protected peptides synthesized on 2-chlorotrityl chloride resin</span> <span class="citation_source-journal">J. Chem. Soc., Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_fpage">2559</span><span class="NLM_x">–</span> <span class="NLM_lpage">2560</span><span class="refDoi"> DOI: 10.1039/c39940002559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1039%2Fc39940002559" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&pages=2559-2560&author=R.+Bollhagenauthor=M.+Schmiedbergerauthor=K.+Barlosauthor=E.+Grell&title=A+new+reagent+for+the+cleavage+of+fully+protected+peptides+synthesized+on+2-chlorotrityl+chloride+resin&doi=10.1039%2Fc39940002559"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1039%2Fc39940002559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39940002559%26sid%3Dliteratum%253Aachs%26aulast%3DBollhagen%26aufirst%3DR.%26aulast%3DSchmiedberger%26aufirst%3DM.%26aulast%3DBarlos%26aufirst%3DK.%26aulast%3DGrell%26aufirst%3DE.%26atitle%3DA%2520new%2520reagent%2520for%2520the%2520cleavage%2520of%2520fully%2520protected%2520peptides%2520synthesized%2520on%25202-chlorotrityl%2520chloride%2520resin%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1994%26spage%3D2559%26epage%3D2560%26doi%3D10.1039%2Fc39940002559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Taichi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiuchi, Y.</span><span> </span><span class="NLM_article-title">Suppression of side reactions during final deprotection employing a strong acid in boc chemistry: Regeneration of methionyl residues from their sulfonium salts</span> <span class="citation_source-journal">Int. J. Pept. Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1007/s10989-009-9185-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1007%2Fs10989-009-9185-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsVentr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=247-253&author=M.+Taichiauthor=T.+Kimuraauthor=Y.+Nishiuchi&title=Suppression+of+side+reactions+during+final+deprotection+employing+a+strong+acid+in+boc+chemistry%3A+Regeneration+of+methionyl+residues+from+their+sulfonium+salts&doi=10.1007%2Fs10989-009-9185-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of Side Reactions During Final Deprotection Employing a Strong Acid in Boc Chemistry: Regeneration of Methionyl Residues from Their Sulfonium Salts</span></div><div class="casAuthors">Taichi, Misako; Kimura, Terutoshi; Nishiuchi, Yuji</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide Research and Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">247-253</span>CODEN:
                <span class="NLM_cas:coden">IJPRFC</span>;
        ISSN:<span class="NLM_cas:issn">1573-3149</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">During global deprotection using a strong acid in Boc chem., the electrophilic alkylating species, i.e. carbocations, and formaldehyde generated from the side-chain protecting groups and the benzyloxymethyl group on the His residue, resp., can cause alkylation of susceptible residues.  To reduce these side reactions, a deprotection procedure using a strong acid such as HF or TFA must always be carried out in the presence of scavengers.  The authors found that addn. of hydroxylamine derivs. could efficiently suppress the side reactions assocd. with formaldehyde and that addn. of 2-mercaptopyridine could not only specifically circumvent alkylation of the Met residue but also convert its sulfonium salt to the Met residue regardless of the substituent species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0YTQzXOLiq7Vg90H21EOLACvtfcHk0liqcNFcDVr_Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsVentr4%253D&md5=79f1d767b6a1239c29ea322c5f797dbb</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs10989-009-9185-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10989-009-9185-0%26sid%3Dliteratum%253Aachs%26aulast%3DTaichi%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DNishiuchi%26aufirst%3DY.%26atitle%3DSuppression%2520of%2520side%2520reactions%2520during%2520final%2520deprotection%2520employing%2520a%2520strong%2520acid%2520in%2520boc%2520chemistry%253A%2520Regeneration%2520of%2520methionyl%2520residues%2520from%2520their%2520sulfonium%2520salts%26jtitle%3DInt.%2520J.%2520Pept.%2520Res.%2520Ther.%26date%3D2009%26volume%3D15%26spage%3D247%26epage%3D253%26doi%3D10.1007%2Fs10989-009-9185-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Inui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muramatsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakakibara, S.</span><span> </span><span class="NLM_article-title">Solution synthesis of human midkine, a novel heparin-binding neurotrophic factor consisting of 121 amino acid residues with five disulphide bonds</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1002/psc.45.o</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.45.o" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=9225243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADyaK2szmvVKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=28-39&author=T.+Inuiauthor=J.+Bodiauthor=S.+Kuboauthor=H.+Nishioauthor=T.+Kimuraauthor=S.+Kojimaauthor=H.+Marutaauthor=T.+Muramatsuauthor=S.+Sakakibara&title=Solution+synthesis+of+human+midkine%2C+a+novel+heparin-binding+neurotrophic+factor+consisting+of+121+amino+acid+residues+with+five+disulphide+bonds&doi=10.1002%2Fpsc.45.o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Solution synthesis of human midkine, a novel heparin-binding neurotrophic factor consisting of 121 amino acid residues with five disulphide bonds</span></div><div class="casAuthors">Inui T; Bodi J; Kubo S; Nishio H; Kimura T; Kojima S; Maruta H; Muramatsu T; Sakakibara S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of peptide science : an official publication of the European Peptide Society</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    </div><div class="casAbstract">Human midkine (hMK), a novel heparin-binding neurotrophic factor consisting of 121 amino acid residues with five intramolecular disulphide bonds, was synthesized by solution procedure in order to demonstrate the usefulness of our newly developed solvent system, a mixture of dichloromethane or chloroform and trifluoroethanol.  The final protected 121-residue peptide was assembled from two large fully protected intermediates, Boc-(1-59)-OH and H-(60-121)-OBzl, in CHL/TFE(3:1, v/v) using water-soluble carbodiimide in the presence of HOOBt as coupling reagents.  After removal of the protecting groups by HF followed by treatment with Hg(OAc)2 in 50% acetic acid, the fully deprotected peptide was subjected to the oxidative folding reaction.  The final product was confirmed to have the correct disulphide structure from its tryptic peptide mapping and to possess the same biological activities as those of the natural product.  In order to clarify the active region of the hMK molecule, the N-terminal half domains [(1-59) and (60-121)] were also synthesized by the same procedure used for the hMK synthesis.  The C-half domain was confirmed to show the full pattern of bioactivities except for the neuronal cell survival activity, while the N-half one showed much less activity in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsR_RsLy2rrEQ0lWbKiCflfW6udTcc2eaG4gwO3C8nJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2szmvVKhuw%253D%253D&md5=91c1f8df5267c8496bc2f60f961f5222</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fpsc.45.o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.45.o%26sid%3Dliteratum%253Aachs%26aulast%3DInui%26aufirst%3DT.%26aulast%3DBodi%26aufirst%3DJ.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DNishio%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DKojima%26aufirst%3DS.%26aulast%3DMaruta%26aufirst%3DH.%26aulast%3DMuramatsu%26aufirst%3DT.%26aulast%3DSakakibara%26aufirst%3DS.%26atitle%3DSolution%2520synthesis%2520of%2520human%2520midkine%252C%2520a%2520novel%2520heparin-binding%2520neurotrophic%2520factor%2520consisting%2520of%2520121%2520amino%2520acid%2520residues%2520with%2520five%2520disulphide%2520bonds%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D1996%26volume%3D2%26spage%3D28%26epage%3D39%26doi%3D10.1002%2Fpsc.45.o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Himmler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratowa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czernilofsky, A. P.</span><span> </span><span class="NLM_article-title">Functional testing of human dopamine d1 and d5 receptors expressed in stable camp-responsive luciferase reporter cell lines</span> <span class="citation_source-journal">J. Recept. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.3109/10799899309073647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.3109%2F10799899309073647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=8383768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaK3sXhtFKru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1993&pages=79-94&author=A.+Himmlerauthor=C.+Stratowaauthor=A.+P.+Czernilofsky&title=Functional+testing+of+human+dopamine+d1+and+d5+receptors+expressed+in+stable+camp-responsive+luciferase+reporter+cell+lines&doi=10.3109%2F10799899309073647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Functional testing of human dopamine D1 and D5 receptors expressed in stable cAMP-responsive luciferase reporter cell lines</span></div><div class="casAuthors">Himmler, A.; Stratowa, C.; Czernilofsky, A. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Receptor Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1-4</span>),
    <span class="NLM_cas:pages">79-94</span>CODEN:
                <span class="NLM_cas:coden">JRERDM</span>;
        ISSN:<span class="NLM_cas:issn">0197-5110</span>.
    </div><div class="casAbstract">Human dopaminergic D1 or D5 receptor genes were transfected into stably transfected CHO cells contg. the cAMP-inducible luciferase gene.  Treatment of these test cell lines with dopamine receptor agonists and antagonists modulated the luciferase expression in a dose-dependent manner.  The rank of potency of dopamine receptor agonists and antagonists was in agreement with reported data obtained from binding studies.  The non-isotopic assay can be performed in microtiter plate format and is far less work intensive than the detn. of adenylyl cyclase activity by direct cAMP measurement.  This technol. could also be utilized for discovery of new classes of compds., e.g. allosteric effectors or non competitive ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOtHC6B5qQw7Vg90H21EOLACvtfcHk0lj6duw6R-Jb1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtFKru7w%253D&md5=569b55337fce761347840f23b95bf86e</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3109%2F10799899309073647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10799899309073647%26sid%3Dliteratum%253Aachs%26aulast%3DHimmler%26aufirst%3DA.%26aulast%3DStratowa%26aufirst%3DC.%26aulast%3DCzernilofsky%26aufirst%3DA.%2BP.%26atitle%3DFunctional%2520testing%2520of%2520human%2520dopamine%2520d1%2520and%2520d5%2520receptors%2520expressed%2520in%2520stable%2520camp-responsive%2520luciferase%2520reporter%2520cell%2520lines%26jtitle%3DJ.%2520Recept.%2520Res.%26date%3D1993%26volume%3D13%26spage%3D79%26epage%3D94%26doi%3D10.3109%2F10799899309073647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Frick, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adkison, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells-Knecht, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woollard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higton, D. M.</span><span> </span><span class="NLM_article-title">Cassette dosing: Rapid in vivo assessment of pharmacokinetics</span> <span class="citation_source-journal">Pharm. Sci. Technol. Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span><span class="refDoi"> DOI: 10.1016/S1461-5347(98)00010-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2FS1461-5347%2898%2900010-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaK1cXislaks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1998&pages=12-18&author=L.+W.+Frickauthor=K.+K.+Adkisonauthor=K.+J.+Wells-Knechtauthor=P.+Woollardauthor=D.+M.+Higton&title=Cassette+dosing%3A+Rapid+in+vivo+assessment+of+pharmacokinetics&doi=10.1016%2FS1461-5347%2898%2900010-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Cassette dosing: rapid in vivo assessment of pharmacokinetics</span></div><div class="casAuthors">Frick, Lloyd W.; Adkison, Kimberly K.; Wells-Knecht, Kevin J.; Woollard, Patrick; Higton, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Science & Technology Today</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-18</span>CODEN:
                <span class="NLM_cas:coden">PSTTF8</span>;
        ISSN:<span class="NLM_cas:issn">1461-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 26 refs. on cassette dosing, which combines many test chems. into one dose soln. and is an attractive method for increasing the throughput of in vivo pharmacokinetic expts.  This dosing technique depends on the sensitivity and selectivity of modern anal. techniques, particularly HPLC/MS/MS.  Cassettes vary in size, but even relatively small ones greatly increase the nos. of compds. investigated by reducing the effort devoted to animal handling, sample processing and sample anal.  The major drawback of cassette dosing is the potential for drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_MeQApZA877Vg90H21EOLACvtfcHk0lj6duw6R-Jb1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislaks7o%253D&md5=2912aaa741529642959a80e409f0a7aa</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2FS1461-5347%2898%2900010-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1461-5347%252898%252900010-8%26sid%3Dliteratum%253Aachs%26aulast%3DFrick%26aufirst%3DL.%2BW.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DWoollard%26aufirst%3DP.%26aulast%3DHigton%26aufirst%3DD.%2BM.%26atitle%3DCassette%2520dosing%253A%2520Rapid%2520in%2520vivo%2520assessment%2520of%2520pharmacokinetics%26jtitle%3DPharm.%2520Sci.%2520Technol.%2520Today%26date%3D1998%26volume%3D1%26spage%3D12%26epage%3D18%26doi%3D10.1016%2FS1461-5347%2898%2900010-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Rie Suzuki, Giles A. Brown, John A. Christopher, Conor C. G. Scully, <span class="NLM_string-name hlFld-ContribAuthor">Miles Congreve</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 905-927. <a href="https://doi.org/10.1021/acs.jmedchem.9b00835" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00835</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00835%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BDevelopments%252Bin%252BTherapeutic%252BPeptides%252Bfor%252Bthe%252BGlucagon-like%252BPeptide%252B1%252Band%252B2%252BReceptors%26aulast%3DSuzuki%26aufirst%3DRie%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D23052019%26date%3D16102019%26date%3D02102019%26volume%3D63%26issue%3D3%26spage%3D905%26epage%3D927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Peng-Yu Yang, Huafei Zou, Candy Lee, Avinash Muppidi, Elizabeth Chao, Qiangwei Fu, Xiaozhou Luo, Danling Wang, Peter G. Schultz, <span class="NLM_string-name hlFld-ContribAuthor">Weijun Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 3218-3223. <a href="https://doi.org/10.1021/acs.jmedchem.7b00768" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00768</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00768%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStapled%25252C%252BLong-Acting%252BGlucagon-like%252BPeptide%252B2%252BAnalog%252Bwith%252BEfficacy%252Bin%252BDextran%252BSodium%252BSulfate%252BInduced%252BMouse%252BColitis%252BModels%26aulast%3DYang%26aufirst%3DPeng-Yu%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D25082017%26date%3D23032018%26date%3D12032018%26volume%3D61%26issue%3D7%26spage%3D3218%26epage%3D3223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan A.  Lafferty</span>, <span class="hlFld-ContribAuthor ">Finbarr P. M.  O’Harte</span>, <span class="hlFld-ContribAuthor ">Nigel  Irwin</span>, <span class="hlFld-ContribAuthor ">Victor A.  Gault</span>, <span class="hlFld-ContribAuthor ">Peter R.  Flatt</span>. </span><span class="cited-content_cbyCitation_article-title">Proglucagon-Derived Peptides as Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Endocrinology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fendo.2021.689678" title="DOI URL">https://doi.org/10.3389/fendo.2021.689678</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fendo.2021.689678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffendo.2021.689678%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Endocrinology%26atitle%3DProglucagon-Derived%252BPeptides%252Bas%252BTherapeutics%26aulast%3DLafferty%26aufirst%3DRyan%2BA.%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mirielle L.  Pauline</span>, <span class="hlFld-ContribAuthor ">Patrick N.  Nation</span>, <span class="hlFld-ContribAuthor ">Pamela R.  Wizzard</span>, <span class="hlFld-ContribAuthor ">Tierah  Hinchliffe</span>, <span class="hlFld-ContribAuthor ">Tong  Wu</span>, <span class="hlFld-ContribAuthor ">Violetta  Dimitriadou</span>, <span class="hlFld-ContribAuthor ">Justine M.  Turner</span>, <span class="hlFld-ContribAuthor ">Paul W.  Wales</span>. </span><span class="cited-content_cbyCitation_article-title">Comparing the Intestinotrophic Effects of 2 Glucagon‐Like Peptide‐2 Analogues in the Treatment of Short‐Bowel Syndrome in Neonatal Piglets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Parenteral and Enteral Nutrition</span><span> <strong>2021,</strong> <em>45 </em>
                                    (3)
                                     , 538-545. <a href="https://doi.org/10.1002/jpen.1853" title="DOI URL">https://doi.org/10.1002/jpen.1853</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jpen.1853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjpen.1853%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Parenteral%2520and%2520Enteral%2520Nutrition%26atitle%3DComparing%252Bthe%252BIntestinotrophic%252BEffects%252Bof%252B2%252BGlucagon%2525E2%252580%252590Like%252BPeptide%2525E2%252580%2525902%252BAnalogues%252Bin%252Bthe%252BTreatment%252Bof%252BShort%2525E2%252580%252590Bowel%252BSyndrome%252Bin%252BNeonatal%252BPiglets%26aulast%3DPauline%26aufirst%3DMirielle%2BL.%26date%3D2021%26date%3D2020%26volume%3D45%26issue%3D3%26spage%3D538%26epage%3D545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan A.  Lafferty</span>, <span class="hlFld-ContribAuthor ">Finbarr P.M.  O’Harte</span>, <span class="hlFld-ContribAuthor ">Nigel  Irwin</span>, <span class="hlFld-ContribAuthor ">Peter R.  Flatt</span>, <span class="hlFld-ContribAuthor ">Victor A.  Gault</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacology of Gut Hormone Mimetics for Obesity and Diabetes. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00035-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00035-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00035-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00035-9%26sid%3Dliteratum%253Aachs%26atitle%3DPharmacology%252Bof%252BGut%252BHormone%252BMimetics%252Bfor%252BObesity%252Band%252BDiabetes%26aulast%3DLafferty%26aufirst%3DRyan%2BA.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tierah  Hinchliffe</span>, <span class="hlFld-ContribAuthor ">Mirielle L.  Pauline</span>, <span class="hlFld-ContribAuthor ">Pamela R.  Wizzard</span>, <span class="hlFld-ContribAuthor ">Patrick N.  Nation</span>, <span class="hlFld-ContribAuthor ">Patricia  Brubaker</span>, <span class="hlFld-ContribAuthor ">Jhenielle R.  Campbell</span>, <span class="hlFld-ContribAuthor ">Yunji  Kim</span>, <span class="hlFld-ContribAuthor ">Violetta  Dimitriadou</span>, <span class="hlFld-ContribAuthor ">Paul W.  Wales</span>, <span class="hlFld-ContribAuthor ">Justine M.  Turner</span>. </span><span class="cited-content_cbyCitation_article-title">Durability of Linear Small‐Intestinal Growth Following Treatment Discontinuation of Long‐Acting Glucagon‐Like Peptide 2 (GLP‐2) Analogues. </span><span class="cited-content_cbyCitation_journal-name">Journal of Parenteral and Enteral Nutrition</span><span> <strong>2020,</strong> <em>181 </em><a href="https://doi.org/10.1002/jpen.2053" title="DOI URL">https://doi.org/10.1002/jpen.2053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jpen.2053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjpen.2053%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Parenteral%2520and%2520Enteral%2520Nutrition%26atitle%3DDurability%252Bof%252BLinear%252BSmall%2525E2%252580%252590Intestinal%252BGrowth%252BFollowing%252BTreatment%252BDiscontinuation%252Bof%252BLong%2525E2%252580%252590Acting%252BGlucagon%2525E2%252580%252590Like%252BPeptide%252B2%252B%252528GLP%2525E2%252580%2525902%252529%252BAnalogues%26aulast%3DHinchliffe%26aufirst%3DTierah%26date%3D2020%26date%3D2020%26volume%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yun  Ding</span>, <span class="hlFld-ContribAuthor ">Joey Paolo  Ting</span>, <span class="hlFld-ContribAuthor ">Jinsha  Liu</span>, <span class="hlFld-ContribAuthor ">Shams  Al-Azzam</span>, <span class="hlFld-ContribAuthor ">Priyanka  Pandya</span>, <span class="hlFld-ContribAuthor ">Sepideh  Afshar</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Amino Acids</span><span> <strong>2020,</strong> <em>52 </em>
                                    (9)
                                     , 1207-1226. <a href="https://doi.org/10.1007/s00726-020-02890-9" title="DOI URL">https://doi.org/10.1007/s00726-020-02890-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00726-020-02890-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00726-020-02890-9%26sid%3Dliteratum%253Aachs%26jtitle%3DAmino%2520Acids%26atitle%3DImpact%252Bof%252Bnon-proteinogenic%252Bamino%252Bacids%252Bin%252Bthe%252Bdiscovery%252Band%252Bdevelopment%252Bof%252Bpeptide%252Btherapeutics%26aulast%3DDing%26aufirst%3DYun%26date%3D2020%26date%3D2020%26volume%3D52%26issue%3D9%26spage%3D1207%26epage%3D1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.E.  Martchenko</span>, <span class="hlFld-ContribAuthor ">M.E.  Sweeney</span>, <span class="hlFld-ContribAuthor ">V.  Dimitriadou</span>, <span class="hlFld-ContribAuthor ">J.A.  Murray</span>, <span class="hlFld-ContribAuthor ">P.L.  Brubaker</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specific and Temporal Effects of Apraglutide, a Novel Long-Acting Glucagon-Like Peptide-2 Receptor Agonist, on Intestinal Growth in Mice. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2020,</strong> <em>373 </em>
                                    (3)
                                     , 347-352. <a href="https://doi.org/10.1124/jpet.119.263947" title="DOI URL">https://doi.org/10.1124/jpet.119.263947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.263947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.263947%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DSite-Specific%252Band%252BTemporal%252BEffects%252Bof%252BApraglutide%25252C%252Ba%252BNovel%252BLong-Acting%252BGlucagon-Like%252BPeptide-2%252BReceptor%252BAgonist%25252C%252Bon%252BIntestinal%252BGrowth%252Bin%252BMice%26aulast%3DMartchenko%26aufirst%3DS.E.%26date%3D2020%26date%3D2020%26volume%3D373%26issue%3D3%26spage%3D347%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Diane M.  Hargrove</span>, <span class="hlFld-ContribAuthor ">Sudarkodi  Alagarsamy</span>, <span class="hlFld-ContribAuthor ">Glenn  Croston</span>, <span class="hlFld-ContribAuthor ">Régent  Laporte</span>, <span class="hlFld-ContribAuthor ">Steve  Qi</span>, <span class="hlFld-ContribAuthor ">Karthik  Srinivasan</span>, <span class="hlFld-ContribAuthor ">Javier  Sueiras-Diaz</span>, <span class="hlFld-ContribAuthor ">Kazimierz  Wiśniewski</span>, <span class="hlFld-ContribAuthor ">Jennifer  Hartwig</span>, <span class="hlFld-ContribAuthor ">Mark  Lu</span>, <span class="hlFld-ContribAuthor ">Alexander P.  Posch</span>, <span class="hlFld-ContribAuthor ">Halina  Wiśniewska</span>, <span class="hlFld-ContribAuthor ">Claudio D.  Schteingart</span>, <span class="hlFld-ContribAuthor ">Pierre J.-M.  Rivière</span>, <span class="hlFld-ContribAuthor ">Violetta  Dimitriadou</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2020,</strong> <em>373 </em>
                                    (2)
                                     , 193-203. <a href="https://doi.org/10.1124/jpet.119.262238" title="DOI URL">https://doi.org/10.1124/jpet.119.262238</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.262238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.262238%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DPharmacological%252BCharacterization%252Bof%252BApraglutide%25252C%252Ba%252BNovel%252BLong-Acting%252BPeptidic%252BGlucagon-Like%252BPeptide-2%252BAgonist%25252C%252Bfor%252Bthe%252BTreatment%252Bof%252BShort%252BBowel%252BSyndrome%26aulast%3DHargrove%26aufirst%3DDiane%2BM.%26date%3D2020%26date%3D2020%26volume%3D373%26issue%3D2%26spage%3D193%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Piotr A.  Mroz</span>, <span class="hlFld-ContribAuthor ">Diego  Perez-Tilve</span>, <span class="hlFld-ContribAuthor ">John P.  Mayer</span>, <span class="hlFld-ContribAuthor ">Richard D.  DiMarchi</span>. </span><span class="cited-content_cbyCitation_article-title">Stereochemical inversion as a route to improved biophysical properties of therapeutic peptides exemplified by glucagon. </span><span class="cited-content_cbyCitation_journal-name">Communications Chemistry</span><span> <strong>2019,</strong> <em>2 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42004-018-0100-5" title="DOI URL">https://doi.org/10.1038/s42004-018-0100-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42004-018-0100-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42004-018-0100-5%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Chemistry%26atitle%3DStereochemical%252Binversion%252Bas%252Ba%252Broute%252Bto%252Bimproved%252Bbiophysical%252Bproperties%252Bof%252Btherapeutic%252Bpeptides%252Bexemplified%252Bby%252Bglucagon%26aulast%3DMroz%26aufirst%3DPiotr%2BA.%26date%3D2019%26date%3D2019%26volume%3D2%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">George M.  Slim</span>, <span class="hlFld-ContribAuthor ">Marihan  Lansing</span>, <span class="hlFld-ContribAuthor ">Pamela  Wizzard</span>, <span class="hlFld-ContribAuthor ">Patrick N.  Nation</span>, <span class="hlFld-ContribAuthor ">Sarah E.  Wheeler</span>, <span class="hlFld-ContribAuthor ">Patricia L.  Brubaker</span>, <span class="hlFld-ContribAuthor ">Palle B.  Jeppesen</span>, <span class="hlFld-ContribAuthor ">Paul W.  Wales</span>, <span class="hlFld-ContribAuthor ">Justine M.  Turner</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Long‐Acting GLP‐2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. </span><span class="cited-content_cbyCitation_journal-name">Journal of Parenteral and Enteral Nutrition</span><span> <strong>2019,</strong> <em>43 </em>
                                    (7)
                                     , 891-898. <a href="https://doi.org/10.1002/jpen.1500" title="DOI URL">https://doi.org/10.1002/jpen.1500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jpen.1500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjpen.1500%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Parenteral%2520and%2520Enteral%2520Nutrition%26atitle%3DNovel%252BLong%2525E2%252580%252590Acting%252BGLP%2525E2%252580%2525902%252BAnalogue%25252C%252BFE%252B203799%252B%252528Apraglutide%252529%25252C%252BEnhances%252BAdaptation%252Band%252BLinear%252BIntestinal%252BGrowth%252Bin%252Ba%252BNeonatal%252BPiglet%252BModel%252Bof%252BShort%252BBowel%252BSyndrome%252Bwith%252BTotal%252BResection%252Bof%252Bthe%252BIleum%26aulast%3DSlim%26aufirst%3DGeorge%2BM.%26date%3D2019%26date%3D2019%26volume%3D43%26issue%3D7%26spage%3D891%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jintao  Gu</span>, <span class="hlFld-ContribAuthor ">Jun  Liu</span>, <span class="hlFld-ContribAuthor ">Tonglie  Huang</span>, <span class="hlFld-ContribAuthor ">Wangqian  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Jia</span>, <span class="hlFld-ContribAuthor ">Nan  Mu</span>, <span class="hlFld-ContribAuthor ">Kuo  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiang  Hao</span>, <span class="hlFld-ContribAuthor ">Weina  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yingqi  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaochang  Xue</span>, <span class="hlFld-ContribAuthor ">Cun  Zhang</span>, <span class="hlFld-ContribAuthor ">Meng  Li</span>. </span><span class="cited-content_cbyCitation_article-title">The protective and anti-inflammatory effects of a modified glucagon-like peptide-2 dimer in inflammatory bowel disease. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2018,</strong> <em>155 </em>, 425-433. <a href="https://doi.org/10.1016/j.bcp.2018.07.027" title="DOI URL">https://doi.org/10.1016/j.bcp.2018.07.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2018.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2018.07.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DThe%252Bprotective%252Band%252Banti-inflammatory%252Beffects%252Bof%252Ba%252Bmodified%252Bglucagon-like%252Bpeptide-2%252Bdimer%252Bin%252Binflammatory%252Bbowel%252Bdisease%26aulast%3DGu%26aufirst%3DJintao%26date%3D2018%26volume%3D155%26spage%3D425%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/medium/jm-2015-01909v_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01909&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/medium/jm-2015-01909v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Sequences of human and rat GLP-2 and an analogue in the clinical development. Differences from the hGLP-2 sequence are marked in bold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01909&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/medium/jm-2015-01909v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. CD spectra of reference peptides <b>1</b>, and <b>2</b>, and compounds <b>73</b> and <b>81</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01909&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/medium/jm-2015-01909v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Stimulation of intestinal growth by compounds <b>2</b> (closed bars) and <b>73</b> (open bars) after daily s.c. administrations for 5 days. Small intestine wet weight for each rat was normalized to body weight and expressed as % increase over the mean of a vehicle control group run in the same experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.5b01909/20160414/images/large/jm-2015-01909v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01909&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 67 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Wideman, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covey, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. J.</span><span> </span><span class="NLM_article-title">A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2744</span><span class="NLM_x">–</span> <span class="NLM_lpage">2752</span><span class="refDoi"> DOI: 10.2337/db07-0563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.2337%2Fdb07-0563" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2007&pages=2744-2752&author=R.+D.+Widemanauthor=S.+D.+Coveyauthor=G.+C.+Webbauthor=D.+J.+Druckerauthor=T.+J.+Kieffer&title=A+switch+from+prohormone+convertase+%28PC%29-2+to+PC1%2F3+expression+in+transplanted+alpha-cells+is+accompanied+by+differential+processing+of+proglucagon+and+improved+glucose+homeostasis+in+mice&doi=10.2337%2Fdb07-0563"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2337%2Fdb07-0563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb07-0563%26sid%3Dliteratum%253Aachs%26aulast%3DWideman%26aufirst%3DR.%2BD.%26aulast%3DCovey%26aufirst%3DS.%2BD.%26aulast%3DWebb%26aufirst%3DG.%2BC.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DKieffer%26aufirst%3DT.%2BJ.%26atitle%3DA%2520switch%2520from%2520prohormone%2520convertase%2520%2528PC%2529-2%2520to%2520PC1%252F3%2520expression%2520in%2520transplanted%2520alpha-cells%2520is%2520accompanied%2520by%2520differential%2520processing%2520of%2520proglucagon%2520and%2520improved%2520glucose%2520homeostasis%2520in%2520mice%26jtitle%3DDiabetes%26date%3D2007%26volume%3D56%26spage%3D2744%26epage%3D2752%26doi%3D10.2337%2Fdb07-0563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Buhl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thim, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kofod, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orskov, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Naturally occurring products of proglucagon 111–160 in the porcine and human small intestine</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">8621</span><span class="NLM_x">–</span> <span class="NLM_lpage">8624</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1988&pages=8621-8624&author=T.+Buhlauthor=L.+Thimauthor=H.+Kofodauthor=C.+Orskovauthor=H.+Harlingauthor=J.+J.+Holst&title=Naturally+occurring+products+of+proglucagon+111%E2%80%93160+in+the+porcine+and+human+small+intestine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DThim%26aufirst%3DL.%26aulast%3DKofod%26aufirst%3DH.%26aulast%3DOrskov%26aufirst%3DC.%26aulast%3DHarling%26aufirst%3DH.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DNaturally%2520occurring%2520products%2520of%2520proglucagon%2520111%25E2%2580%2593160%2520in%2520the%2520porcine%2520and%2520human%2520small%2520intestine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1988%26volume%3D263%26spage%3D8621%26epage%3D8624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Munroe, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kooshesh, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizkalla, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demchyshyn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamboj, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumner-Smith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crivici, A.</span><span> </span><span class="NLM_article-title">Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">1569</span><span class="NLM_x">–</span> <span class="NLM_lpage">1573</span><span class="refDoi"> DOI: 10.1073/pnas.96.4.1569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1073%2Fpnas.96.4.1569" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=1569-1573&author=D.+G.+Munroeauthor=A.+K.+Guptaauthor=F.+Koosheshauthor=T.+B.+Vyasauthor=G.+Rizkallaauthor=H.+Wangauthor=L.+Demchyshynauthor=Z.+J.+Yangauthor=R.+K.+Kambojauthor=H.+Chenauthor=K.+McCallumauthor=M.+Sumner-Smithauthor=D.+J.+Druckerauthor=A.+Crivici&title=Prototypic+G+protein-coupled+receptor+for+the+intestinotrophic+factor+glucagon-like+peptide+2&doi=10.1073%2Fpnas.96.4.1569"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.4.1569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.4.1569%26sid%3Dliteratum%253Aachs%26aulast%3DMunroe%26aufirst%3DD.%2BG.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DKooshesh%26aufirst%3DF.%26aulast%3DVyas%26aufirst%3DT.%2BB.%26aulast%3DRizkalla%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DDemchyshyn%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DZ.%2BJ.%26aulast%3DKamboj%26aufirst%3DR.%2BK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMcCallum%26aufirst%3DK.%26aulast%3DSumner-Smith%26aufirst%3DM.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DCrivici%26aufirst%3DA.%26atitle%3DPrototypic%2520G%2520protein-coupled%2520receptor%2520for%2520the%2520intestinotrophic%2520factor%2520glucagon-like%2520peptide%25202%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D1569%26epage%3D1573%26doi%3D10.1073%2Fpnas.96.4.1569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Pedersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brix, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunddal, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenkilde, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orskov, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine</span> <span class="citation_source-journal">Peptides</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.1016/j.peptides.2015.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2Fj.peptides.2015.02.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=20-28&author=J.+Pedersenauthor=N.+B.+Pedersenauthor=S.+W.+Brixauthor=K.+V.+Grunddalauthor=M.+M.+Rosenkildeauthor=B.+Hartmannauthor=C.+Orskovauthor=S.+S.+Poulsenauthor=J.+J.+Holst&title=The+glucagon-like+peptide+2+receptor+is+expressed+in+enteric+neurons+and+not+in+the+epithelium+of+the+intestine&doi=10.1016%2Fj.peptides.2015.02.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2015.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2015.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DJ.%26aulast%3DPedersen%26aufirst%3DN.%2BB.%26aulast%3DBrix%26aufirst%3DS.%2BW.%26aulast%3DGrunddal%26aufirst%3DK.%2BV.%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26aulast%3DHartmann%26aufirst%3DB.%26aulast%3DOrskov%26aufirst%3DC.%26aulast%3DPoulsen%26aufirst%3DS.%2BS.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520glucagon-like%2520peptide%25202%2520receptor%2520is%2520expressed%2520in%2520enteric%2520neurons%2520and%2520not%2520in%2520the%2520epithelium%2520of%2520the%2520intestine%26jtitle%3DPeptides%26date%3D2015%26volume%3D67%26spage%3D20%26epage%3D28%26doi%3D10.1016%2Fj.peptides.2015.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 2</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">1759</span><span class="NLM_x">–</span> <span class="NLM_lpage">1764</span><span class="refDoi"> DOI: 10.1210/jcem.86.4.7386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1210%2Fjcem.86.4.7386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=11297614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVCksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2001&pages=1759-1764&author=D.+J.+Drucker&title=Glucagon-like+peptide+2&doi=10.1210%2Fjcem.86.4.7386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 2</span></div><div class="casAuthors">Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1759-1764</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review with 81 refs.  Glucagon-like peptide 2 (GLP-2) is a 33 amino acid peptide-encoded carboxyterminal to the sequence of GLP-1 in the proglucagon gene.  Both GLP-1 and GLP-2 are secreted from gut endocrine cells and promote nutrient absorption through distinct mechanisms of action.  GLP-2 regulates gastric motility, gastric acid secretion, intestinal hexose transport, and increases the barrier function of the gut epithelium.  GLP-2 significantly enhances the surface area of the mucosal epithelium via stimulation of crypt cell proliferation and inhibition of apoptosis in the enterocyte and crypt compartments.  The cytoprotective and reparative effects of GLP-2 are evident in rodent models of exptl. intestinal injury.  GLP-2 reduces mortality and decreases mucosal injury, cytokine expression, and bacterial septicemia in the setting of small and large bowel inflammation.  GLP-2 also enhances nutrient absorption and gut adaptation in rodents or humans with short bowel syndrome.  The actions of GLP-2 are transduced by the GLP-2 receptor, a G protein-coupled receptor expressed in gut endocrine cells of the stomach, small bowel, and colon.  Activation of GLP-2 receptor signaling in heterologous cells promotes resistance to apoptotic injury in vitro.  The cytoprotective, reparative, and energy-retentive properties of GLP-2 suggests that GLP-2 may potentially be useful for the treatment of human disorders characterized by injury and/or dysfunction of the intestinal mucosal epithelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzFyysyDV6erVg90H21EOLACvtfcHk0livTlX3ceNsqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVCksL0%253D&md5=bea3fcff269a4b6955383fe7204d7e02</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1210%2Fjcem.86.4.7386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.86.4.7386%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DGlucagon-like%2520peptide%25202%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2001%26volume%3D86%26spage%3D1759%26epage%3D1764%26doi%3D10.1210%2Fjcem.86.4.7386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2</span> <span class="citation_source-journal">Regul. Pept.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/S0167-0115(00)00185-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2FS0167-0115%2800%2900185-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=11033052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntF2htbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2000&pages=45-51&author=J.+J.+Holst&title=Gut+hormones+as+pharmaceuticals.+From+enteroglucagon+to+GLP-1+and+GLP-2&doi=10.1016%2FS0167-0115%2800%2900185-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2</span></div><div class="casAuthors">Holst, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">45-51</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 77 refs. is given on the glucagon-like peptides of the gut and their physiol. and pharmacol. potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2tDt8Jc8Co7Vg90H21EOLACvtfcHk0livTlX3ceNsqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntF2htbs%253D&md5=af90fb08baa95a2cdecb59e55b1b2870</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0167-0115%2800%2900185-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-0115%252800%252900185-3%26sid%3Dliteratum%253Aachs%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DGut%2520hormones%2520as%2520pharmaceuticals.%2520From%2520enteroglucagon%2520to%2520GLP-1%2520and%2520GLP-2%26jtitle%3DRegul.%2520Pept.%26date%3D2000%26volume%3D93%26spage%3D45%26epage%3D51%26doi%3D10.1016%2FS0167-0115%2800%2900185-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Estall, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2</span> <span class="citation_source-journal">Annu. Rev. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span><span class="refDoi"> DOI: 10.1146/annurev.nutr.26.061505.111223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1146%2Fannurev.nutr.26.061505.111223" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=391-411&author=J.+L.+Estallauthor=D.+J.+Drucker&title=Glucagon-like+peptide-2&doi=10.1146%2Fannurev.nutr.26.061505.111223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1146%2Fannurev.nutr.26.061505.111223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.nutr.26.061505.111223%26sid%3Dliteratum%253Aachs%26aulast%3DEstall%26aufirst%3DJ.%2BL.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DGlucagon-like%2520peptide-2%26jtitle%3DAnnu.%2520Rev.%2520Nutr.%26date%3D2006%26volume%3D26%26spage%3D391%26epage%3D411%26doi%3D10.1146%2Fannurev.nutr.26.061505.111223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wallis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forbes, A.</span><span> </span><span class="NLM_article-title">Review article: Glucagon-like peptide 2--current applications and future directions</span> <span class="citation_source-journal">Aliment. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.1111/j.1365-2036.2006.03193.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1111%2Fj.1365-2036.2006.03193.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=17217448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Glurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=365-372&author=K.+Wallisauthor=J.+R.+Waltersauthor=A.+Forbes&title=Review+article%3A+Glucagon-like+peptide+2%2D%2Dcurrent+applications+and+future+directions&doi=10.1111%2Fj.1365-2036.2006.03193.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Review article: glucagon-like peptide 2 - current applications and future directions</span></div><div class="casAuthors">Wallis, K.; Walters, J. R. F.; Forbes, A.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">365-372</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide 2 (GLP-2) is an important peptide growth factor secreted from the human intestine.  The trophic properties of GLP-2 are very specific to the gut where it is pivotal in the regulation of mucosal morphol., function and integrity.  This review details the current understanding of the mol. biol. of GLP-2, its mechanisms of action and physiol. properties.  A major focus is the discussion of recent clin. data evaluating the use of GLP-2 as a therapeutic agent.  Relevant articles were identified using Medline searches and from the ref. lists of key papers.  In the treatment of short bowel syndrome, GLP-2 has been shown to be highly effective in improving fluid absorption.  In Crohn's disease, GLP-2 is superior to placebo in the induction of remission.  Early data also suggest that the effects of GLP-2 on bone metab. can provide a new treatment approach for patients with osteoporosis.  In the future, the pos. effects of GLP-2 on intestinal barrier function, splanchnic perfusion and mucosal healing could be utilized to expand its therapeutic application to other causes of intestinal injury.  However, important safety aspects need to be considered when using this potent growth-promoting agent for a long term.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOfM-8VKLCp7Vg90H21EOLACvtfcHk0lh5rcw_UuRjyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Glurg%253D&md5=51c699d29898a231b644fbf753b6bb9e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2036.2006.03193.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2036.2006.03193.x%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DK.%26aulast%3DWalters%26aufirst%3DJ.%2BR.%26aulast%3DForbes%26aufirst%3DA.%26atitle%3DReview%2520article%253A%2520Glucagon-like%2520peptide%25202--current%2520applications%2520and%2520future%2520directions%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2007%26volume%3D25%26spage%3D365%26epage%3D372%26doi%3D10.1111%2Fj.1365-2036.2006.03193.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Thulesen, J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator</span> <span class="citation_source-journal">Curr. Protein Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span><span class="refDoi"> DOI: 10.2174/1389203043486946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.2174%2F1389203043486946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=14965320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVCmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=51-65&author=J.+Thulesen&title=Glucagon-like+peptide+2+%28GLP-2%29%2C+an+intestinotrophic+mediator&doi=10.2174%2F1389203043486946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator</span></div><div class="casAuthors">Thulesen, J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Protein and Peptide Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-65</span>CODEN:
                <span class="NLM_cas:coden">CPPSCM</span>;
        ISSN:<span class="NLM_cas:issn">1389-2037</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide 2 (GLP-2) is a newly discovered gastrointestinal peptide with 33% sequence homol. to glucagon.  GLP-2 has attracted interest because of its potent intestinotrophic endocrine/paracrine actions.  The peptide, consisting of 33 amino acids, results from expression of the glucagon gene in the enteroendocrine L-cells of the intestinal mucosa, from where it is released mainly in response to luminal contact with unabsorbed nutrients.  In addn. to mucosal growth, GLP-2 enhances activities of several intestinal brush-border enzymes, and it delays gastric transit, thereby increasing the intestinal capacity for nutrient absorption.  Thus, it appears that GLP-2 serves to ensure an optimal intestinal capacity.  The physiol. responses following exogenous administration of GLP-2 have been intensely investigated, and these appear to be rather specific for the gut, which is concordant with the localization of the GLP-2 receptor.  In addn., treatment with GLP-2 in exptl. animal models of several enteropathies indicates that GLP-2 ameliorates most of the obsd. intestinal abnormalities in these conditions.  Following secretion to the blood stream, the intact peptide is degraded rather rapidly by an aminopeptidase.  To circumvent the rapid and widespread metab. of intact GLP-2, degrdn.-resistant synthetic GLP-2 analogs have been developed together with other approaches, such as inhibition of the GLP-2 degrading enzyme.  This is of particular interest with respect to developing GLP-2 into a useful therapeutic agent in conditions with compromised intestinal function, since the first clin. trial has already indicated the potential of GLP-2 treatment in patients with short bowel syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxoJuIHb_JB7Vg90H21EOLACvtfcHk0lj7xqkOKwkWtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVCmt70%253D&md5=f78a264eb5a30f5830600a5b0741c553</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F1389203043486946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389203043486946%26sid%3Dliteratum%253Aachs%26aulast%3DThulesen%26aufirst%3DJ.%26atitle%3DGlucagon-like%2520peptide%25202%2520%2528GLP-2%2529%252C%2520an%2520intestinotrophic%2520mediator%26jtitle%3DCurr.%2520Protein%2520Pept.%2520Sci.%26date%3D2004%26volume%3D5%26spage%3D51%26epage%3D65%26doi%3D10.2174%2F1389203043486946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusta, B.</span><span> </span><span class="NLM_article-title">Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2</span> <span class="citation_source-journal">Annu. Rev. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span><span class="refDoi"> DOI: 10.1146/annurev-physiol-021113-170317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1146%2Fannurev-physiol-021113-170317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=24161075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVCmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=561-583&author=D.+J.+Druckerauthor=B.+Yusta&title=Physiology+and+pharmacology+of+the+enteroendocrine+hormone+glucagon-like+peptide-2&doi=10.1146%2Fannurev-physiol-021113-170317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2</span></div><div class="casAuthors">Drucker, Daniel J.; Yusta, Bernardo</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">561-583</span>CODEN:
                <span class="NLM_cas:coden">ARPHAD</span>;
        ISSN:<span class="NLM_cas:issn">0066-4278</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid proglucagon-derived peptide secreted from enteroendocrine L cells.  GLP-2 circulates at low basal levels in the fasting period, and plasma levels rise rapidly after food ingestion.  Renal clearance and enzymic inactivation control the elimination of bioactive GLP-2.  GLP-2 increases mesenteric blood flow and activates proabsorptive pathways in the gut, facilitating nutrient absorption.  GLP-2 also enhances gut barrier function and induces proliferative and cytoprotective pathways in the small bowel.  The actions of GLP-2 are transduced via a single G protein-coupled receptor (GLP-2R), expressed predominantly within the gastrointestinal tract.  Disruption of GLP-2R signaling increases susceptibility to gut injury and impairs the adaptive mucosal response to refeeding.  Sustained augmentation of GLP-2R signaling reduces the requirement for parenteral nutrition in human subjects with short-bowel syndrome.  Hence GLP-2 integrates nutrient-derived signals to optimize mucosal integrity and energy absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol4vDm4UO_zrVg90H21EOLACvtfcHk0lgAYg-DHFHJDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVCmtro%253D&md5=fa17b789eb9ec08042186b1d89d143a4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1146%2Fannurev-physiol-021113-170317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-physiol-021113-170317%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DYusta%26aufirst%3DB.%26atitle%3DPhysiology%2520and%2520pharmacology%2520of%2520the%2520enteroendocrine%2520hormone%2520glucagon-like%2520peptide-2%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2014%26volume%3D76%26spage%3D561%26epage%3D583%26doi%3D10.1146%2Fannurev-physiol-021113-170317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asa, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span> </span><span class="NLM_article-title">Induction of intestinal epithelial proliferation by glucagon-like peptide 2</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">7911</span><span class="NLM_x">–</span> <span class="NLM_lpage">7916</span><span class="refDoi"> DOI: 10.1073/pnas.93.15.7911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1073%2Fpnas.93.15.7911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=8755576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaK28XksFSrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=7911-7916&author=D.+J.+Druckerauthor=P.+Erlichauthor=S.+L.+Asaauthor=P.+L.+Brubaker&title=Induction+of+intestinal+epithelial+proliferation+by+glucagon-like+peptide+2&doi=10.1073%2Fpnas.93.15.7911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of intestinal epithelial proliferation by glucagon-like peptide 2</span></div><div class="casAuthors">Drucker, Daniel J.; Ehrlich, Peter; Asa, Sylvia L.; Brubaker, Patrical L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7911-7916</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Injury, inflammation, or resection of the small intestine results in severe compromise of intestinal function.  Nevertheless, therapeutic strategies for enhancing growth and repair of the intestinal mucosal epithelium are currently not available.  We demonstrate that nude mice bearing s.c. proglucagon-producing tumors exhibit marked proliferation of the small intestinal epithelium.  The factor responsible for inducing intestinal proliferation was identified as glucagon-like peptide 2 (GLP-2), a 33-amino acid peptide with no previously ascribed biol. function.  GLP-2 stimulated crypt cell proliferation and consistently induced a marked increase in bowel wt. and villus growth of the jejunum and ileum that was evident within 4 days after initiation of GLP-2 administration.  These observations define a novel biol. role for GLP-2 as an intestinal-derived peptide stimulator of small bowel epithelial proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo49R9X6QMYXLVg90H21EOLACvtfcHk0lgAYg-DHFHJDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFSrtbw%253D&md5=5c75a93928611978a52f2ef00ee32088</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.15.7911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.15.7911%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DErlich%26aufirst%3DP.%26aulast%3DAsa%26aufirst%3DS.%2BL.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26atitle%3DInduction%2520of%2520intestinal%2520epithelial%2520proliferation%2520by%2520glucagon-like%2520peptide%25202%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D7911%26epage%3D7916%26doi%3D10.1073%2Fpnas.93.15.7911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Tsai, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asa, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Intestinal growth-promoting properties of glucagon-like peptide-2 in mice</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">E77</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1997&pages=E77-84&author=C.+H.+Tsaiauthor=M.+Hillauthor=S.+L.+Asaauthor=P.+L.+Brubakerauthor=D.+J.+Drucker&title=Intestinal+growth-promoting+properties+of+glucagon-like+peptide-2+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DC.%2BH.%26aulast%3DHill%26aufirst%3DM.%26aulast%3DAsa%26aufirst%3DS.%2BL.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DIntestinal%2520growth-promoting%2520properties%2520of%2520glucagon-like%2520peptide-2%2520in%2520mice%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1997%26volume%3D273%26spage%3DE77%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Meier, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nauck, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinze, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetze, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulut, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallwitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1053/j.gastro.2005.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1053%2Fj.gastro.2005.10.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2006&pages=44-54&author=J.+J.+Meierauthor=M.+A.+Nauckauthor=A.+Pottauthor=K.+Heinzeauthor=O.+Goetzeauthor=K.+Bulutauthor=W.+E.+Schmidtauthor=B.+Gallwitzauthor=J.+J.+Holst&title=Glucagon-like+peptide+2+stimulates+glucagon+secretion%2C+enhances+lipid+absorption%2C+and+inhibits+gastric+acid+secretion+in+humans&doi=10.1053%2Fj.gastro.2005.10.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2005.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2005.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26aulast%3DNauck%26aufirst%3DM.%2BA.%26aulast%3DPott%26aufirst%3DA.%26aulast%3DHeinze%26aufirst%3DK.%26aulast%3DGoetze%26aufirst%3DO.%26aulast%3DBulut%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DW.%2BE.%26aulast%3DGallwitz%26aufirst%3DB.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DGlucagon-like%2520peptide%25202%2520stimulates%2520glucagon%2520secretion%252C%2520enhances%2520lipid%2520absorption%252C%2520and%2520inhibits%2520gastric%2520acid%2520secretion%2520in%2520humans%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D130%26spage%3D44%26epage%3D54%26doi%3D10.1053%2Fj.gastro.2005.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hsieh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longuet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maida, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahrami, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adeli, K.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">997</span><span class="NLM_x">–</span> <span class="NLM_lpage">1005</span><span class="refDoi"> DOI: 10.1053/j.gastro.2009.05.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1053%2Fj.gastro.2009.05.051" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=997-1005&author=J.+Hsiehauthor=C.+Longuetauthor=A.+Maidaauthor=J.+Bahramiauthor=E.+Xuauthor=C.+L.+Bakerauthor=P.+L.+Brubakerauthor=D.+J.+Druckerauthor=K.+Adeli&title=Glucagon-like+peptide-2+increases+intestinal+lipid+absorption+and+chylomicron+production+via+CD36&doi=10.1053%2Fj.gastro.2009.05.051"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2009.05.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2009.05.051%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DJ.%26aulast%3DLonguet%26aufirst%3DC.%26aulast%3DMaida%26aufirst%3DA.%26aulast%3DBahrami%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DE.%26aulast%3DBaker%26aufirst%3DC.%2BL.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DAdeli%26aufirst%3DK.%26atitle%3DGlucagon-like%2520peptide-2%2520increases%2520intestinal%2520lipid%2520absorption%2520and%2520chylomicron%2520production%2520via%2520CD36%26jtitle%3DGastroenterology%26date%3D2009%26volume%3D137%26spage%3D997%26epage%3D1005%26doi%3D10.1053%2Fj.gastro.2009.05.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Bremholm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henriksen, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2 increases mesenteric blood flow in humans</span> <span class="citation_source-journal">Scand. J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">319</span><span class="refDoi"> DOI: 10.1080/00365520802538195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1080%2F00365520802538195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=19005872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1equr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=314-319&author=L.+Bremholmauthor=M.+Hornumauthor=B.+M.+Henriksenauthor=S.+Larsenauthor=J.+J.+Holst&title=Glucagon-like+peptide-2+increases+mesenteric+blood+flow+in+humans&doi=10.1080%2F00365520802538195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide-2 increases mesenteric blood flow in humans</span></div><div class="casAuthors">Bremholm, Lasse; Hornum, Mads; Henriksen, Birthe Merete; Larsen, Steen; Holst, Jens Juul</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-319</span>CODEN:
                <span class="NLM_cas:coden">SJGRA4</span>;
        ISSN:<span class="NLM_cas:issn">0036-5521</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Mesenteric blood flow is believed to be influenced by digestion and absorption of ingested macronutrients.  We hypothesized that the intestinotrophic hormone, GLP-2 (glucagons-like peptide 2), may be involved in the regulation of mesenteric blood flow.  Changes in mesenteric blood flow were measured by Doppler ultrasound scanning of the superior mesenteric artery (SMA).  The aim of the study was to demonstrate the influence of GLP-2 on this flow, expressed as changes in resistance index (RI).  A homogeneous group of 10 fasting healthy volunteers completed a 2-day trial.  On day 1, a std. meal was given, and RI measured in the SMA.  On day 2, GLP-2 was infused i.v. at rates of 0.5, 1.0 and 2.0 pmol/kg/min over 3×45 min sepd. by a 15-20 min rest period.  After a further 15-20 min of rest, 450 nmol synthetic GLP-2 was given s.c..  RI in the SMA was measured before, during and after the meal and GLP-2 infusions.  After i.v. infusion of GLP-2, the following decreases in RI were obsd.: 0.5 pmol/kg/min: 2.7% (range 0-6.3%), 1.0 pmol/kg/min: 6.7% (range 0.4-15.9%), 2.0 pmol/kg/min: 15.3% (range 9.6-22.7%) p<0.00802.  When given s.c., GLP-2 elicited a max. av. change in RI of 15.6% (range 5.0-28.1%).  The std. meal elicited a 14.7% (range 8.8-21.6%) change, p<0.020 There was a similar change in RI over time (0-90 min) after a std. meal and after s.c. GLP-2, p<0.005.  Our study showed a significant assocn. between i.v. and s.c. administration of synthetic GLP-2 and changes in mesenteric blood flow.  An exponential dose-response relationship was obsd. after i.v. infusion.  The meal-induced changes in mesenteric blood flow over time were similar to those obtained by s.c. GLP-2.  Thus, our results support the hypothesis that GLP-2 is an important regulator of mesenteric blood flow.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6NX4dU8aOeLVg90H21EOLACvtfcHk0lhATXnyQk1GMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1equr8%253D&md5=5a317c3a06e002ae57421ff1ce433ac1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1080%2F00365520802538195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00365520802538195%26sid%3Dliteratum%253Aachs%26aulast%3DBremholm%26aufirst%3DL.%26aulast%3DHornum%26aufirst%3DM.%26aulast%3DHenriksen%26aufirst%3DB.%2BM.%26aulast%3DLarsen%26aufirst%3DS.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DGlucagon-like%2520peptide-2%2520increases%2520mesenteric%2520blood%2520flow%2520in%2520humans%26jtitle%3DScand.%2520J.%2520Gastroenterol.%26date%3D2009%26volume%3D44%26spage%3D314%26epage%3D319%26doi%3D10.1080%2F00365520802538195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Stephens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoll, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottrell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helmrath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrin, D. G.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in tpn-fed neonatal piglets</span> <span class="citation_source-journal">Am. J. Physiol. Regul. Integr. Comp. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">R283</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span><span class="refDoi"> DOI: 10.1152/ajpregu.00588.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1152%2Fajpregu.00588.2005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2006&pages=R283-289&author=J.+Stephensauthor=B.+Stollauthor=J.+Cottrellauthor=X.+Changauthor=M.+Helmrathauthor=D.+G.+Burrin&title=Glucagon-like+peptide-2+acutely+increases+proximal+small+intestinal+blood+flow+in+tpn-fed+neonatal+piglets&doi=10.1152%2Fajpregu.00588.2005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1152%2Fajpregu.00588.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpregu.00588.2005%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DJ.%26aulast%3DStoll%26aufirst%3DB.%26aulast%3DCottrell%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DX.%26aulast%3DHelmrath%26aufirst%3DM.%26aulast%3DBurrin%26aufirst%3DD.%2BG.%26atitle%3DGlucagon-like%2520peptide-2%2520acutely%2520increases%2520proximal%2520small%2520intestinal%2520blood%2520flow%2520in%2520tpn-fed%2520neonatal%2520piglets%26jtitle%3DAm.%2520J.%2520Physiol.%2520Regul.%2520Integr.%2520Comp.%2520Physiol.%26date%3D2006%26volume%3D290%26spage%3DR283%26epage%3D289%26doi%3D10.1152%2Fajpregu.00588.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Nagell, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wettergren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortensen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1</span> <span class="citation_source-journal">Scand. J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">358</span><span class="refDoi"> DOI: 10.1080/00365520410004424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1080%2F00365520410004424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=15125467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFCnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2004&pages=353-358&author=C.+F.+Nagellauthor=A.+Wettergrenauthor=J.+F.+Pedersenauthor=D.+Mortensenauthor=J.+J.+Holst&title=Glucagon-like+peptide-2+inhibits+antral+emptying+in+man%2C+but+is+not+as+potent+as+glucagon-like+peptide-1&doi=10.1080%2F00365520410004424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1</span></div><div class="casAuthors">Nagell, C. F.; Wettergren, A.; Pedersen, J. F.; Mortensen, D.; Holst, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-358</span>CODEN:
                <span class="NLM_cas:coden">SJGRA4</span>;
        ISSN:<span class="NLM_cas:issn">0036-5521</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis</span>)
        </div><div class="casAbstract">GLP-1 (glucagon-like peptide-1) and GLP-2 (glucagon-like peptide-2) are released in equimolar amts. in response to meal ingestion.  GLP-1 inhibits gastric emptying and reduces postprandial gastric and exocrine pancreatic secretion and may play a physiol. regulatory role in controlling appetite and energy intake in humans.  The role of GLP-2 is more uncertain.  Based on the results of animal studies, it was suggested that GLP-2 may induce intestinal epithelial growth and inhibit gastric motility.  The aim of this study was to det. to what extent GLP-2 alone or together with GLP-1 inhibits gastric emptying and the sensation of hunger in man.  Eight healthy volunteers were tested in a double-blind, placebo-controlled fashion.  Antral emptying of a liq. meal and hunger ratings were detd. using ultrasound technol. and visual analog scales scoring during infusions of saline, GLP-2 (0.5, and 1.0 pmol kg body wt min), GLP-1 (0.5 pmol kg body wt min) or GLP-1 and GLP-2 (0.5 pmol kg body wt min).  The GLP-2 infusions resulted in a dose-dependent increase in antral emptying time (35%; ns and 75%; P = 0.049) compared to saline, but GLP-2 was less potent than GLP-1, which increased the antral emptying time by 192% (P < 0.001).  Addn. of GLP-2 to the GLP-1 infusion did not alter the antral emptying time compared with GLP-1 alone.  The GLP-1 infusion decreased the sensation of hunger compared with saline (P = 0.023), whereas the 2 GLP-2 infusions had no significant effect.  Addn. of GLP-2 to the GLP-1 infusion did not decrease the sensation of hunger further.  Both GLP-1 and GLP-2 inhibit antral emptying in man, but GLP-1 is more potent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmDASIseiU8rVg90H21EOLACvtfcHk0lizVBP80xpILQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFCnt7o%253D&md5=302b23d3dc4da159f5ecd969ed994099</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F00365520410004424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00365520410004424%26sid%3Dliteratum%253Aachs%26aulast%3DNagell%26aufirst%3DC.%2BF.%26aulast%3DWettergren%26aufirst%3DA.%26aulast%3DPedersen%26aufirst%3DJ.%2BF.%26aulast%3DMortensen%26aufirst%3DD.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DGlucagon-like%2520peptide-2%2520inhibits%2520antral%2520emptying%2520in%2520man%252C%2520but%2520is%2520not%2520as%2520potent%2520as%2520glucagon-like%2520peptide-1%26jtitle%3DScand.%2520J.%2520Gastroenterol.%26date%3D2004%26volume%3D39%26spage%3D353%26epage%3D358%26doi%3D10.1080%2F00365520410004424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sigalet, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaji, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharkey, K. A.</span><span> </span><span class="NLM_article-title">Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2</span> <span class="citation_source-journal">Am. J. Physiol. Gastrointest. Liver Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">293</span><span class="NLM_x">, </span> <span class="NLM_fpage">G211</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1152/ajpgi.00530.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1152%2Fajpgi.00530.2006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2007&pages=G211-221&author=D.+L.+Sigaletauthor=L.+E.+Wallaceauthor=J.+J.+Holstauthor=G.+R.+Martinauthor=T.+Kajiauthor=H.+Tanakaauthor=K.+A.+Sharkey&title=Enteric+neural+pathways+mediate+the+anti-inflammatory+actions+of+glucagon-like+peptide+2&doi=10.1152%2Fajpgi.00530.2006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.00530.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.00530.2006%26sid%3Dliteratum%253Aachs%26aulast%3DSigalet%26aufirst%3DD.%2BL.%26aulast%3DWallace%26aufirst%3DL.%2BE.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DG.%2BR.%26aulast%3DKaji%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DSharkey%26aufirst%3DK.%2BA.%26atitle%3DEnteric%2520neural%2520pathways%2520mediate%2520the%2520anti-inflammatory%2520actions%2520of%2520glucagon-like%2520peptide%25202%26jtitle%3DAm.%2520J.%2520Physiol.%2520Gastrointest.%2520Liver%2520Physiol.%26date%3D2007%26volume%3D293%26spage%3DG211%26epage%3D221%26doi%3D10.1152%2Fajpgi.00530.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Alavi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palazzo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, R.</span><span> </span><span class="NLM_article-title">Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2</span> <span class="citation_source-journal">J. Pediatr. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">851</span><span class="refDoi"> DOI: 10.1053/jpsu.2000.6861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1053%2Fjpsu.2000.6861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10873024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADC%252BD3cvps1Kitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=847-851&author=K.+Alaviauthor=M.+Z.+Schwartzauthor=J.+P.+Palazzoauthor=R.+Prasad&title=Treatment+of+inflammatory+bowel+disease+in+a+rodent+model+with+the+intestinal+growth+factor+glucagon-like+peptide-2&doi=10.1053%2Fjpsu.2000.6861"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2</span></div><div class="casAuthors">Alavi K; Schwartz M Z; Palazzo J P; Prasad R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pediatric surgery</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">847-51</span>
        ISSN:<span class="NLM_cas:issn">0022-3468</span>.
    </div><div class="casAbstract">BACKGROUND/PURPOSE:  Microinjection of a Fisher (F344) rat zygote with human HLA-B27 and beta2-microglobulin genes induces spontaneous chronic gastrointestinal (GI) inflammation similar to lesions seen in patients with inflammatory bowel disease (IBD).  This study was designed to evaluate the potential therapeutic benefit of GLP-2, an intestinal growth factor, in this transgenic rat model of IBD.  METHODS:  Five F344 (control) and 10 HLA-B27 (on a F344 background) rats at 25 weeks of age were used.  Rats were divided into the following 3 groups: group 1, F344 rats, no treatment (n = 5); group 2, HLA-B27, no treatment (n = 5); and group 3, HLA-B27, treated with a 14-day systemic infusion (via the jugular vein) of GLP-2 at 50 microg/kg/d (n = 5).  After infusion, all rats underwent laparotomy, and the intestine from the ligament of Treitz to the rectum was harvested.  Total mucosal damage (percent surface area) was measured using image analysis software (Sigmascan 2.0).  Microscopic analysis was performed by a blinded reviewer and scored as follows: 0, no inflammation; 1, mild inflammation; 2, moderate inflammation; and 3, severe inflammation.  Colonic mucosal total RNA was assayed for tumor necrosis factor alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-2 (IL-2), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), internal standard, mRNA by reverse transcriptase polymerase chain reaction.  Statistical analysis was performed using analysis of variance (ANOVA) and expressed as mean +/- SEM.  RESULTS:  Normal F344 rats did not show evidence of gross or histological lesions in the small or large intestine.  GLP-2 reduced total mucosal damage from 9.0% +/- 0.7% in group 2 to 0.9% +/- 0.5% in group 3 (P < .01).  The histological lesion score was reduced from 7.0 +/- 0.6 in group 2 to 4.4 +/- 0.8 in group 3 (P < .01).  Furthermore, GLP-2 reduced the mean band intensity (MBI) of TNF-alpha (0.4 +/- 0.04 in group 2 to 0 in group 3, P < .01) and IFN-gamma (0.3 +/- 0.02 in group 2 to 0 in group 3, P < .01).  CONCLUSIONS:  These data show for the first time that GLP-2 significantly reduces gross (90% decrease) and histological (40% decrease) lesions in this rat model of IBD.  This is further supported by a significant decrease in gene expression of the inflammatory mediators TNF-alpha (100% decrease) and IFN-gamma (100% decrease).  These data suggest a potential therapeutic role for GLP-2 in IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvBDi0Vltjy1MGsG_HTXYFfW6udTcc2eZahgu6lvQV-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvps1Kitg%253D%253D&md5=e0ab22e4f8badab5a90945d71b6c9e62</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1053%2Fjpsu.2000.6861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fjpsu.2000.6861%26sid%3Dliteratum%253Aachs%26aulast%3DAlavi%26aufirst%3DK.%26aulast%3DSchwartz%26aufirst%3DM.%2BZ.%26aulast%3DPalazzo%26aufirst%3DJ.%2BP.%26aulast%3DPrasad%26aufirst%3DR.%26atitle%3DTreatment%2520of%2520inflammatory%2520bowel%2520disease%2520in%2520a%2520rodent%2520model%2520with%2520the%2520intestinal%2520growth%2520factor%2520glucagon-like%2520peptide-2%26jtitle%3DJ.%2520Pediatr.%2520Surg.%26date%3D2000%26volume%3D35%26spage%3D847%26epage%3D851%26doi%3D10.1053%2Fjpsu.2000.6861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Hartmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harr, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeppesen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojdemann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortensen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">In vivo and in vitro degradation of glucagon-like peptide-2 in humans</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">2884</span><span class="NLM_x">–</span> <span class="NLM_lpage">2888</span><span class="refDoi"> DOI: 10.1210/jcem.85.8.6717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1210%2Fjcem.85.8.6717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10946898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnslahsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2000&pages=2884-2888&author=B.+Hartmannauthor=M.+B.+Harrauthor=P.+B.+Jeppesenauthor=M.+Wojdemannauthor=C.+F.+Deaconauthor=P.+B.+Mortensenauthor=J.+J.+Holst&title=In+vivo+and+in+vitro+degradation+of+glucagon-like+peptide-2+in+humans&doi=10.1210%2Fjcem.85.8.6717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo and in vitro degradation of glucagon-like peptide-2 in humans</span></div><div class="casAuthors">Hartmann, Bolette; Harr, Mette B.; Jeppesen, Palle B.; Wojdemann, Morten; Deacon, Carolyn F.; Mortensen, Per B.; Holst, Jens J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2884-2888</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Glucagon-like peptide-2 (GLP-2), an intestinal product of glucagon gene expression which induces intestinal growth in mice, has been proposed as a treatment for intestinal insufficiency.  GLP-2 is metabolized extensively by dipeptidyl peptidase IV (DPP-IV) in rats, but less is known about its fate in humans.  Therefore, GLP-2 metab. was investigated in healthy volunteers after (1) a 500-Cal mixed meal (n = 6), (2) iv infusion of synthetic human GLP-2 (0.8 pmol/kg/min; n = 8), (3) a s.c. bolus injection (400 μg; n = 9), and (4) in vitro incubation in plasma and blood (1000 pmol/L; n = 4) .  GLP-2 concns. were detd. by N-terminal RIA measuring only intact GLP-2, side-viewing RIA measuring intact and degraded forms [e.g. GLP-2-(3-33) arising from DPP-IV degrdn.], and high performance liq. chromatog. (HPLC).  Meal ingestion elevated plasma GLP-2 (intact, 16 ± 3 to 73 ± 10 pmol/L at 90 min), and HPLC revealed two immunoreactive components: intact GLP-2 (57 ± 2%) and GLP-2-(3-33).  GLP-2 infusion increased plasma levels [intact, 9 ± 4 to 131 ± 11 pmol/L; total, 23 ± 7 to 350 ± 18 pmol/L; the differences represent GLP-2-(3-33)].  The elimination t1/2 values were 7.2 ± 2 min (intact GLP-2) and 27.4 ± 5.4 min [GLP-2-(3-33)], and MCRs were 6.8 ± 0.6 and 1.9 ± 0.3 mL/kg/min, resp.  S.c. injection increased intact GLP-2 to maximally 1493 ± 250 pmol/L at 45 min, whereas total GLP-2 increased to 2793 ± 477 pmol/L at 90 min.  At 60 min, plasma contained 69 ± 1% intact GLP-2.  In vitro the t1/2 values were 8.0 ± 1.5 h (plasma) and 3.3 ± 0.3 h (blood).  GLP-2-(3-33) was the only degrdn. product identified by HPLC, and a DPP-IV inhibitor abolished the degrdn. of GLP-2 in vitro.  We conclude that GLP-2 is extensively degraded to GLP-2-(3-33) in humans, presumably by DPP-IV.  Nevertheless, 69% remains intact 1 h after GLP-2 injection, supporting the possibility of s.c. use in patients with intestinal insufficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoezfRJnBcJG7Vg90H21EOLACvtfcHk0lhXhpfu5LatqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnslahsb4%253D&md5=4e9dd22c8d3ff5f5e0301162ad60dee8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1210%2Fjcem.85.8.6717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.85.8.6717%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DB.%26aulast%3DHarr%26aufirst%3DM.%2BB.%26aulast%3DJeppesen%26aufirst%3DP.%2BB.%26aulast%3DWojdemann%26aufirst%3DM.%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26aulast%3DMortensen%26aufirst%3DP.%2BB.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DIn%2520vivo%2520and%2520in%2520vitro%2520degradation%2520of%2520glucagon-like%2520peptide-2%2520in%2520humans%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2000%26volume%3D85%26spage%3D2884%26epage%3D2888%26doi%3D10.1210%2Fjcem.85.8.6717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crivici, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumner-Smith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeForest, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span> </span><span class="NLM_article-title">Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span><span class="refDoi"> DOI: 10.1038/nbt0797-673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1038%2Fnbt0797-673" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1997&pages=673-677&author=D.+J.+Druckerauthor=Q.+Shiauthor=A.+Criviciauthor=M.+Sumner-Smithauthor=W.+Tavaresauthor=M.+Hillauthor=L.+DeForestauthor=S.+Cooperauthor=P.+L.+Brubaker&title=Regulation+of+the+biological+activity+of+glucagon-like+peptide+2+in+vivo+by+dipeptidyl+peptidase+IV&doi=10.1038%2Fnbt0797-673"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt0797-673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0797-673%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DCrivici%26aufirst%3DA.%26aulast%3DSumner-Smith%26aufirst%3DM.%26aulast%3DTavares%26aufirst%3DW.%26aulast%3DHill%26aufirst%3DM.%26aulast%3DDeForest%26aufirst%3DL.%26aulast%3DCooper%26aufirst%3DS.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26atitle%3DRegulation%2520of%2520the%2520biological%2520activity%2520of%2520glucagon-like%2520peptide%25202%2520in%2520vivo%2520by%2520dipeptidyl%2520peptidase%2520IV%26jtitle%3DNat.%2520Biotechnol.%26date%3D1997%26volume%3D15%26spage%3D673%26epage%3D677%26doi%3D10.1038%2Fnbt0797-673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Thulesen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastrup, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissow, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeppesen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orskov, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, S. S.</span><span> </span><span class="NLM_article-title">The truncated metabolite GLP-2 (3–33) interacts with the GLP-2 receptor as a partial agonist</span> <span class="citation_source-journal">Regul. Pept.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1016/S0167-0115(01)00316-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2FS0167-0115%2801%2900316-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=11738243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovVCjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2002&pages=9-15&author=J.+Thulesenauthor=L.+B.+Knudsenauthor=B.+Hartmannauthor=S.+Hastrupauthor=H.+Kissowauthor=P.+B.+Jeppesenauthor=C.+Orskovauthor=J.+J.+Holstauthor=S.+S.+Poulsen&title=The+truncated+metabolite+GLP-2+%283%E2%80%9333%29+interacts+with+the+GLP-2+receptor+as+a+partial+agonist&doi=10.1016%2FS0167-0115%2801%2900316-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist</span></div><div class="casAuthors">Thulesen, Jesper; Knudsen, Lotte Bjerre; Hartmann, Bolette; Hastrup, Sven; Kissow, Hannelouise; Jeppesen, Palle Bekker; Orskov, Cathrine; Holst, Jens Juul; Poulsen, Steen Seier</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-15</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The therapeutic potential of the intestinotrophic mediator glucagon-like peptide-2 (1-33) [GLP-2 (1-33)] has increased interest in the pharmacokinetics of the peptide.  This study was undertaken to investigate whether the primary degrdn. product GLP-2 (3-33) interacts with the GLP-2 receptor.  Functional (cAMP) and binding in vitro studies were carried out in cells expressing the transfected human GLP-2 receptor.  Furthermore, a biol. response of GLP-2 (3-33) was tested in vivo.  Mice were allocated to groups treated for 10 days (twice daily) with: (1) 5 μg GLP-2 (1-33), (2) 25 μg GLP-2 (3-33), (3) 5 μg GLP-2 (1-33) + 100 μg GLP-2 (3-33), or (4) 5 μg GLP-2 (1-33) + 500 μg GLP-2 (3-33).  The intestine was investigated for growth changes.  GLP-2 (3-33) bound to the GLP-2 receptor with a binding affinity of 7.5% of that of GLP-2 (1-33).  The cAMP accumulation was stimulated with an efficacy of 15% and a potency more than two orders of magnitude lower than that of GLP-2 (1-33).  Increasing doses of GLP-2 (3-33) (10-7-10-5 M) caused a shift to the right in the dose-response curve of GLP-2 (1-33).  Treatment of mice with either GLP-2 (1-33) or (3-33) induced significant growth responses in both the small and large intestines, but the response induced by GLP-2 (3-33) was much smaller.  Co-administration of 500 μg of GLP-2 (3-33) and 5 μg GLP-2 (1-33) resulted in a growth response that was smaller than that of 5 μg GLP-2 (1-33) alone.  Consistent with the obsd. in vivo activities, our functional studies and binding data indicate that GLP-2 (3-33) acts as a partial agonist with potential competitive antagonistic properties on the GLP-2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbdvWbDih5a7Vg90H21EOLACvtfcHk0liduDJPfzu34g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovVCjt74%253D&md5=9b363b142168519ca7be07aac37ee47e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0167-0115%2801%2900316-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-0115%252801%252900316-0%26sid%3Dliteratum%253Aachs%26aulast%3DThulesen%26aufirst%3DJ.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DHartmann%26aufirst%3DB.%26aulast%3DHastrup%26aufirst%3DS.%26aulast%3DKissow%26aufirst%3DH.%26aulast%3DJeppesen%26aufirst%3DP.%2BB.%26aulast%3DOrskov%26aufirst%3DC.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DPoulsen%26aufirst%3DS.%2BS.%26atitle%3DThe%2520truncated%2520metabolite%2520GLP-2%2520%25283%25E2%2580%259333%2529%2520interacts%2520with%2520the%2520GLP-2%2520receptor%2520as%2520a%2520partial%2520agonist%26jtitle%3DRegul.%2520Pept.%26date%3D2002%26volume%3D103%26spage%3D9%26epage%3D15%26doi%3D10.1016%2FS0167-0115%2801%2900316-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Larsen, B. D.; Petersen, Y. M.</span><span> </span><span class="NLM_article-title">Selective glucagon-like-peptide-2 (GLP-2) analogues</span>. WO2008056155,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=B.+D.+Larsen&author=Y.+M.+Petersen&title=Selective+glucagon-like-peptide-2+%28GLP-2%29+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DB.%2BD.%26atitle%3DSelective%2520glucagon-like-peptide-2%2520%2528GLP-2%2529%2520analogues%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Just, R.; Bovbjerg, K. L.; Riber, D.; Russel, W. S.</span><span> </span><span class="NLM_article-title">Glucagon-like-peptide-2 (GLP-2) analogues</span>. WO2013164484,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Just&author=K.+L.+Bovbjerg&author=D.+Riber&author=W.+S.+Russel&title=Glucagon-like-peptide-2+%28GLP-2%29+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJust%26aufirst%3DR.%26atitle%3DGlucagon-like-peptide-2%2520%2528GLP-2%2529%2520analogues%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeForest, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span> </span><span class="NLM_article-title">Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">G1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1997&pages=G1252-1262&author=D.+J.+Druckerauthor=L.+DeForestauthor=P.+L.+Brubaker&title=Intestinal+response+to+growth+factors+administered+alone+or+in+combination+with+human+%5BGly2%5Dglucagon-like+peptide+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DDeForest%26aufirst%3DL.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26atitle%3DIntestinal%2520response%2520to%2520growth%2520factors%2520administered%2520alone%2520or%2520in%2520combination%2520with%2520human%2520%255BGly2%255Dglucagon-like%2520peptide%25202%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1997%26volume%3D273%26spage%3DG1252%26epage%3D1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Boushey, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusta, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">E937</span><span class="NLM_x">–</span> <span class="NLM_lpage">947</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1999&pages=E937-947&author=R.+P.+Bousheyauthor=B.+Yustaauthor=D.+J.+Drucker&title=Glucagon-like+peptide+2+decreases+mortality+and+reduces+the+severity+of+indomethacin-induced+murine+enteritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoushey%26aufirst%3DR.%2BP.%26aulast%3DYusta%26aufirst%3DB.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DGlucagon-like%2520peptide%25202%2520decreases%2520mortality%2520and%2520reduces%2520the%2520severity%2520of%2520indomethacin-induced%2520murine%2520enteritis%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1999%26volume%3D277%26spage%3DE937%26epage%3D947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Scott, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNaughton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meddings, J. B.</span><span> </span><span class="NLM_article-title">GLP-2 augments the adaptive response to massive intestinal resection in rat</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">G911</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1998&pages=G911-921&author=R.+B.+Scottauthor=D.+Kirkauthor=W.+K.+MacNaughtonauthor=J.+B.+Meddings&title=GLP-2+augments+the+adaptive+response+to+massive+intestinal+resection+in+rat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DR.%2BB.%26aulast%3DKirk%26aufirst%3DD.%26aulast%3DMacNaughton%26aufirst%3DW.%2BK.%26aulast%3DMeddings%26aufirst%3DJ.%2BB.%26atitle%3DGLP-2%2520augments%2520the%2520adaptive%2520response%2520to%2520massive%2520intestinal%2520resection%2520in%2520rat%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1998%26volume%3D275%26spage%3DG911%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Washizawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Openo, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegler, T. R.</span><span> </span><span class="NLM_article-title">Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats</span> <span class="citation_source-journal">JPEN, J. Parenter. Enteral Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span><span class="refDoi"> DOI: 10.1177/0148607104028006399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1177%2F0148607104028006399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=15568286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVGgtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2004&pages=399-409&author=N.+Washizawaauthor=L.+H.+Guauthor=L.+Guauthor=K.+P.+Openoauthor=D.+P.+Jonesauthor=T.+R.+Ziegler&title=Comparative+effects+of+glucagon-like+peptide-2+%28GLP-2%29%2C+growth+hormone+%28GH%29%2C+and+keratinocyte+growth+factor+%28KGF%29+on+markers+of+gut+adaptation+after+massive+small+bowel+resection+in+rats&doi=10.1177%2F0148607104028006399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats</span></div><div class="casAuthors">Washizawa, Naohiro; Gu, Li H.; Gu, Liang; Openo, Kyle P.; Jones, Dean P.; Ziegler, Thomas R.</div><div class="citationInfo"><span class="NLM_cas:title">JPEN, Journal of Parenteral and Enteral Nutrition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">399-409</span>CODEN:
                <span class="NLM_cas:coden">JPENDU</span>;
        ISSN:<span class="NLM_cas:issn">0148-6071</span>.
    
            (<span class="NLM_cas:orgname">American Society for Parenteral and Enteral Nutrition</span>)
        </div><div class="casAbstract">Administration of specific growth factors exert gut-trophic effects in animal models of massive small bowel resection (SBR); however, little comparative data are available.  The authors' aim was to compare effects of a human glucagon-like peptide-2 (GLP-2) analog, recombinant growth hormone (GH) and recombinant keratinocyte growth factor (KGF) on jejunal, ileal, and colonic growth and functional indexes after 80% SBR in rats.  Thirty-seven male rats underwent small bowel transection (sham operation) with s.c. saline administration (control; Tx-S) or 80% midjejuno-ileal resection (Rx) and treatment with either s.c. saline (Rx-S), GLP-2 at 0.2 mg/kg/d (Rx-GLP-2), GH at 3.0 mg/kg/d (Rx-GH), or KGF at 3.0 mg/kg/d (Rx-KGF) for 7 days.  All groups were pair-fed to intake of Rx-S rats.  Gut mucosal cell growth indexes (wet wt., DNA and protein content, villus height, crypt depth, and total mucosal height) were measured.  Expression of the cytoprotective trefoil peptide TFF3 was detd. by Western blot.  Gut mucosal concns. of the tripeptide glutathione (L-glutamyl-L-cysteinyl-glycine) and glutathione disulfide (GSSG) were measured by HPLC and the glutathione/GSSG ratio calcd.  SBR increased adaptive growth indexes in jejunal, ileal, and colonic mucosa.  GLP-2 treatment increased jejunal villus height and jejunal total mucosal height compared with effects of resection alone or resection with GH or KGF treatment.  Both GH and KGF modestly increased colonic crypt depth after SBR.  SBR did not affect small bowel or colonic goblet cell no. or TFF3 expression; however, goblet cell no. and TFF3 expression in both small bowel and colon were markedly up-regulated by KGF treatment and unaffected by GLP-2 and GH.  SBR oxidized the ileal and colonic mucosal glutathione/GSSG redox pools.  GLP-2 treatment after SBR increased the glutathione/GSSG ratio in jejunum, whereas KGF had an intermediate effect.  In addn., GLP-2 (but not GH or KGF) prevented the SBR-induced oxidn. of the glutathione/GSSG pools in both ileum and colon.  Thus, GLP-2 exerts superior trophic effects on jejunal growth and also improves mucosal glutathione redox status throughout the bowel after massive SBR in rats.  Both GH and KGF increase colonic mucosal growth in this model.  KGF alone potently increases gut mucosal goblet cell no. and expression of the cytoprotective trefoil peptide TFF3.  The differential effects of GLP-2, GH and KGF administration in this model of short bowel syndrome suggest that individual therapy with these growth factors may not be an adequate strategy to maximally improve adaptive gut mucosal growth and cytoprotection after massive small intestinal resection.  Future research should address the use of these agents in combination in short bowel syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsuJQpGLkTsLVg90H21EOLACvtfcHk0like2QgoafqtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVGgtLrK&md5=4b25f18d2621053dccefbcaae9630b05</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1177%2F0148607104028006399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0148607104028006399%26sid%3Dliteratum%253Aachs%26aulast%3DWashizawa%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DL.%2BH.%26aulast%3DGu%26aufirst%3DL.%26aulast%3DOpeno%26aufirst%3DK.%2BP.%26aulast%3DJones%26aufirst%3DD.%2BP.%26aulast%3DZiegler%26aufirst%3DT.%2BR.%26atitle%3DComparative%2520effects%2520of%2520glucagon-like%2520peptide-2%2520%2528GLP-2%2529%252C%2520growth%2520hormone%2520%2528GH%2529%252C%2520and%2520keratinocyte%2520growth%2520factor%2520%2528KGF%2529%2520on%2520markers%2520of%2520gut%2520adaptation%2520after%2520massive%2520small%2520bowel%2520resection%2520in%2520rats%26jtitle%3DJPEN%252C%2520J.%2520Parenter.%2520Enteral%2520Nutr.%26date%3D2004%26volume%3D28%26spage%3D399%26epage%3D409%26doi%3D10.1177%2F0148607104028006399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Tavakkolizadeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kormi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seifert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edelman, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinner, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whang, E. E.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 2: A new treatment for chemotherapy-induced enteritis</span> <span class="citation_source-journal">J. Surg. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1006/jsre.2000.5917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1006%2Fjsre.2000.5917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10816354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjt1ansLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2000&pages=77-82&author=A.+Tavakkolizadehauthor=R.+Shenauthor=P.+Abrahamauthor=N.+Kormiauthor=P.+Seifertauthor=E.+R.+Edelmanauthor=D.+O.+Jacobsauthor=M.+J.+Zinnerauthor=S.+W.+Ashleyauthor=E.+E.+Whang&title=Glucagon-like+peptide+2%3A+A+new+treatment+for+chemotherapy-induced+enteritis&doi=10.1006%2Fjsre.2000.5917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like Peptide 2: A New Treatment for Chemotherapy-Induced Enteritis</span></div><div class="casAuthors">Tavakkolizadeh, A.; Shen, R.; Abraham, P.; Kormi, N.; Seifert, P.; Edelman, E. R.; Jacobs, D. O.; Zinner, M. J.; Ashley, S. W.; Whang, E. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-82</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Background.  Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models.  The authors hypothesized that GLP-2 administration would be beneficial in chemotherapy-induced enteritis either by preventing injury or by promoting recovery.  Material and methods.  Rats received no drug (control), chemotherapy alone [5-fluorouracil (5-FU), 190 mg/kg, i.p.] (Chemo), 5-FU followed by 3 days of GLP-2 analog (ALX-0600, 0.1 μg, s.c. twice daily) (CH-G), or GLP-2 analog for 6 days prior to 5-FU and for 3 days afterward (G-CH-G).  Animals were pair fed.  Rats received 5-bromo-2-deoxyuridine (Br-dU, 50 mg/kg, 2.5 h prior to sacrifice on Day 3 postchemotherapy) for immunohistochem. assessment of cellular proliferation.  Results.  Chemotherapy induced significant redns. in body wt., villus height, and crypt depth compared with controls.  Intestinal wet wt., villus height, and crypt depth were significantly higher for the CH-G group compared with the Chemo group.  The CH-G group also showed a significant improvement in villus height compared with the G-CH-G group.  Crypt depth, but not jejunal wet wt. or villus height, was significantly improved in the G-CH-G group compared with the Chemo group.  The percentage of Br-dU-labeled cells in the intestinal crypts did not differ among the groups.  Conclusions.  These results suggest, for the first time, that GLP-2 treatment initiated after chemotherapy administration enhances intestinal recovery.  In contrast, GLP-2 treatment initiated prior to chemotherapy administration to prevent injury has less beneficial effect.  GLP-2 administration may be beneficial to patients suffering from chemotherapy-induced enteritis.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrccfqZiB86Z7Vg90H21EOLACvtfcHk0liGggEWk6aQPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjt1ansLw%253D&md5=0662220d0c9469725d05c979f923adf9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1006%2Fjsre.2000.5917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjsre.2000.5917%26sid%3Dliteratum%253Aachs%26aulast%3DTavakkolizadeh%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DAbraham%26aufirst%3DP.%26aulast%3DKormi%26aufirst%3DN.%26aulast%3DSeifert%26aufirst%3DP.%26aulast%3DEdelman%26aufirst%3DE.%2BR.%26aulast%3DJacobs%26aufirst%3DD.%2BO.%26aulast%3DZinner%26aufirst%3DM.%2BJ.%26aulast%3DAshley%26aufirst%3DS.%2BW.%26aulast%3DWhang%26aufirst%3DE.%2BE.%26atitle%3DGlucagon-like%2520peptide%25202%253A%2520A%2520new%2520treatment%2520for%2520chemotherapy-induced%2520enteritis%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2000%26volume%3D91%26spage%3D77%26epage%3D82%26doi%3D10.1006%2Fjsre.2000.5917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Boushey, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusta, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">687</span><span class="NLM_x">–</span> <span class="NLM_lpage">693</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=687-693&author=R.+P.+Bousheyauthor=B.+Yustaauthor=D.+J.+Drucker&title=Glucagon-like+peptide+%28GLP%29-2+reduces+chemotherapy-associated+mortality+and+enhances+cell+survival+in+cells+expressing+a+transfected+GLP-2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoushey%26aufirst%3DR.%2BP.%26aulast%3DYusta%26aufirst%3DB.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DGlucagon-like%2520peptide%2520%2528GLP%2529-2%2520reduces%2520chemotherapy-associated%2520mortality%2520and%2520enhances%2520cell%2520survival%2520in%2520cells%2520expressing%2520a%2520transfected%2520GLP-2%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D687%26epage%3D693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Torres, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thim, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milliat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vozenin-Brotons, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, U. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahnfelt-Ronne, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourhis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benderitter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francois, A.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat</span> <span class="citation_source-journal">Int. J. Radiat. Oncol., Biol., Phys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1563</span><span class="NLM_x">–</span> <span class="NLM_lpage">1571</span><span class="refDoi"> DOI: 10.1016/j.ijrobp.2007.08.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2Fj.ijrobp.2007.08.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=18035212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlCrs7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2007&pages=1563-1571&author=S.+Torresauthor=L.+Thimauthor=F.+Milliatauthor=M.+C.+Vozenin-Brotonsauthor=U.+B.+Olsenauthor=I.+Ahnfelt-Ronneauthor=J.+Bourhisauthor=M.+Benderitterauthor=A.+Francois&title=Glucagon-like+peptide-2+improves+both+acute+and+late+experimental+radiation+enteritis+in+the+rat&doi=10.1016%2Fj.ijrobp.2007.08.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat</span></div><div class="casAuthors">Torres, Sandra; Thim, Lars; Milliat, Fabien; Vozenin-Brotons, Marie-Catherine; Olsen, Ulfe Bang; Ahnfelt-Ronne, Ian; Bourhis, Jean; Benderitter, Marc; Francois, Agnes</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Oncology, Biology, Physics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1563-1571</span>CODEN:
                <span class="NLM_cas:coden">IOBPD3</span>;
        ISSN:<span class="NLM_cas:issn">0360-3016</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Acute and/or chronic radiation enteritis can develop after radiotherapy for pelvic cancers.  Exptl. and clin. observations have provided evidence of a role played by acute mucosal disruption in the appearance of late effects.  The therapeutic potential of acute administration of glucagon-like peptide-2 (GLP-2) against acute and chronic intestinal injury was investigated in this study.  Intestinal segments were surgically exteriorized and exposed to 16.7 or 19 Gy x-rays.  The rats were treated once daily with vehicle or a protease-resistant GLP-2 deriv. for 14 days before irradn., with or without 7 days of GLP-2 after treatment.  Macroscopic and microscopic observations were made 2 and 15 wk after radiation exposure.  In the control animals, GLP-2 induced an increase in intestinal mucosal mass, along with an increase in villus height and crypt depth.  GLP-2 administration before and after irradn. completely prevented the acute radiation-induced mucosal ulcerations obsd. after exposure to 16.7 Gy.  GLP-2 treatment strikingly reduced the late radiation damage obsd. after 19 Gy irradn.  Microscopic observations revealed an improved organization of the intestinal wall and an efficient wound healing process, esp. in the smooth muscle layers.  GLP-2 has a clear therapeutic potential against both acute and chronic radiation enteritis.  This therapeutic effect is mediated through an increased mucosal mass before tissue injury and the stimulation of still unknown mechanisms of tissue response to radiation damage.  Although these preliminary results still need to be confirmed, GLP-2 might be a way to limit patient discomfort during radiotherapy and reduce the risk of consequential late effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqVBLw2jTXT7Vg90H21EOLACvtfcHk0ljvNUwMWhr_cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlCrs7jL&md5=914f882451bd5854541f36baedcde411</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ijrobp.2007.08.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijrobp.2007.08.051%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DS.%26aulast%3DThim%26aufirst%3DL.%26aulast%3DMilliat%26aufirst%3DF.%26aulast%3DVozenin-Brotons%26aufirst%3DM.%2BC.%26aulast%3DOlsen%26aufirst%3DU.%2BB.%26aulast%3DAhnfelt-Ronne%26aufirst%3DI.%26aulast%3DBourhis%26aufirst%3DJ.%26aulast%3DBenderitter%26aufirst%3DM.%26aulast%3DFrancois%26aufirst%3DA.%26atitle%3DGlucagon-like%2520peptide-2%2520improves%2520both%2520acute%2520and%2520late%2520experimental%2520radiation%2520enteritis%2520in%2520the%2520rat%26jtitle%3DInt.%2520J.%2520Radiat.%2520Oncol.%252C%2520Biol.%252C%2520Phys.%26date%3D2007%26volume%3D69%26spage%3D1563%26epage%3D1571%26doi%3D10.1016%2Fj.ijrobp.2007.08.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">DaCambra, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusta, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumner-Smith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crivici, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span> </span><span class="NLM_article-title">Structural determinants for activity of glucagon-like peptide-2</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">8888</span><span class="NLM_x">–</span> <span class="NLM_lpage">8894</span><span class="refDoi"> DOI: 10.1021/bi000497p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi000497p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=8888-8894&author=M.+P.+DaCambraauthor=B.+Yustaauthor=M.+Sumner-Smithauthor=A.+Criviciauthor=D.+J.+Druckerauthor=P.+L.+Brubaker&title=Structural+determinants+for+activity+of+glucagon-like+peptide-2&doi=10.1021%2Fbi000497p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fbi000497p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi000497p%26sid%3Dliteratum%253Aachs%26aulast%3DDaCambra%26aufirst%3DM.%2BP.%26aulast%3DYusta%26aufirst%3DB.%26aulast%3DSumner-Smith%26aufirst%3DM.%26aulast%3DCrivici%26aufirst%3DA.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26atitle%3DStructural%2520determinants%2520for%2520activity%2520of%2520glucagon-like%2520peptide-2%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D8888%26epage%3D8894%26doi%3D10.1021%2Fbi000497p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Venneti, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewage, C. M.</span><span> </span><span class="NLM_article-title">Conformational and molecular interaction studies of glucagon-like peptide-2 with its N-terminal extracellular receptor domain</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">585</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1016/j.febslet.2010.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2Fj.febslet.2010.12.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=585&publication_year=2011&pages=346-352&author=K.+C.+Vennetiauthor=C.+M.+Hewage&title=Conformational+and+molecular+interaction+studies+of+glucagon-like+peptide-2+with+its+N-terminal+extracellular+receptor+domain&doi=10.1016%2Fj.febslet.2010.12.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2010.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2010.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DVenneti%26aufirst%3DK.%2BC.%26aulast%3DHewage%26aufirst%3DC.%2BM.%26atitle%3DConformational%2520and%2520molecular%2520interaction%2520studies%2520of%2520glucagon-like%2520peptide-2%2520with%2520its%2520N-terminal%2520extracellular%2520receptor%2520domain%26jtitle%3DFEBS%2520Lett.%26date%3D2011%26volume%3D585%26spage%3D346%26epage%3D352%26doi%3D10.1016%2Fj.febslet.2010.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Marier, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beliveau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouksassi, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesavan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahir, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caminis, J.</span><span> </span><span class="NLM_article-title">Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1289</span><span class="NLM_x">–</span> <span class="NLM_lpage">1299</span><span class="refDoi"> DOI: 10.1177/0091270008320605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1177%2F0091270008320605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=18974283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlyrs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=1289-1299&author=J.+F.+Marierauthor=M.+Beliveauauthor=M.+S.+Mouksassiauthor=P.+Shawauthor=J.+Cyranauthor=J.+Kesavanauthor=J.+Wallensauthor=H.+Zahirauthor=D.+Wellsauthor=J.+Caminis&title=Pharmacokinetics%2C+safety%2C+and+tolerability+of+teduglutide%2C+a+glucagon-like+peptide-2+%28GLP-2%29+analog%2C+following+multiple+ascending+subcutaneous+administrations+in+healthy+subjects&doi=10.1177%2F0091270008320605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects</span></div><div class="casAuthors">Marier, Jean-Francois; Beliveau, Martin; Mouksassi, Mohamad-Samer; Shaw, Paula; Cyran, Jane; Kesavan, Jothi; Wallens, John; Zahir, Hamim; Wells, David; Caminis, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1289-1299</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, is currently being evaluated for the treatment of short-bowel syndrome, Crohn's disease, and other gastrointestinal disorders.  The pharmacokinetics, safety, and tolerability of teduglutide in healthy subjects (N = 64) were assessed following daily s.c. administrations for 8 days in a double-blinded, randomized, placebo-controlled, ascending-dose study.  Teduglutide treatments were administered as a 50-mg/mL (10, 15, 20, 25, 30, 50, and 80 mg) or 20-mg/mL (20 mg) formulation.  Blood samples were collected on days 1 and 8, and plasma concns. of teduglutide were measured using a liq. chromatog./tandem mass spectrometry method.  Mean systemic exposures to teduglutide were very similar on days 1 and 8, suggesting minimal, if any, accumulation following once-daily repeated administrations.  The apparent clearance of teduglutide following administration of the 50-mg/mL formulation was const. over the dose range, with mean values in male and female subjects of 0.155 and 0.159 L/h/kg, resp.  Peak plasma concns. and total exposure of teduglutide after s.c. injection of a 20-mg/mL formulation (1.0 mL) were approx. 15% and 78% higher than those obsd. with the 50-mg/mL formulation (0.4 mL), resp.  Teduglutide treatments were safe and well tolerated.  All but 1 adverse event was assessed as mild or moderate in severity.  No relationship between teduglutide treatments and frequency of adverse events was obsd., with the exception of injection site pain, which increased as a function of dose and injected vol.  Results from the current study will assist in the dose selection in future efficacy studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfwvOVdhK00LVg90H21EOLACvtfcHk0ljNhurMKX9UJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlyrs7bP&md5=3355be2323958e3f2bc5081c67af6557</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1177%2F0091270008320605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270008320605%26sid%3Dliteratum%253Aachs%26aulast%3DMarier%26aufirst%3DJ.%2BF.%26aulast%3DBeliveau%26aufirst%3DM.%26aulast%3DMouksassi%26aufirst%3DM.%2BS.%26aulast%3DShaw%26aufirst%3DP.%26aulast%3DCyran%26aufirst%3DJ.%26aulast%3DKesavan%26aufirst%3DJ.%26aulast%3DWallens%26aufirst%3DJ.%26aulast%3DZahir%26aufirst%3DH.%26aulast%3DWells%26aufirst%3DD.%26aulast%3DCaminis%26aufirst%3DJ.%26atitle%3DPharmacokinetics%252C%2520safety%252C%2520and%2520tolerability%2520of%2520teduglutide%252C%2520a%2520glucagon-like%2520peptide-2%2520%2528GLP-2%2529%2520analog%252C%2520following%2520multiple%2520ascending%2520subcutaneous%2520administrations%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D1289%26epage%3D1299%26doi%3D10.1177%2F0091270008320605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Jeppesen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilroy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertkiewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allard, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Keefe, S. J.</span><span> </span><span class="NLM_article-title">Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">902</span><span class="NLM_x">–</span> <span class="NLM_lpage">914</span><span class="refDoi"> DOI: 10.1136/gut.2010.218271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1136%2Fgut.2010.218271" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=902-914&author=P.+B.+Jeppesenauthor=R.+Gilroyauthor=M.+Pertkiewiczauthor=J.+P.+Allardauthor=B.+Messingauthor=S.+J.+O%E2%80%99Keefe&title=Randomised+placebo-controlled+trial+of+teduglutide+in+reducing+parenteral+nutrition+and%2For+intravenous+fluid+requirements+in+patients+with+short+bowel+syndrome&doi=10.1136%2Fgut.2010.218271"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1136%2Fgut.2010.218271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.2010.218271%26sid%3Dliteratum%253Aachs%26aulast%3DJeppesen%26aufirst%3DP.%2BB.%26aulast%3DGilroy%26aufirst%3DR.%26aulast%3DPertkiewicz%26aufirst%3DM.%26aulast%3DAllard%26aufirst%3DJ.%2BP.%26aulast%3DMessing%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DS.%2BJ.%26atitle%3DRandomised%2520placebo-controlled%2520trial%2520of%2520teduglutide%2520in%2520reducing%2520parenteral%2520nutrition%2520and%252For%2520intravenous%2520fluid%2520requirements%2520in%2520patients%2520with%2520short%2520bowel%2520syndrome%26jtitle%3DGut%26date%3D2011%26volume%3D60%26spage%3D902%26epage%3D914%26doi%3D10.1136%2Fgut.2010.218271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Vipperla, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Keefe, S. J.</span><span> </span><span class="NLM_article-title">Targeted therapy of short-bowel syndrome with teduglutide: The new kid on the block</span> <span class="citation_source-journal">Clin. Exp. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">495</span><span class="refDoi"> DOI: 10.2147/CEG.S42665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.2147%2FCEG.S42665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=25525380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADC%252BC2MvhtVKnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=489-495&author=K.+Vipperlaauthor=S.+J.+O%E2%80%99Keefe&title=Targeted+therapy+of+short-bowel+syndrome+with+teduglutide%3A+The+new+kid+on+the+block&doi=10.2147%2FCEG.S42665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block</span></div><div class="casAuthors">Vipperla Kishore; O'Keefe Stephen J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and experimental gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">489-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Extensive intestinal resection impairs the absorptive capacity and results in short-bowel syndrome-associated intestinal failure (SBS-IF), when fluid, electrolyte, acid-base, micro-, and macronutrient homeostasis cannot be maintained on a conventional oral diet.  Several factors, including the length and site of the resected intestine, anatomical conformation of the remnant bowel, and the degree of postresection intestinal adaptation determine the disease severity.  While mild SBS patients achieve nutritional autonomy with dietary modification (eg, hyperphagia, small frequent meals, and oral rehydration fluids), those with moderate-to-severe disease may develop SBS-IF and become dependent on parenteral support (PS) in the form of intravenous fluids and/or nutrition for sustenance of life.  SBS-IF is a chronic debilitating disease associated with a poor quality of life, and carries significant morbidity and health care costs.  Medical management of SBS-IF is primarily focused on individually tailored symptomatic treatment strategies, such as antisecretory and antidiarrheal agents to mitigate fluid losses, and PS.  However, PS administration is associated with potentially life-threatening complications, such as central venous thromboses, bloodstream infections, and liver disease.  In pursuit of a targeted therapy to augment intestinal adaptation, research over the past 2 decades has identified glucagon-like peptide, an intestinotrophic gut peptide that has been shown to enhance intestinal absorptive capacity by causing an increase in the villus length, crypt depth, and mesenteric blood flow and by decreasing gastrointestinal motility and secretions.  Teduglutide, a recombinant analog of glucagon-like peptide-2, is the first targeted therapeutic agent to gain approval for use in adult SBS-IF.  Teduglutide was shown to result in significant (20%-100%) reduction in PS-volume requirement and have a satisfactory safety profile in three randomized control trials.  Further research is warranted to see if reduction in PS dependency translates to improved quality of life and reduced PS-associated complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3dPpQYTDtzxOk4JA3soTqfW6udTcc2eaaX-uShF2Pqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvhtVKnsw%253D%253D&md5=bae90c8939596fbea0040ea8bca119fa</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2147%2FCEG.S42665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCEG.S42665%26sid%3Dliteratum%253Aachs%26aulast%3DVipperla%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DS.%2BJ.%26atitle%3DTargeted%2520therapy%2520of%2520short-bowel%2520syndrome%2520with%2520teduglutide%253A%2520The%2520new%2520kid%2520on%2520the%2520block%26jtitle%3DClin.%2520Exp.%2520Gastroenterol.%26date%3D2014%26volume%3D7%26spage%3D489%26epage%3D495%26doi%3D10.2147%2FCEG.S42665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Jeppesen, P. B.</span><span> </span><span class="NLM_article-title">Teduglutide for the treatment of short bowel syndrome</span> <span class="citation_source-journal">Drugs Today (Barc)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">614</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=24191254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADC%252BC2c7jtVynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=599-614&author=P.+B.+Jeppesen&title=Teduglutide+for+the+treatment+of+short+bowel+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Teduglutide for the treatment of short bowel syndrome</span></div><div class="casAuthors">Jeppesen P B</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">599-614</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Glucagon-like peptide 2 (GLP-2) decreases gastric and intestinal motility, reduces gastric secretions, promotes intestinal growth and improves post-resection structural and functional adaptation in short bowel syndrome (SBS).  Teduglutide, an analogue of GLP-2, has a prolonged half-life and provides intestinotrophic effects with once-daily subcutaneous injection in patients with SBS.  This monograph reviews the preclinical and clinical data that provide the scientific rationale for the use of teduglutide in this orphan condition.  Teduglutide increases intestinal absorption and diminishes the need for parenteral support in patients with SBS.  The adverse event profile is consistent with the underlying disease and the known mechanism of action of teduglutide.  Following its positive regulatory review and approval by the European Medicines Agency and the U.S.  Food and Drug Administration in 2012, teduglutide has moved from the research setting to clinical practice, offering a new treatment paradigm for this burdensome and potentially life-threatening condition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR89KumefERg4NpW7w2tapOfW6udTcc2eY4GIcouLtnbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7jtVynug%253D%253D&md5=959ebcca6adcacfdd718825485c904d3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJeppesen%26aufirst%3DP.%2BB.%26atitle%3DTeduglutide%2520for%2520the%2520treatment%2520of%2520short%2520bowel%2520syndrome%26jtitle%3DDrugs%2520Today%2520%2528Barc%2529%26date%3D2013%26volume%3D49%26spage%3D599%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Naberhuis, J. K.; Tappenden, K. A.</span><span> </span><span class="NLM_article-title">Teduglutide for safe reduction of parenteral nutrient and/or fluid requirements in adults: A systematic review</span>.  <span class="citation_source-journal">JPEN, J. Parenter. Enteral Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span>. [Online early access]. DOI: <span class="refDoi"> DOI: 10.1177/0148607115582063</span> . Published Online: April 16, 2015.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1177%2F0148607115582063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+K.+Naberhuis&author=K.+A.+Tappenden&title=Teduglutide+for+safe+reduction+of+parenteral+nutrient+and%2For+fluid+requirements+in+adults%3A+A+systematic+review&doi=10.1177%2F0148607115582063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1177%2F0148607115582063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0148607115582063%26sid%3Dliteratum%253Aachs%26aulast%3DNaberhuis%26aufirst%3DJ.%2BK.%26atitle%3DTeduglutide%2520for%2520safe%2520reduction%2520of%2520parenteral%2520nutrient%2520and%252For%2520fluid%2520requirements%2520in%2520adults%253A%2520A%2520systematic%2520review%26jtitle%3DJPEN%252C%2520J.%2520Parenter.%2520Enteral%2520Nutr.%26date%3D2015%26doi%3D10.1177%2F0148607115582063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Seidner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youssef, N. N.</span><span> </span><span class="NLM_article-title">Effect of teduglutide, a glucagon-like peptide 2 analog, on citrulline levels in patients with short bowel syndrome in two phase III randomized trials</span> <span class="citation_source-journal">Clin. Transl. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e93</span><span class="refDoi"> DOI: 10.1038/ctg.2015.15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1038%2Fctg.2015.15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=26111125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOmtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=e93&author=D.+L.+Seidnerauthor=F.+Jolyauthor=N.+N.+Youssef&title=Effect+of+teduglutide%2C+a+glucagon-like+peptide+2+analog%2C+on+citrulline+levels+in+patients+with+short+bowel+syndrome+in+two+phase+III+randomized+trials&doi=10.1038%2Fctg.2015.15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials</span></div><div class="casAuthors">Seidner, Douglas L.; Joly, Francisca; Youssef, Nader N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e93</span>CODEN:
                <span class="NLM_cas:coden">CTGLAG</span>;
        ISSN:<span class="NLM_cas:issn">2155-384X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objectives: In clin. trials, treatment with the glucagon-like peptide 2 analog teduglutide was assocd. with improved fluid and nutrient absorption and increased intestinal villus height and crypt depth in patients with short bowel syndrome (SBS).  Plasma citrulline, an amino acid produced by enterocytes, is considered a measure of enterocyte mass.  This anal. assessed changes in plasma citrulline levels in patients with SBS in 2 phase III clin. studies of teduglutide.  Methods: Both teduglutide studies (0.05 or 0.10 mg/kg/day in CL0600-004 and 0.05 mg/kg/day in CL0600-020) were phase III, 24-wk, double-blind, and placebo controlled.  Plasma citrulline levels were analyzed and validated by liq. chromatog. coupled to tandem mass spectrometry.  Results: In both the CL0600-004 and CL0600-020 studies, change in mean plasma citrulline concns. at Week 24 vs. baseline was significantly greater with teduglutide compared with placebo (10.9 (0.05-mg/kg/day dose) and 15.7 (0.10-mg/kg/day dose) vs. 2.0 μmol/L and 20.6 vs. 0.7 μmol/L, resp., for each study (P≤0.0001 for each comparison with placebo)).  Teduglutide treatment was assocd. with redns. from baseline in PS (parenteral support) vol. requirements; however, a significant correlation between PS redn. and increase in plasma citrulline at Week 24 was obsd. in only one out of the three teduglutide treatment groups.  Conclusions: In 2 phase III studies, patients receiving teduglutide had significant increases in plasma citrulline at Week 24 compared with patients receiving placebo.  Increases in plasma citrulline concns. likely reflect enterocyte mass expansion, but no clear correlation was detected between change in plasma citrulline and change in weekly PS vol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZN_z0fYksrLVg90H21EOLACvtfcHk0ljZs6AO0I-pHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOmtrfI&md5=906c3c54a4d82ee596b75f39b7c2cc68</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fctg.2015.15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fctg.2015.15%26sid%3Dliteratum%253Aachs%26aulast%3DSeidner%26aufirst%3DD.%2BL.%26aulast%3DJoly%26aufirst%3DF.%26aulast%3DYoussef%26aufirst%3DN.%2BN.%26atitle%3DEffect%2520of%2520teduglutide%252C%2520a%2520glucagon-like%2520peptide%25202%2520analog%252C%2520on%2520citrulline%2520levels%2520in%2520patients%2520with%2520short%2520bowel%2520syndrome%2520in%2520two%2520phase%2520III%2520randomized%2520trials%26jtitle%3DClin.%2520Transl.%2520Gastroenterol.%26date%3D2015%26volume%3D6%26spage%3De93%26doi%3D10.1038%2Fctg.2015.15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Buchman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou-Assi, S. G.</span><span> </span><span class="NLM_article-title">Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn’s disease</span> <span class="citation_source-journal">Inflamm. Bowel Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">962</span><span class="NLM_x">–</span> <span class="NLM_lpage">973</span><span class="refDoi"> DOI: 10.1002/ibd.21117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fibd.21117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=19821509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADC%252BC3czjvFejsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=962-973&author=A.+L.+Buchmanauthor=S.+Katzauthor=J.+C.+Fangauthor=C.+N.+Bernsteinauthor=S.+G.+Abou-Assi&title=Teduglutide%2C+a+novel+mucosally+active+analog+of+glucagon-like+peptide-2+%28GLP-2%29+for+the+treatment+of+moderate+to+severe+Crohn%E2%80%99s+disease&doi=10.1002%2Fibd.21117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease</span></div><div class="casAuthors">Buchman Alan L; Katz Seymour; Fang John C; Bernstein Charles N; Abou-Assi Souheil G</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">962-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Teduglutide, an analog of glucagon-like peptide-2 (GLP-2), is associated with trophic effects on gut mucosa.  Its role in the treatment of active Crohn's disease (CD) was assessed in a pilot, randomized, placebo-controlled, double-blinded, dose-ranging study.  METHODS:  Subjects with moderate-to-severe CD were randomized 1:1:1:1 to placebo or 1 of 3 doses of teduglutide (0.05, 0.10, or 0.20 mg/kg daily) delivered as a daily subcutaneous injection for 8 weeks.  The primary outcome measure was the percentage of subjects in each group that responded to treatment, defined as a decrease in Crohn's Disease Activity Index (CDAI) score to <150 or a decrease of > 100 points.  At week 8 there was an optional 12-week open-label period of treatment with teduglutide 0.10 mg/kg/d.  RESULTS:  One hundred subjects were enrolled and 71 completed the study.  The mean baseline CDAI score was 290.8 +/- 57.6 and was similar across groups.  There were numerically higher response and remission rates in all teduglutide-treated groups as compared with placebo, although the percentage of subjects who achieved a clinical response or remission was more substantial, and seen as early as week 2 of treatment in the highest dose (0.2 mg/kg/d) group (44% response and 32% remission versus 32% response and 20% remission in the placebo group).  Of subjects who had not achieved remission during the 8-week placebo-controlled phase in the higher-dose group, 50% achieved remission during the more prolonged, open-label treatment phase.  Plasma citrulline was similar across groups at baseline, but increased substantially over time in all teduglutide groups when compared with placebo at week 8.  Adverse events were not different between placebo and active treatment groups.  CONCLUSIONS:  Teduglutide is a novel and potentially effective therapy for inducing remission and mucosal healing in patients with active moderate-to-severe CD.  Further clinical investigation of this growth factor is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSp9OMg9pT7OIhLSh9fo81bfW6udTcc2eYSkru4KOd4N7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czjvFejsw%253D%253D&md5=c86ed439b08e2bdcd72e3ba427fbb48e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fibd.21117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fibd.21117%26sid%3Dliteratum%253Aachs%26aulast%3DBuchman%26aufirst%3DA.%2BL.%26aulast%3DKatz%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DJ.%2BC.%26aulast%3DBernstein%26aufirst%3DC.%2BN.%26aulast%3DAbou-Assi%26aufirst%3DS.%2BG.%26atitle%3DTeduglutide%252C%2520a%2520novel%2520mucosally%2520active%2520analog%2520of%2520glucagon-like%2520peptide-2%2520%2528GLP-2%2529%2520for%2520the%2520treatment%2520of%2520moderate%2520to%2520severe%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2010%26volume%3D16%26spage%3D962%26epage%3D973%26doi%3D10.1002%2Fibd.21117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Larsen, B. D.; Petersen, Y. M.; Ebbehoej, K.</span><span> </span><span class="NLM_article-title">Glucagon-like-peptide-2 (GLP-2) analogues</span>. WO2006117565,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=B.+D.+Larsen&author=Y.+M.+Petersen&author=K.+Ebbehoej&title=Glucagon-like-peptide-2+%28GLP-2%29+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DB.%2BD.%26atitle%3DGlucagon-like-peptide-2%2520%2528GLP-2%2529%2520analogues%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Schon, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisfaludy, L.</span><span> </span><span class="NLM_article-title">Formation of aminosuccinyl peptides during acidolytic deprotection followed by their transformation to piperazine-2,5-dione derivatives in neutral media</span> <span class="citation_source-journal">Int. J. Pept. Protein Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.1111/j.1399-3011.1979.tb01960.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1111%2Fj.1399-3011.1979.tb01960.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=43840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaL3cXhvFyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1979&pages=485-494&author=I.+Schonauthor=L.+Kisfaludy&title=Formation+of+aminosuccinyl+peptides+during+acidolytic+deprotection+followed+by+their+transformation+to+piperazine-2%2C5-dione+derivatives+in+neutral+media&doi=10.1111%2Fj.1399-3011.1979.tb01960.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Formation of aminosuccinyl peptides during acidolytic deprotection followed by their transformation to piperazine-2,5-dione derivatives in neutral media</span></div><div class="casAuthors">Schon, Istvan; Kisfaludy, Lajos</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-94</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">The acidolytic deblocking of Me3CO2C-Leu-Asp(OCMe3)-Phe-NH2 by prolonged treatment with 4N HCl/HOAc gave succinimide peptide I, which was partially transformed to piperazinedione II during purifn. by column chromatog. on silica gel in neutral media.  The study of succinimide formation for different reaction conditions and for several aspartic acid-contg. peptides showed that succinimides were formed in strongly acidic media from aspartyl peptides contg. a free β-carboxyl group.  II did not form in CF3CO2H.  For tripeptides contg. Asp in position 2, the influence of the C-terminal residue was greater than that of the N-terminal residue on both the rate of formation of succinimide and its further transformation to the piperazinedione deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqscjf_fPhEi7Vg90H21EOLACvtfcHk0litRmwwibAueA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhvFyktro%253D&md5=340da5ae65fb5d3b8fc6428d215e5388</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1979.tb01960.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1979.tb01960.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchon%26aufirst%3DI.%26aulast%3DKisfaludy%26aufirst%3DL.%26atitle%3DFormation%2520of%2520aminosuccinyl%2520peptides%2520during%2520acidolytic%2520deprotection%2520followed%2520by%2520their%2520transformation%2520to%2520piperazine-2%252C5-dione%2520derivatives%2520in%2520neutral%2520media%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1979%26volume%3D14%26spage%3D485%26epage%3D494%26doi%3D10.1111%2Fj.1399-3011.1979.tb01960.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Suli-Vargha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ilas, J.</span><span> </span><span class="NLM_article-title">1,4-diazepine-2,5-dione ring formation during solid phase synthesis of peptides containing aspartic acid beta -benzyl ester</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span><span class="refDoi"> DOI: 10.1002/psc.885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=17853501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=742-748&author=H.+Suli-Varghaauthor=G.+Schlosserauthor=J.+Ilas&title=1%2C4-diazepine-2%2C5-dione+ring+formation+during+solid+phase+synthesis+of+peptides+containing+aspartic+acid+beta+-benzyl+ester&doi=10.1002%2Fpsc.885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">1,4-Diazepine-2,5-dione ring formation during solid phase synthesis of peptides containing aspartic acid β-benzyl ester</span></div><div class="casAuthors">Suli-Vargha, Helga; Schlosser, Gitta; Ilas, Janez</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">742-748</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The Fmoc-based SPPS of H-Xaa-Asp(OBzl)-Yaa-Gly-NH2 sequences results in side reactions yielding not only aspartimide peptides and piperidide derivs., but also 1,4-diazepine-2,5-dione-peptides.  Evidence is presented to show that the 1,4-diazepine-2,5-dione deriv. is formed from the aspartimide peptide.  The rate of this ring transformation depends primarily on the tendency to aspartimide and piperidide formation, which is influenced by the nature of the amino acid following the aspartic acid β-benzyl ester (Xaa).  However the bulkiness of the amino acid side chain preceding the aspartic acid β-benzyl ester (Yaa) is also important.  Under certain conditions the 1,4-diazepine-2,5-dione peptide deriv. may even be formed dominantly, which is a highly undesirable side reaction in peptide synthesis, but which provides a new way for the synthesis of diazepine peptide derivs. with targeted biol. or pharmacol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr167YjGN7ELbVg90H21EOLACvtfcHk0liufKD3TuiYsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktbrL&md5=38aed3967e09a28cb36e536f195c4114</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fpsc.885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.885%26sid%3Dliteratum%253Aachs%26aulast%3DSuli-Vargha%26aufirst%3DH.%26aulast%3DSchlosser%26aufirst%3DG.%26aulast%3DIlas%26aufirst%3DJ.%26atitle%3D1%252C4-diazepine-2%252C5-dione%2520ring%2520formation%2520during%2520solid%2520phase%2520synthesis%2520of%2520peptides%2520containing%2520aspartic%2520acid%2520beta%2520-benzyl%2520ester%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2007%26volume%3D13%26spage%3D742%26epage%3D748%26doi%3D10.1002%2Fpsc.885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Mergler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, F.</span><span> </span><span class="NLM_article-title">The aspartimide problem in Fmoc-based SPPS. Part III</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">650</span><span class="NLM_x">–</span> <span class="NLM_lpage">657</span><span class="refDoi"> DOI: 10.1002/psc.668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=15849777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFygsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=650-657&author=M.+Merglerauthor=F.+Dick&title=The+aspartimide+problem+in+Fmoc-based+SPPS.+Part+III&doi=10.1002%2Fpsc.668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The aspartimide problem in Fmoc-based SPPS. Part III</span></div><div class="casAuthors">Mergler, M.; Dick, F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">650-657</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A newly developed Fmoc-Asp deriv., Fmoc-Asp β-(2,3,4-trimethyl-pent-3-yl) ester (Fmoc = 9-fluorenylmethyloxycarbonyl), has been tried in the Fmoc-based SPPS of H-Val-Lys-Asp-Xaa-Tyr-Ile-OH, a well-established peptide model for studying base-catalyzed aspartimide formation.  When synthesizing the hexapeptide incorporating Gly, Arg(Pbf), Asn(Mtt), Asp(OtBu) or Cys(Acm) for Xaa, considerable amts. of aspartimide-related byproducts were to be expected.  The Asp3 β-carboxy protecting group and the duration of exposure to bases were varied.  Byproduct formation could be reduced by incorporation of the new Asp deriv. more efficiently than by introducing the less bulky Asp(OMpe).  Significant improvements were obsd. in cases of prolonged contact with piperidine or DBU.  Both β-carboxy protecting groups were superior to the std. Asp(OtBu) which was also included in this study, but the addnl. stabilization gained by our new protecting group was valuable esp. in syntheses of long peptides or difficult sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoht36BP3nB7bVg90H21EOLACvtfcHk0lgKC3LSV4lY_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFygsLrM&md5=42458f1c5fb2429da9d07c925fa2f190</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fpsc.668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.668%26sid%3Dliteratum%253Aachs%26aulast%3DMergler%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DF.%26atitle%3DThe%2520aspartimide%2520problem%2520in%2520Fmoc-based%2520SPPS.%2520Part%2520III%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2005%26volume%3D11%26spage%3D650%26epage%3D657%26doi%3D10.1002%2Fpsc.668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Mergler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sax, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahelin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vorherr, T.</span><span> </span><span class="NLM_article-title">The aspartimide problem in Fmoc-based SPPS. Part II</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">518</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1002/psc.473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=12952393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1Wjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=518-526&author=M.+Merglerauthor=F.+Dickauthor=B.+Saxauthor=C.+Stahelinauthor=T.+Vorherr&title=The+aspartimide+problem+in+Fmoc-based+SPPS.+Part+II&doi=10.1002%2Fpsc.473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The aspartimide problem in Fmoc-based SPPS. Part II</span></div><div class="casAuthors">Mergler, M.; Dick, F.; Sax, B.; Staehelin, C.; Vorherr, T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">518-526</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The sequence dependence of base-catalyzed aspartimide formation during Fmoc-based SPPS (Fmoc = 9-fluorenylmethyloxycarbonyl) was systematically studied employing the peptide models H-Val-Lys-Asp-Xaa-Tyr-Ile-OH.  The extent of formation of aspartimide and related byproducts was detd. by RP-HPLC.  Considerable amts. of byproducts were formed in the case of Xaa = Asp(OtBu), Arg(Pbf), Asn(Mtt), Cys(Acm) and unprotected Thr.  Aspartimide formation could be diminished by incorporation of Asp(OMpe) or by employing milder methods for Fmoc cleavage, e.g. hexamethyleneimine/N-methylpyrrolidine/HOBt/NMP/DMSO 4:50:4:71:71 (vol./vol./w/vol./vol.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru4Fttj0z8J7Vg90H21EOLACvtfcHk0lgLhn58AaRpQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1Wjsbk%253D&md5=3bd78007418963ed009af0fc220c9143</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fpsc.473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.473%26sid%3Dliteratum%253Aachs%26aulast%3DMergler%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DF.%26aulast%3DSax%26aufirst%3DB.%26aulast%3DStahelin%26aufirst%3DC.%26aulast%3DVorherr%26aufirst%3DT.%26atitle%3DThe%2520aspartimide%2520problem%2520in%2520Fmoc-based%2520SPPS.%2520Part%2520II%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2003%26volume%3D9%26spage%3D518%26epage%3D526%26doi%3D10.1002%2Fpsc.473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Mergler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sax, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vorherr, T.</span><span> </span><span class="NLM_article-title">The aspartimide problem in Fmoc-based SPPS. Part I</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1002/psc.430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=12587881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht12qtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=36-46&author=M.+Merglerauthor=F.+Dickauthor=B.+Saxauthor=P.+Weilerauthor=T.+Vorherr&title=The+aspartimide+problem+in+Fmoc-based+SPPS.+Part+I&doi=10.1002%2Fpsc.430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The aspartimide problem in Fmoc-based SPPS. Part I</span></div><div class="casAuthors">Mergler, M.; Dick, F.; Sax, B.; Weiler, P.; Vorherr, T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-46</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A variety of Asp β-carboxy protecting groups, Hmb backbone protection and a range of Fmoc cleavage protocols have been employed in the syntheses of the model hexapeptide H-VKDGYI-OH to investigate the aspartimide problem in more detail.  The extent of formation of aspartimide and aspartimide-related byproducts was detd. by RP-HPLC.  This study included three new Fmoc-Asp-OH derivs.: the β-(4-pyridyldiphenylmethyl) and β-(9-phenylfluoren-9-yl) esters and the orthoester Fmoc-β-(4-methyl-2,6,7-trioxabicyclo[2.2.2]oct-1-yl)alanine.  3-Methylpent-3-yl protection of the Asp side chain resulted in significant improvements with respect to aspartimide formation.  Complete suppression was achieved using the combination OtBu side chain protection and Hmb backbone protection for the preceding Gly residue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFzqypZqV6AbVg90H21EOLACvtfcHk0lgLhn58AaRpQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht12qtbo%253D&md5=0622d6d24a4c4bf78e7b6ccbe86e3bc6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fpsc.430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.430%26sid%3Dliteratum%253Aachs%26aulast%3DMergler%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DF.%26aulast%3DSax%26aufirst%3DB.%26aulast%3DWeiler%26aufirst%3DP.%26aulast%3DVorherr%26aufirst%3DT.%26atitle%3DThe%2520aspartimide%2520problem%2520in%2520Fmoc-based%2520SPPS.%2520Part%2520I%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2003%26volume%3D9%26spage%3D36%26epage%3D46%26doi%3D10.1002%2Fpsc.430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Lauer, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, G. B.</span><span> </span><span class="NLM_article-title">Sequence dependence of aspartimide formation during 9-fluorenylmethoxycarbonyl solid-phase peptide synthesis</span> <span class="citation_source-journal">Lett. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span><span class="refDoi"> DOI: 10.1007/BF00117955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1007%2FBF00117955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaK2MXkvFyqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1995&pages=197-205&author=J.+L.+Lauerauthor=C.+G.+Fieldsauthor=G.+B.+Fields&title=Sequence+dependence+of+aspartimide+formation+during+9-fluorenylmethoxycarbonyl+solid-phase+peptide+synthesis&doi=10.1007%2FBF00117955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence dependence of aspartimide formation during 9-fluorenylmethoxycarbonyl solid-phase peptide synthesis</span></div><div class="casAuthors">Lauer, Janelle L.; Fields, Cynthia G.; Fields, Gregg B.</div><div class="citationInfo"><span class="NLM_cas:title">Letters in Peptide Science</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">197-205</span>CODEN:
                <span class="NLM_cas:coden">LPSCEM</span>;
        ISSN:<span class="NLM_cas:issn">0929-5666</span>.
    </div><div class="casAbstract">The authors have examd. the sequence dependence of aspartimide formation during 9-fluorenylmethoxycarbonyl (Fmoc)-based solid-phase synthesis of the peptide Bz-Val-Lys(Boc)-Asp(OtBu)-X-Tyr(tBu)-Ile-OH [Boc = tert-butoxycarbonyl, tBu = tert-butyl; X = (protected) amino acid residue].  The extent of aspartimide formation and subsequent conversion to the α- or β-piperidide was characterized and quantitated by anal. reversed-phase HPLC and fast atom bombardment mass spectrometry.  Aspartimide formation occurred for X = Arg(Pmc), Asn(Trt), Asp(OtBu), Cys(Acm), Gly, Ser, Thr, and Thr(tBu) (Pmc = 2,2,5,7,8-pentamthylchroman-6-sulfonyl, Trt = trityl, Acm = acetamidomethyl).  No single approach was found that could inhibit this side reaction for all sequences.  The most effective combinations, in general, for minimization of aspartimide formation were (i) tert-Bu side-chain protection of aspartate, piperidine for removal of the Fmoc group, and either 1-hydroxybenzotriazole or 2,4-dinitrophenol as an additive to the piperidine soln.; or (ii) 1-adamantyl side-chain protection of aspartate and DBU for removal of the Fmoc group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS626dukxJwLVg90H21EOLACvtfcHk0lgTswTOwhgZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvFyqsrk%253D&md5=61de60c8979c01616bfac2cce4443460</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2FBF00117955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00117955%26sid%3Dliteratum%253Aachs%26aulast%3DLauer%26aufirst%3DJ.%2BL.%26aulast%3DFields%26aufirst%3DC.%2BG.%26aulast%3DFields%26aufirst%3DG.%2BB.%26atitle%3DSequence%2520dependence%2520of%2520aspartimide%2520formation%2520during%25209-fluorenylmethoxycarbonyl%2520solid-phase%2520peptide%2520synthesis%26jtitle%3DLett.%2520Pept.%2520Sci.%26date%3D1995%26volume%3D1%26spage%3D197%26epage%3D205%26doi%3D10.1007%2FBF00117955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Wade, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tregear, G. W.</span><span> </span><span class="NLM_article-title">Base-induced side reactions in fmoc-solid phase peptide synthesis: Minimization by use of piperazine as N-alpha deprotection reagent</span> <span class="citation_source-journal">Lett. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1007/BF02443569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1007%2FBF02443569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkslOrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=107-112&author=J.+D.+Wadeauthor=M.+N.+Mathieuauthor=M.+Macrisauthor=G.+W.+Tregear&title=Base-induced+side+reactions+in+fmoc-solid+phase+peptide+synthesis%3A+Minimization+by+use+of+piperazine+as+N-alpha+deprotection+reagent&doi=10.1007%2FBF02443569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Base-induced side reactions in Fmoc-solid phase peptide synthesis: minimization by use of piperazine as Nα-deprotection reagent</span></div><div class="casAuthors">Wade, John D.; Mathieu, Marc N.; Macris, Mary; Tregear, Geoffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Letters in Peptide Science</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-112</span>CODEN:
                <span class="NLM_cas:coden">LPSCEM</span>;
        ISSN:<span class="NLM_cas:issn">0929-5666</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">Base-induced aspartimide (cyclic imide) and subsequent base adduct formation in the Fmoc-based solid-phase synthesis of sensitive peptide sequences are serious side reactions that are difficult to both anticipate and control.  The effect of extended treatment of piperazine as an Nα-Fmoc deprotection reagent on two sensitive peptide sequences, H-Val-Lys-Asp-Gly-Tyr-Ile-OH and H-Leu-Thr-Glu-Asp-Asn-Lys-OH, was examd.  For comparison, other bases were also investigated, including piperidine, 1-hydroxypiperidine, tetrabutylammonium fluoride (TBAF), and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).  The results showed that all bases induced varying degrees of both aspartimide and, in some cases, base adduct formation, although piperazine caused the least side reaction.  Use of N-(2-hydroxy-4-methoxybenzyl) (Hmb) peptide backbone amide protection was confirmed to confer complete protection against side reaction.  In the absence of such protection, for all bases, the use of 1-hydroxybenzotriazole (HOBt) as additive had some, but not complete, beneficial effect in further reducing side reaction.  Best results were obtained with piperazine contg. 0.1M of HOBt, indicating that this reagent merits serious consideration for Nα-deprotection in the Fmoc-solid phase synthesis of base-sensitive sequences.  A further advantage of this reagent is that it causes little racemization of resin-bound C-terminal cysteine, an occasionally serious base-mediated problem in Fmoc-solid phase assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKjq3YLF6mSrVg90H21EOLACvtfcHk0ljsGkh7DsPYRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkslOrt7c%253D&md5=43112d82e771f9dd8a93413ad4578dd4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2FBF02443569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02443569%26sid%3Dliteratum%253Aachs%26aulast%3DWade%26aufirst%3DJ.%2BD.%26aulast%3DMathieu%26aufirst%3DM.%2BN.%26aulast%3DMacris%26aufirst%3DM.%26aulast%3DTregear%26aufirst%3DG.%2BW.%26atitle%3DBase-induced%2520side%2520reactions%2520in%2520fmoc-solid%2520phase%2520peptide%2520synthesis%253A%2520Minimization%2520by%2520use%2520of%2520piperazine%2520as%2520N-alpha%2520deprotection%2520reagent%26jtitle%3DLett.%2520Pept.%2520Sci.%26date%3D2000%26volume%3D7%26spage%3D107%26epage%3D112%26doi%3D10.1007%2FBF02443569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Okada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, K.</span><span> </span><span class="NLM_article-title">Synthesis of beta −1- and beta −2-adamantyl aspartates and their evaluation for peptide synthesis</span> <span class="citation_source-journal">J. Chem. Soc., Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_fpage">1532</span><span class="NLM_x">–</span> <span class="NLM_lpage">1534</span><span class="refDoi"> DOI: 10.1039/C39870001532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1039%2FC39870001532" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&pages=1532-1534&author=Y.+Okadaauthor=S.+Iguchiauthor=K.+Kawasaki&title=Synthesis+of+beta+%E2%88%921-+and+beta+%E2%88%922-adamantyl+aspartates+and+their+evaluation+for+peptide+synthesis&doi=10.1039%2FC39870001532"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1039%2FC39870001532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC39870001532%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DIguchi%26aufirst%3DS.%26aulast%3DKawasaki%26aufirst%3DK.%26atitle%3DSynthesis%2520of%2520beta%2520%25E2%2588%25921-%2520and%2520beta%2520%25E2%2588%25922-adamantyl%2520aspartates%2520and%2520their%2520evaluation%2520for%2520peptide%2520synthesis%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1987%26spage%3D1532%26epage%3D1534%26doi%3D10.1039%2FC39870001532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Karlstrom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unden, A.</span><span> </span><span class="NLM_article-title">Design of protecting groups for the beta-carboxylic group of aspartic acid that minimize base-catalyzed aspartimide formation</span> <span class="citation_source-journal">Int. J. Pept. Protein Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span><span class="refDoi"> DOI: 10.1111/j.1399-3011.1996.tb00846.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1111%2Fj.1399-3011.1996.tb00846.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=8919050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADyaK2s%252FnvV2htw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1996&pages=305-311&author=A.+Karlstromauthor=A.+Unden&title=Design+of+protecting+groups+for+the+beta-carboxylic+group+of+aspartic+acid+that+minimize+base-catalyzed+aspartimide+formation&doi=10.1111%2Fj.1399-3011.1996.tb00846.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Design of protecting groups for the beta-carboxylic group of aspartic acid that minimize base-catalyzed aspartimide formation</span></div><div class="casAuthors">Karlstrom A; Unden A</div><div class="citationInfo"><span class="NLM_cas:title">International journal of peptide and protein research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-11</span>
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">With the objectives of developing new protecting groups for the beta-carboxyl group of aspartic acid that are resistant to base-catalyzed aspartimide formation and of evaluating the importance of sterical factors in the design of such protecting groups, four new alkyl ester derivatives of aspartic acid were synthesized.  The beta-3-pentyl, beta-4-heptyl, beta-2,6-dimethyl-4-heptyl and the recently described beta-2,4-dimethyl-3-pentyl esters of Boc-aspartic acid were incorporated into model peptides, and the resin-bound protected peptides were treated with 20% piperidine for 10 h.  The levels of aspartimide-related side products were compared with the previously reported beta-cyclohexyl, beta-menthyl and beta-2-adamantyl esters of aspartic acid.  The results show that bulky, acyclic, aliphatic protecting groups (in particular the 2,4-dimethyl-3-pentyl ester) are significantly more resistant to base-catalyzed aspartimide formation than comparably rigid cyclic alkyl esters that under the same reaction conditions form several-fold more aspartimide-related side products.  Using elevated temperatures to overcome difficult couplings leads to the formation of significant amounts of aspartimide when aspartic acid is protected with the cyclohexyl group, but the 2,4-dimethyl-3-pentyl protecting group offers excellent protection under these conditions.  The use of the 2,4-dimethyl-3-pentyl protecting group will allow the use of orthogonally removable base-labile protecting groups in Boc chemistry and suggests a design of protecting groups for other nucleophile-sensitive trifunctional amino acids in both Boc and Fmoc chemistry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4-8FHcUthGoJKJbLTgsvCfW6udTcc2eaTYSR0QQq3Erntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252FnvV2htw%253D%253D&md5=a6a761589e2b6648ee4c098a7cc83585</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1996.tb00846.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1996.tb00846.x%26sid%3Dliteratum%253Aachs%26aulast%3DKarlstrom%26aufirst%3DA.%26aulast%3DUnden%26aufirst%3DA.%26atitle%3DDesign%2520of%2520protecting%2520groups%2520for%2520the%2520beta-carboxylic%2520group%2520of%2520aspartic%2520acid%2520that%2520minimize%2520base-catalyzed%2520aspartimide%2520formation%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1996%26volume%3D48%26spage%3D305%26epage%3D311%26doi%3D10.1111%2Fj.1399-3011.1996.tb00846.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Quibell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peckman, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span> </span><span class="NLM_article-title">Suppression of piperidine-mediated side product formation for Asp(OBut)-containing peptides by the use of N-(2-hydroxy-4-methoxybenzyl) (Hmb) backbone amide protection</span> <span class="citation_source-journal">J. Chem. Soc., Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_fpage">2343</span><span class="NLM_x">–</span> <span class="NLM_lpage">2344</span><span class="refDoi"> DOI: 10.1039/c39940002343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1039%2Fc39940002343" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&pages=2343-2344&author=M.+Quibellauthor=D.+Owenauthor=L.+C.+Peckmanauthor=T.+Johnson&title=Suppression+of+piperidine-mediated+side+product+formation+for+Asp%28OBut%29-containing+peptides+by+the+use+of+N-%282-hydroxy-4-methoxybenzyl%29+%28Hmb%29+backbone+amide+protection&doi=10.1039%2Fc39940002343"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2Fc39940002343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39940002343%26sid%3Dliteratum%253Aachs%26aulast%3DQuibell%26aufirst%3DM.%26aulast%3DOwen%26aufirst%3DD.%26aulast%3DPeckman%26aufirst%3DL.%2BC.%26aulast%3DJohnson%26aufirst%3DT.%26atitle%3DSuppression%2520of%2520piperidine-mediated%2520side%2520product%2520formation%2520for%2520Asp%2528OBut%2529-containing%2520peptides%2520by%2520the%2520use%2520of%2520N-%25282-hydroxy-4-methoxybenzyl%2529%2520%2528Hmb%2529%2520backbone%2520amide%2520protection%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1994%26spage%3D2343%26epage%3D2344%26doi%3D10.1039%2Fc39940002343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Cardona, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberle, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barthelemy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beythien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneeberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keyte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. D.</span><span> </span><span class="NLM_article-title">Application of Dmb-dipeptides in the Fmoc SPPS of difficult and aspartimide-prone sequences</span> <span class="citation_source-journal">Int. J. Pept. Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span><span class="refDoi"> DOI: 10.1007/s10989-008-9154-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1007%2Fs10989-008-9154-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1aisLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=285-292&author=V.+Cardonaauthor=I.+Eberleauthor=S.+Barthelemyauthor=J.+Beythienauthor=B.+Doernerauthor=P.+Schneebergerauthor=J.+Keyteauthor=P.+D.+White&title=Application+of+Dmb-dipeptides+in+the+Fmoc+SPPS+of+difficult+and+aspartimide-prone+sequences&doi=10.1007%2Fs10989-008-9154-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Application of DMB-dipeptides in the Fmoc SPPS of difficult and aspartimide-prone sequences</span></div><div class="casAuthors">Cardona, V.; Eberle, I.; Barthelemy, S.; Beythien, J.; Doerner, B.; Schneeberger, P.; Keyte, J.; White, P. D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide Research and Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">285-292</span>CODEN:
                <span class="NLM_cas:coden">IJPRFC</span>;
        ISSN:<span class="NLM_cas:issn">1573-3149</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Mutter's pseudoproline dipeptides and Sheppard's Hmb (Hmb = 2-hydroxy-4-methoxy-1-methylbenzene) derivs. are powerful tools for enhancing synthetic efficiency in Fmoc SPPS (Fmoc = 9-fluorenylmethoxycarbonyl, SPPS = solid phase peptide synthesis).  They work by exploiting the natural propensity of N-alkyl amino acids to disrupt the formation of the secondary structures during peptide assembly.  Their use results in better and more predictable acylation and deprotection kinetics, enhanced reaction rates, and improved yields of crude products.  However, these approaches have certain limitations: pseudoproline dipeptides can only be used for sequences contg. serine or threonine, and the coupling of the amino acid following the Hmb residue can be extremely difficult.  To alleviate some of these shortcomings, we have prepd. a range of Fmoc-Aaa-(Dmb)Gly-OH (Dmb = 2,4-dimethoxy-1-methylbenzene) dipeptides and tested their efficacy in the synthesis of a no. of challenging hydrophobic peptides.  We also compared the efficiency of N-Dmb against N-Hmb backbone protection in preventing aspartimide formation in the Fmoc SPPS of peptides contg. the Asp-Gly sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkMA-kRWfVc7Vg90H21EOLACvtfcHk0lidSVxiKifmAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1aisLfE&md5=1d2e632730d47e0a835723956c9d7a6e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs10989-008-9154-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10989-008-9154-z%26sid%3Dliteratum%253Aachs%26aulast%3DCardona%26aufirst%3DV.%26aulast%3DEberle%26aufirst%3DI.%26aulast%3DBarthelemy%26aufirst%3DS.%26aulast%3DBeythien%26aufirst%3DJ.%26aulast%3DDoerner%26aufirst%3DB.%26aulast%3DSchneeberger%26aufirst%3DP.%26aulast%3DKeyte%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DP.%2BD.%26atitle%3DApplication%2520of%2520Dmb-dipeptides%2520in%2520the%2520Fmoc%2520SPPS%2520of%2520difficult%2520and%2520aspartimide-prone%2520sequences%26jtitle%3DInt.%2520J.%2520Pept.%2520Res.%2520Ther.%26date%3D2008%26volume%3D14%26spage%3D285%26epage%3D292%26doi%3D10.1007%2Fs10989-008-9154-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Röder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henklein, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisshoff, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mugge, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patzel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpino Louis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henklein, P.</span><span> </span><span class="NLM_article-title">On the use of N-dicyclopropylmethyl aspartyl-glycine synthone for backbone amide protection</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1002/psc.1196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.1196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=19924731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADC%252BD1Mfjtl2nsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=65-70&author=R.+R%C3%B6derauthor=P.+Henkleinauthor=H.+Weisshoffauthor=C.+Muggeauthor=M.+Patzelauthor=U.+Schubertauthor=A.+Carpino+Louisauthor=P.+Henklein&title=On+the+use+of+N-dicyclopropylmethyl+aspartyl-glycine+synthone+for+backbone+amide+protection&doi=10.1002%2Fpsc.1196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">On the use of N-dicyclopropylmethyl aspartyl-glycine synthone for backbone amide protection</span></div><div class="casAuthors">Roder Rene; Henklein Petra; Weisshoff Hardy; Mugge Clemens; Patzel Michael; Schubert Ulrich; Carpino Louis A; Henklein Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of peptide science : an official publication of the European Peptide Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To prevent aspartimide formation and related side products in Asp-Xaa, particularly Asp-Gly-containing peptides, usually the 2-hydroxy-4-methoxybenzyl (Hmb) backbone amide protection is applied for peptide synthesis according to the Fmoc-protocols.  In the present study, the usefulness of the recently proposed acid-labile dicyclopropylmethyl (Dcpm) protectant was analyzed.  Despite the significant steric hindrance of this bulky group, N-terminal H-(Dcpm)Gly-peptides are quantitatively acylated by potent acylating agents, and alternatively the dipeptide Fmoc-Asp(OtBu)-(Dcpm)Gly-OH derivative can be used as a building block.  In contrast to the Hmb group, Dcpm is inert toward acylations, but is readily removed in the acid deprotection and resin-cleavage step.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTptinzJq0hujAyhZbj3lKdfW6udTcc2eZmWDlBRaipNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mfjtl2nsg%253D%253D&md5=3b1b61bb08df66b94361f4dae1afdbdc</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fpsc.1196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.1196%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6der%26aufirst%3DR.%26aulast%3DHenklein%26aufirst%3DP.%26aulast%3DWeisshoff%26aufirst%3DH.%26aulast%3DMugge%26aufirst%3DC.%26aulast%3DPatzel%26aufirst%3DM.%26aulast%3DSchubert%26aufirst%3DU.%26aulast%3DCarpino%2BLouis%26aufirst%3DA.%26aulast%3DHenklein%26aufirst%3DP.%26atitle%3DOn%2520the%2520use%2520of%2520N-dicyclopropylmethyl%2520aspartyl-glycine%2520synthone%2520for%2520backbone%2520amide%2520protection%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2010%26volume%3D16%26spage%3D65%26epage%3D70%26doi%3D10.1002%2Fpsc.1196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Barlos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatzi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stavropoulos, G.</span><span> </span><span class="NLM_article-title">2-chlorotrityl chloride resin. Studies on anchoring of Fmoc-amino acids and peptide cleavage</span> <span class="citation_source-journal">Int. J. Pept. Protein Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">520</span><span class="refDoi"> DOI: 10.1111/j.1399-3011.1991.tb00769.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1111%2Fj.1399-3011.1991.tb00769.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1917309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaK3MXltFGjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1991&pages=513-520&author=K.+Barlosauthor=O.+Chatziauthor=D.+Gatosauthor=G.+Stavropoulos&title=2-chlorotrityl+chloride+resin.+Studies+on+anchoring+of+Fmoc-amino+acids+and+peptide+cleavage&doi=10.1111%2Fj.1399-3011.1991.tb00769.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">2-Chlorotrityl chloride resin.  Studies on anchoring of Fmoc-aminio acids and peptide cleavage</span></div><div class="casAuthors">Barlos, Kleomenis; Chatzi, Olga; Gatos, Dimitrios; Stavropoulos, George</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">513-20</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">The esterification of 2-chlorotrityl chloride resin with 9-fluorenylmethoxycarbonyl (Fmoc) amino acids in the presence of EtN(CHMe2)2 is studied under various conditions.  High esterification yields are obtained using 0.6 equiv. Fmoc-amino acid/mmol resin in CH2Cl2 or ClCH2CH2Cl in 25 min at room temp.  The reaction proceeds without byproduct formation even in the case of Fmoc-Asn-OH and Fmoc-Gln-OH.  The quant. and easy cleavage of amino acids and peptides from 2-chlorotrityl resin using AcOH/CF3CH2OH/CH2Cl2 mixts. is accomplished within 15-60 min at room temp. while tert-Bu type protecting groups remain unaffected.  Under these exceptionally mild conditions, 2-chlorotrityl cations generated during the cleavage of amino acids and peptides from resin do not attack the nucleophilic side chains of tryptophan, methionine, and tyrosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ5Em66XBXF7Vg90H21EOLACvtfcHk0ljnRiFPCTFKAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXltFGjur4%253D&md5=2ac32b2f179e3b9e2a4977b6d7fa0aaa</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1991.tb00769.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1991.tb00769.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarlos%26aufirst%3DK.%26aulast%3DChatzi%26aufirst%3DO.%26aulast%3DGatos%26aufirst%3DD.%26aulast%3DStavropoulos%26aufirst%3DG.%26atitle%3D2-chlorotrityl%2520chloride%2520resin.%2520Studies%2520on%2520anchoring%2520of%2520Fmoc-amino%2520acids%2520and%2520peptide%2520cleavage%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1991%26volume%3D37%26spage%3D513%26epage%3D520%26doi%3D10.1111%2Fj.1399-3011.1991.tb00769.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Yamazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagaya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terauchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukumoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takase, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukahara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagakawa, J.</span><span> </span><span class="NLM_article-title">A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists</span> <span class="citation_source-journal">Biomed. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.2220/biomedres.34.129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.2220%2Fbiomedres.34.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=23782746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVart7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=129-136&author=K.+Yamazakiauthor=T.+Kagayaauthor=M.+Watanabeauthor=H.+Terauchiauthor=D.+Iidaauthor=H.+Fukumotoauthor=S.+Suzukiauthor=T.+Araiauthor=M.+Aokiauthor=K.+Takaseauthor=T.+Seikiauthor=K.+Tsukaharaauthor=J.+Nagakawa&title=A+novel+truncated+glucagon-like+peptide+2+%28GLP-2%29+as+a+tool+for+analyzing+GLP-2+receptor+agonists&doi=10.2220%2Fbiomedres.34.129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists</span></div><div class="casAuthors">Yamazaki, Kazuto; Kagaya, Takaki; Watanabe, Misako; Terauchi, Hiroki; Iida, Daisuke; Fukumoto, Hironori; Suzuki, Shuichi; Arai, Tohru; Aoki, Mika; Takase, Kazuma; Seiki, Takashi; Tsukahara, Kappei; Nagakawa, Junichi</div><div class="citationInfo"><span class="NLM_cas:title">Biomedical Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">129-136</span>CODEN:
                <span class="NLM_cas:coden">BRESD5</span>;
        ISSN:<span class="NLM_cas:issn">0388-6107</span>.
    
            (<span class="NLM_cas:orgname">Biomedical Research Press</span>)
        </div><div class="casAbstract">Glucagon-like peptide 2 (GLP-2) is an intestinotropic peptide that binds to GLP-2 receptor (GLP-2R), a class-B G protein-coupled receptor.  The GLP-2R antagonist GLP-2(3-33) has relatively high partial agonistic activity, and there are as yet no ideal known potent GLP-2R antagonists.  We therefore prepd. several truncated forms of human GLP-2 and characterized them by binding and reporter assays to find antagonists more potent than GLP-2(3-33).  We found that GLP-2(11-33) was the most potent orthosteric GLP-2R antagonist, with binding activity almost equal to those of GLP-2 and GLP-2(3-33) and weaker intrinsic agonistic activity than GLP-2(3-33).  GLP-2(11-33) retained weak agonistic activity toward human, cynomolgus monkey, dog, and Syrian hamster GLP-2Rs.  However, it had no agonistic activity toward rat GLP-2R.  GLP-2(11-33) potentiated the agonistic activity of an ago-allosteric modulator of GLP-2R, compd. 1 (N-[1-(2,5-dichlorothiophen-3-yl)-2-(phenylsulfanyl)ethylidene]hydroxylamine), synergistically toward human GLP-2R.  In the case of rat GLP-2R, GLP-2(11-33) decreased the agonistic activity of compd. 1, although GLP-2 and GLP-2(3-33) increased this activity additively.  These findings suggest that the binding sites of the ago-allosteric modulator and GLP-2 overlap, at least in rat GLP-2R.  GLP-2(11-33) is a novel, useful tool for analyzing the mode of action of agonists and ago-allosteric modulators of GLP-2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSIbf14scXjrVg90H21EOLACvtfcHk0ljnRiFPCTFKAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVart7rF&md5=f7ec5629c9d425e19cfc44b613eab564</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2220%2Fbiomedres.34.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2220%252Fbiomedres.34.129%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DKagaya%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DTerauchi%26aufirst%3DH.%26aulast%3DIida%26aufirst%3DD.%26aulast%3DFukumoto%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DArai%26aufirst%3DT.%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DTakase%26aufirst%3DK.%26aulast%3DSeiki%26aufirst%3DT.%26aulast%3DTsukahara%26aufirst%3DK.%26aulast%3DNagakawa%26aufirst%3DJ.%26atitle%3DA%2520novel%2520truncated%2520glucagon-like%2520peptide%25202%2520%2528GLP-2%2529%2520as%2520a%2520tool%2520for%2520analyzing%2520GLP-2%2520receptor%2520agonists%26jtitle%3DBiomed.%2520Res.%26date%3D2013%26volume%3D34%26spage%3D129%26epage%3D136%26doi%3D10.2220%2Fbiomedres.34.129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Goke, R.; Hareter, A.; Vahl, T.; Bode, H.-P.; Hoffmann, E.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-1 receptor in relation to its ligand</span>. In  <span class="citation_source-book">The insulinotropic gut hormone glucagon-like peptide-1</span>; <span class="NLM_contrib-group">Fehmann, H. C.; Goke, B.</span>, Eds.; <span class="NLM_publisher-name">Karger</span>: <span class="NLM_publisher-loc">Basel</span>,<span class="NLM_x"> </span><span class="NLM_year">1997</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&pages=85-104&author=R.+Goke&author=A.+Hareter&author=T.+Vahl&author=H.-P.+Bode&author=E.+Hoffmannauthor=H.+C.+Fehmann&author=B.+Goke&title=The+insulinotropic+gut+hormone+glucagon-like+peptide-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGoke%26aufirst%3DR.%26atitle%3DGlucagon-like%2520peptide-1%2520receptor%2520in%2520relation%2520to%2520its%2520ligand%26btitle%3DThe%2520insulinotropic%2520gut%2520hormone%2520glucagon-like%2520peptide-1%26aulast%3DFehmann%26aufirst%3DH.%2BC.%26pub%3DKarger%26date%3D1997%26spage%3D85%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Pollaro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinis, C.</span><span> </span><span class="NLM_article-title">Strategies to prolong the plasma residence time of peptide drugs</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1039/c0md00111b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1039%2Fc0md00111b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeku7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=319-324&author=L.+Pollaroauthor=C.+Heinis&title=Strategies+to+prolong+the+plasma+residence+time+of+peptide+drugs&doi=10.1039%2Fc0md00111b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to prolong the plasma residence time of peptide drugs</span></div><div class="casAuthors">Pollaro, Lisa; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-324</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Peptides are an attractive class of mols. for the development of therapeutics because they combine unique properties such as high binding affinity, excellent target specificity, low toxicity and a relatively small mass.  However, the short in vivo half-life of peptides which is typically only a few minutes had hampered the development of a larger no. of peptide leads into drugs.  The main reasons for the fast elimination of peptides from the circulation are enzymic degrdn. and/or fast renal clearance.  To prolong the half-life of peptides, their proteolytic stability can be improved by chem. modification strategies and the rate of clearance can be reduced by conjugating the peptides to mols. that prevent their elimination through the kidney.  In this article the authors review the latter class of strategies that aims at prolonging the in vivo plasma residence time of peptides.  Techniques including peptide drug linkage to large polymers, fusion to long-lived proteins such as albumin or the Fc fragment of Ig and conjugation to small mol. albumin-binding tags are discussed and the peptide-conjugate half-lives achieved are compared.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-bQjUGU2Y6LVg90H21EOLACvtfcHk0lhGDydZN40BMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeku7%252FJ&md5=03e0faa35f4ce24670ae6c59861b883a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1039%2Fc0md00111b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0md00111b%26sid%3Dliteratum%253Aachs%26aulast%3DPollaro%26aufirst%3DL.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DStrategies%2520to%2520prolong%2520the%2520plasma%2520residence%2520time%2520of%2520peptide%2520drugs%26jtitle%3DMedChemComm%26date%3D2010%26volume%3D1%26spage%3D319%26epage%3D324%26doi%3D10.1039%2Fc0md00111b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Neumiller, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R. K.</span><span> </span><span class="NLM_article-title">Liraglutide: A once-daily incretin mimetic for the treatment of type 2 diabetes mellitus</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1444</span><span class="refDoi"> DOI: 10.1345/aph.1M134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1345%2Faph.1M134" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2009&pages=1433-1444&author=J.+J.+Neumillerauthor=R.+K.+Campbell&title=Liraglutide%3A+A+once-daily+incretin+mimetic+for+the+treatment+of+type+2+diabetes+mellitus&doi=10.1345%2Faph.1M134"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1345%2Faph.1M134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1M134%26sid%3Dliteratum%253Aachs%26aulast%3DNeumiller%26aufirst%3DJ.%2BJ.%26aulast%3DCampbell%26aufirst%3DR.%2BK.%26atitle%3DLiraglutide%253A%2520A%2520once-daily%2520incretin%2520mimetic%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2009%26volume%3D43%26spage%3D1433%26epage%3D1444%26doi%3D10.1345%2Faph.1M134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Ahmed, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balment, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, N.</span><span> </span><span class="NLM_article-title">Renal action of acute chloroquine and paracetamol administration in the anesthetized, fluid-balanced rat</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">478</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span><span class="refDoi"> DOI: 10.1124/jpet.103.051037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1124%2Fjpet.103.051037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=12721325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlslGltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=478-483&author=M.+H.+Ahmedauthor=R.+J.+Balmentauthor=N.+Ashton&title=Renal+action+of+acute+chloroquine+and+paracetamol+administration+in+the+anesthetized%2C+fluid-balanced+rat&doi=10.1124%2Fjpet.103.051037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Renal action of acute chloroquine and paracetamol administration in the anesthetized, fluid-balanced rat</span></div><div class="casAuthors">Ahmed, Mohamed H.; Balment, Richard J.; Ashton, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">478-483</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Chloroquine induces diuresis, natriuresis, and an increase in glomerular filtration rate (GFR) in the rat.  These responses are modified in rats with analgesic nephropathy induced by long-term paracetamol (acetaminophen) administration.  Here, the effects of acute paracetamol treatment on renal function and the response to chloroquine are reported.  Under intraval anesthesia (100 mg/kg) male Sprague-Dawley rats were infused with 2.5% dextrose for 3 h.  After a control hour, they received either vehicle, chloroquine (0.04 mg/h), paracetamol (priming dose of 210 mg/kg followed by 110 mg/kg/h) or chloroquine and paracetamol over the next hour.  Compared with vehicle, chloroquine infusion resulted in increases in GFR (2.4 vs. 4.8 mL/min), urine flow (4.2 vs. 10.4 mL/h), and sodium excretion (47.7 vs. 171.2 μmol/h) and a redn. in urine osmolality (223.2 vs. 121.7 mOsM/kg).  Paracetamol reduced sodium excretion but had no effect on urine flow, GFR, or urine osmolality.  When combined, paracetamol blocked the chloroquine-induced diuresis (3.9 mL/h) and natriuresis (22.6 μmol/h), attenuated the increase in glomerular filtration rate (3.5 mL/min), and raised urine osmolality (280.0 mOsM/kg).  The differing effects of acute and long-term paracetamol treatment on basal and chloroquine-mediated renal function suggest that the length of prior exposure to paracetamol, and thus the presence of analgesic nephropathy, is an important determinant of the renal response to chloroquine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCJVbDf1XFAbVg90H21EOLACvtfcHk0lh1P_7e7BmQoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlslGltLo%253D&md5=d83aeeaa384f1a488f53181cc1a7ae1e</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.051037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.051037%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DM.%2BH.%26aulast%3DBalment%26aufirst%3DR.%2BJ.%26aulast%3DAshton%26aufirst%3DN.%26atitle%3DRenal%2520action%2520of%2520acute%2520chloroquine%2520and%2520paracetamol%2520administration%2520in%2520the%2520anesthetized%252C%2520fluid-balanced%2520rat%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26spage%3D478%26epage%3D483%26doi%3D10.1124%2Fjpet.103.051037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Bailon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, C. Y.</span><span> </span><span class="NLM_article-title">PEG-modified biopharmaceuticals</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span><span class="refDoi"> DOI: 10.1517/17425240802650568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1517%2F17425240802650568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=19236204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktVahsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=1-16&author=P.+Bailonauthor=C.+Y.+Won&title=PEG-modified+biopharmaceuticals&doi=10.1517%2F17425240802650568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">PEG-modified biopharmaceuticals</span></div><div class="casAuthors">Bailon, Pascal; Won, Chee-Youb</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Delivery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-16</span>CODEN:
                <span class="NLM_cas:coden">EODDAW</span>;
        ISSN:<span class="NLM_cas:issn">1742-5247</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  PEGylation is a process in which one or more units of chem. activated polyethylene glycol reacts with a biomol., usually a protein, peptide, small mol. or oligonucleotide, creating a putative new mol. entity possessing physicochem. and physiol. characteristics that are distinct from its predecessor mols.  In recent years, PEGylation has been used not only as a drug delivery technol. but used also as a drug modification technol. to transform existing biopharmaceuticals clin. more efficacious than before their PEGylation.  PEGylation bestows several useful properties upon the native mol., resulting in improved pharmacokinetic and pharmacodynamic properties, which in turn enable the native mol. to achieve max. clin. potency.  In addn., PEGylation results in sustained clin. response with minimal dose and less frequency of dosing, leading to improved quality of life via increased patient compliance and reduced cost.  During the course of development of various pegylated protein therapeutics, several new insights have been gained.  This review article focuses on the approaches, strategies and the utilization of modern PEGylation concepts in the design and development of well-characterized pegylated protein therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf5II9oQ0hJLVg90H21EOLACvtfcHk0lhcgX5juFzvvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktVahsw%253D%253D&md5=acb7ff4e9a7e77a6135f47be428a46bf</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1517%2F17425240802650568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425240802650568%26sid%3Dliteratum%253Aachs%26aulast%3DBailon%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DC.%2BY.%26atitle%3DPEG-modified%2520biopharmaceuticals%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2009%26volume%3D6%26spage%3D1%26epage%3D16%26doi%3D10.1517%2F17425240802650568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Jonsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dogan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herne, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahmsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nygren, P. A.</span><span> </span><span class="NLM_article-title">Engineering of a femtomolar affinity binding protein to human serum albumin</span> <span class="citation_source-journal">Protein Eng., Des. Sel.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">527</span><span class="refDoi"> DOI: 10.1093/protein/gzn028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1093%2Fprotein%2Fgzn028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=18499681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslGhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=515-527&author=A.+Jonssonauthor=J.+Doganauthor=N.+Herneauthor=L.+Abrahmsenauthor=P.+A.+Nygren&title=Engineering+of+a+femtomolar+affinity+binding+protein+to+human+serum+albumin&doi=10.1093%2Fprotein%2Fgzn028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering of a femtomolar affinity binding protein to human serum albumin</span></div><div class="casAuthors">Jonsson, Andreas; Dogan, Jakob; Herne, Nina; Abrahmsen, Lars; Nygren, Per-Aake</div><div class="citationInfo"><span class="NLM_cas:title">Protein Engineering, Design & Selection</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">515-527</span>CODEN:
                <span class="NLM_cas:coden">PEDSBR</span>;
        ISSN:<span class="NLM_cas:issn">1741-0126</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">We describe the development of a novel serum albumin binding protein showing an extremely high affinity (KD) for HSA in the femtomolar range.  Using a naturally occurring 46-residue three-helix bundle albumin binding domain (ABD) of nanomolar affinity for HSA as template, 15 residues were targeted for a combinatorial protein engineering strategy to identify variants showing improved HSA affinities.  Sequencing of 55 unique phage display-selected clones showed a strong bias for wild-type residues at nine positions, whereas various changes were obsd. at other positions, including charge shifts.  Addnl., a few non-designed substitutions appeared.  On the basis of the sequences of 12 variants showing high overall binding affinities and slow dissocn. rate kinetics, a set of seven-second generation' variants were constructed.  One variant denoted ABD035 displaying wild-type-like secondary structure content and excellent thermal denaturation/renaturation properties showed an apparent affinity for HSA in the range of 50-500 fM, corresponding to several orders of magnitude improvement compared with the wild-type domain.  The ABD035 variant also showed an improved affinity toward serum albumin from a no. of other species, and a capture expt. involving human serum indicated that the selectivity for serum albumin had not been compromised from the affinity engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdDKnGtvKyWbVg90H21EOLACvtfcHk0lhcgX5juFzvvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslGhu70%253D&md5=ef527a653ec09e553ee2aaa4ea7b5358</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2Fgzn028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252Fgzn028%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DA.%26aulast%3DDogan%26aufirst%3DJ.%26aulast%3DHerne%26aufirst%3DN.%26aulast%3DAbrahmsen%26aufirst%3DL.%26aulast%3DNygren%26aufirst%3DP.%2BA.%26atitle%3DEngineering%2520of%2520a%2520femtomolar%2520affinity%2520binding%2520protein%2520to%2520human%2520serum%2520albumin%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D2008%26volume%3D21%26spage%3D515%26epage%3D527%26doi%3D10.1093%2Fprotein%2Fgzn028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Nilvebrant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hober, S.</span><span> </span><span class="NLM_article-title">The albumin-binding domain as a scaffold for protein engineering</span> <span class="citation_source-journal">Comput. Struct. Biotechnol. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e201303009</span><span class="refDoi"> DOI: 10.5936/csbj.201303009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.5936%2Fcsbj.201303009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=24688717" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=e201303009&author=J.+Nilvebrantauthor=S.+Hober&title=The+albumin-binding+domain+as+a+scaffold+for+protein+engineering&doi=10.5936%2Fcsbj.201303009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.5936%2Fcsbj.201303009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5936%252Fcsbj.201303009%26sid%3Dliteratum%253Aachs%26aulast%3DNilvebrant%26aufirst%3DJ.%26aulast%3DHober%26aufirst%3DS.%26atitle%3DThe%2520albumin-binding%2520domain%2520as%2520a%2520scaffold%2520for%2520protein%2520engineering%26jtitle%3DComput.%2520Struct.%2520Biotechnol.%2520J.%26date%3D2013%26volume%3D6%26spage%3De201303009%26doi%3D10.5936%2Fcsbj.201303009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Bollhagen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmiedberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grell, E.</span><span> </span><span class="NLM_article-title">A new reagent for the cleavage of fully protected peptides synthesized on 2-chlorotrityl chloride resin</span> <span class="citation_source-journal">J. Chem. Soc., Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_fpage">2559</span><span class="NLM_x">–</span> <span class="NLM_lpage">2560</span><span class="refDoi"> DOI: 10.1039/c39940002559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1039%2Fc39940002559" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&pages=2559-2560&author=R.+Bollhagenauthor=M.+Schmiedbergerauthor=K.+Barlosauthor=E.+Grell&title=A+new+reagent+for+the+cleavage+of+fully+protected+peptides+synthesized+on+2-chlorotrityl+chloride+resin&doi=10.1039%2Fc39940002559"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1039%2Fc39940002559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39940002559%26sid%3Dliteratum%253Aachs%26aulast%3DBollhagen%26aufirst%3DR.%26aulast%3DSchmiedberger%26aufirst%3DM.%26aulast%3DBarlos%26aufirst%3DK.%26aulast%3DGrell%26aufirst%3DE.%26atitle%3DA%2520new%2520reagent%2520for%2520the%2520cleavage%2520of%2520fully%2520protected%2520peptides%2520synthesized%2520on%25202-chlorotrityl%2520chloride%2520resin%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1994%26spage%3D2559%26epage%3D2560%26doi%3D10.1039%2Fc39940002559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Taichi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiuchi, Y.</span><span> </span><span class="NLM_article-title">Suppression of side reactions during final deprotection employing a strong acid in boc chemistry: Regeneration of methionyl residues from their sulfonium salts</span> <span class="citation_source-journal">Int. J. Pept. Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1007/s10989-009-9185-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1007%2Fs10989-009-9185-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsVentr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=247-253&author=M.+Taichiauthor=T.+Kimuraauthor=Y.+Nishiuchi&title=Suppression+of+side+reactions+during+final+deprotection+employing+a+strong+acid+in+boc+chemistry%3A+Regeneration+of+methionyl+residues+from+their+sulfonium+salts&doi=10.1007%2Fs10989-009-9185-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of Side Reactions During Final Deprotection Employing a Strong Acid in Boc Chemistry: Regeneration of Methionyl Residues from Their Sulfonium Salts</span></div><div class="casAuthors">Taichi, Misako; Kimura, Terutoshi; Nishiuchi, Yuji</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide Research and Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">247-253</span>CODEN:
                <span class="NLM_cas:coden">IJPRFC</span>;
        ISSN:<span class="NLM_cas:issn">1573-3149</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">During global deprotection using a strong acid in Boc chem., the electrophilic alkylating species, i.e. carbocations, and formaldehyde generated from the side-chain protecting groups and the benzyloxymethyl group on the His residue, resp., can cause alkylation of susceptible residues.  To reduce these side reactions, a deprotection procedure using a strong acid such as HF or TFA must always be carried out in the presence of scavengers.  The authors found that addn. of hydroxylamine derivs. could efficiently suppress the side reactions assocd. with formaldehyde and that addn. of 2-mercaptopyridine could not only specifically circumvent alkylation of the Met residue but also convert its sulfonium salt to the Met residue regardless of the substituent species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0YTQzXOLiq7Vg90H21EOLACvtfcHk0lhRxr1w5c6KaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsVentr4%253D&md5=79f1d767b6a1239c29ea322c5f797dbb</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs10989-009-9185-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10989-009-9185-0%26sid%3Dliteratum%253Aachs%26aulast%3DTaichi%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DNishiuchi%26aufirst%3DY.%26atitle%3DSuppression%2520of%2520side%2520reactions%2520during%2520final%2520deprotection%2520employing%2520a%2520strong%2520acid%2520in%2520boc%2520chemistry%253A%2520Regeneration%2520of%2520methionyl%2520residues%2520from%2520their%2520sulfonium%2520salts%26jtitle%3DInt.%2520J.%2520Pept.%2520Res.%2520Ther.%26date%3D2009%26volume%3D15%26spage%3D247%26epage%3D253%26doi%3D10.1007%2Fs10989-009-9185-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Inui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muramatsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakakibara, S.</span><span> </span><span class="NLM_article-title">Solution synthesis of human midkine, a novel heparin-binding neurotrophic factor consisting of 121 amino acid residues with five disulphide bonds</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1002/psc.45.o</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1002%2Fpsc.45.o" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=9225243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A280%3ADyaK2szmvVKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=28-39&author=T.+Inuiauthor=J.+Bodiauthor=S.+Kuboauthor=H.+Nishioauthor=T.+Kimuraauthor=S.+Kojimaauthor=H.+Marutaauthor=T.+Muramatsuauthor=S.+Sakakibara&title=Solution+synthesis+of+human+midkine%2C+a+novel+heparin-binding+neurotrophic+factor+consisting+of+121+amino+acid+residues+with+five+disulphide+bonds&doi=10.1002%2Fpsc.45.o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Solution synthesis of human midkine, a novel heparin-binding neurotrophic factor consisting of 121 amino acid residues with five disulphide bonds</span></div><div class="casAuthors">Inui T; Bodi J; Kubo S; Nishio H; Kimura T; Kojima S; Maruta H; Muramatsu T; Sakakibara S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of peptide science : an official publication of the European Peptide Society</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    </div><div class="casAbstract">Human midkine (hMK), a novel heparin-binding neurotrophic factor consisting of 121 amino acid residues with five intramolecular disulphide bonds, was synthesized by solution procedure in order to demonstrate the usefulness of our newly developed solvent system, a mixture of dichloromethane or chloroform and trifluoroethanol.  The final protected 121-residue peptide was assembled from two large fully protected intermediates, Boc-(1-59)-OH and H-(60-121)-OBzl, in CHL/TFE(3:1, v/v) using water-soluble carbodiimide in the presence of HOOBt as coupling reagents.  After removal of the protecting groups by HF followed by treatment with Hg(OAc)2 in 50% acetic acid, the fully deprotected peptide was subjected to the oxidative folding reaction.  The final product was confirmed to have the correct disulphide structure from its tryptic peptide mapping and to possess the same biological activities as those of the natural product.  In order to clarify the active region of the hMK molecule, the N-terminal half domains [(1-59) and (60-121)] were also synthesized by the same procedure used for the hMK synthesis.  The C-half domain was confirmed to show the full pattern of bioactivities except for the neuronal cell survival activity, while the N-half one showed much less activity in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsR_RsLy2rrEQ0lWbKiCflfW6udTcc2ebUoNlHCW4Tv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2szmvVKhuw%253D%253D&md5=91c1f8df5267c8496bc2f60f961f5222</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fpsc.45.o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.45.o%26sid%3Dliteratum%253Aachs%26aulast%3DInui%26aufirst%3DT.%26aulast%3DBodi%26aufirst%3DJ.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DNishio%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DKojima%26aufirst%3DS.%26aulast%3DMaruta%26aufirst%3DH.%26aulast%3DMuramatsu%26aufirst%3DT.%26aulast%3DSakakibara%26aufirst%3DS.%26atitle%3DSolution%2520synthesis%2520of%2520human%2520midkine%252C%2520a%2520novel%2520heparin-binding%2520neurotrophic%2520factor%2520consisting%2520of%2520121%2520amino%2520acid%2520residues%2520with%2520five%2520disulphide%2520bonds%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D1996%26volume%3D2%26spage%3D28%26epage%3D39%26doi%3D10.1002%2Fpsc.45.o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Himmler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratowa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czernilofsky, A. P.</span><span> </span><span class="NLM_article-title">Functional testing of human dopamine d1 and d5 receptors expressed in stable camp-responsive luciferase reporter cell lines</span> <span class="citation_source-journal">J. Recept. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.3109/10799899309073647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.3109%2F10799899309073647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=8383768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaK3sXhtFKru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1993&pages=79-94&author=A.+Himmlerauthor=C.+Stratowaauthor=A.+P.+Czernilofsky&title=Functional+testing+of+human+dopamine+d1+and+d5+receptors+expressed+in+stable+camp-responsive+luciferase+reporter+cell+lines&doi=10.3109%2F10799899309073647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Functional testing of human dopamine D1 and D5 receptors expressed in stable cAMP-responsive luciferase reporter cell lines</span></div><div class="casAuthors">Himmler, A.; Stratowa, C.; Czernilofsky, A. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Receptor Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1-4</span>),
    <span class="NLM_cas:pages">79-94</span>CODEN:
                <span class="NLM_cas:coden">JRERDM</span>;
        ISSN:<span class="NLM_cas:issn">0197-5110</span>.
    </div><div class="casAbstract">Human dopaminergic D1 or D5 receptor genes were transfected into stably transfected CHO cells contg. the cAMP-inducible luciferase gene.  Treatment of these test cell lines with dopamine receptor agonists and antagonists modulated the luciferase expression in a dose-dependent manner.  The rank of potency of dopamine receptor agonists and antagonists was in agreement with reported data obtained from binding studies.  The non-isotopic assay can be performed in microtiter plate format and is far less work intensive than the detn. of adenylyl cyclase activity by direct cAMP measurement.  This technol. could also be utilized for discovery of new classes of compds., e.g. allosteric effectors or non competitive ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOtHC6B5qQw7Vg90H21EOLACvtfcHk0lguTgAPnY07cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtFKru7w%253D&md5=569b55337fce761347840f23b95bf86e</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3109%2F10799899309073647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10799899309073647%26sid%3Dliteratum%253Aachs%26aulast%3DHimmler%26aufirst%3DA.%26aulast%3DStratowa%26aufirst%3DC.%26aulast%3DCzernilofsky%26aufirst%3DA.%2BP.%26atitle%3DFunctional%2520testing%2520of%2520human%2520dopamine%2520d1%2520and%2520d5%2520receptors%2520expressed%2520in%2520stable%2520camp-responsive%2520luciferase%2520reporter%2520cell%2520lines%26jtitle%3DJ.%2520Recept.%2520Res.%26date%3D1993%26volume%3D13%26spage%3D79%26epage%3D94%26doi%3D10.3109%2F10799899309073647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Frick, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adkison, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells-Knecht, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woollard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higton, D. M.</span><span> </span><span class="NLM_article-title">Cassette dosing: Rapid in vivo assessment of pharmacokinetics</span> <span class="citation_source-journal">Pharm. Sci. Technol. Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span><span class="refDoi"> DOI: 10.1016/S1461-5347(98)00010-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=10.1016%2FS1461-5347%2898%2900010-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;key=1%3ACAS%3A528%3ADyaK1cXislaks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1998&pages=12-18&author=L.+W.+Frickauthor=K.+K.+Adkisonauthor=K.+J.+Wells-Knechtauthor=P.+Woollardauthor=D.+M.+Higton&title=Cassette+dosing%3A+Rapid+in+vivo+assessment+of+pharmacokinetics&doi=10.1016%2FS1461-5347%2898%2900010-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Cassette dosing: rapid in vivo assessment of pharmacokinetics</span></div><div class="casAuthors">Frick, Lloyd W.; Adkison, Kimberly K.; Wells-Knecht, Kevin J.; Woollard, Patrick; Higton, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Science & Technology Today</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-18</span>CODEN:
                <span class="NLM_cas:coden">PSTTF8</span>;
        ISSN:<span class="NLM_cas:issn">1461-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 26 refs. on cassette dosing, which combines many test chems. into one dose soln. and is an attractive method for increasing the throughput of in vivo pharmacokinetic expts.  This dosing technique depends on the sensitivity and selectivity of modern anal. techniques, particularly HPLC/MS/MS.  Cassettes vary in size, but even relatively small ones greatly increase the nos. of compds. investigated by reducing the effort devoted to animal handling, sample processing and sample anal.  The major drawback of cassette dosing is the potential for drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_MeQApZA877Vg90H21EOLACvtfcHk0lhcsHmRt7khgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislaks7o%253D&md5=2912aaa741529642959a80e409f0a7aa</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2FS1461-5347%2898%2900010-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1461-5347%252898%252900010-8%26sid%3Dliteratum%253Aachs%26aulast%3DFrick%26aufirst%3DL.%2BW.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DWoollard%26aufirst%3DP.%26aulast%3DHigton%26aufirst%3DD.%2BM.%26atitle%3DCassette%2520dosing%253A%2520Rapid%2520in%2520vivo%2520assessment%2520of%2520pharmacokinetics%26jtitle%3DPharm.%2520Sci.%2520Technol.%2520Today%26date%3D1998%26volume%3D1%26spage%3D12%26epage%3D18%26doi%3D10.1016%2FS1461-5347%2898%2900010-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i30"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01909">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_66404"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01909">10.1021/acs.jmedchem.5b01909</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><i>In vitro,</i> PK, PPB, and helicity data with statistical parameters, protocol for helicity determinations, and physiochemical properties of analogues <b>1</b>, <b>2</b>, and <b>4</b>–<b>86</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01909/suppl_file/jm5b01909_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01909/suppl_file/jm5b01909_si_001.pdf">jm5b01909_si_001.pdf (100.06 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01909&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01909%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01909" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                727KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67997a689b433c94","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
